Protocol AC -064A201 
A multicenter, randomized, double -blind, placebo -controlled, dose -response study to investigate the 
biological activity, safety, tolerability, and pharmacokinetics of ACT -334441 in subjects with systemic 
lupus erythematosus  
 
Study Registry ID: [REMOVED]  
 
 This study was sponsored by Actelion Pharmaceuticals.  
Study sponsorship was transferred to Idorsia Pharmaceuticals in July 2018.  
 
 
  
 
TPL-000052_v10  
  
ACT- 334441  
Systemic Lupus Erythematosus  
Protocol  AC- 064A201  
A multicenter, randomized, do uble-blind, placebo -controlled,  dose- response study 
to investigate the biological activity, safety, tolerability, and pharmacokinetics  of 
ACT -334441 in subjects  with systemic lupus erythematosus  
 
 
Study Phase:  1/2 
EudraCT Number: 2014-002984-14 
Status and version: Final Version 2  
Date:  25 March  2015 
Actelion document number 
(Doc No.):  D-15.156 
 
Confidentiality statement  
The information contained in this document,  especially unpublished data , is the property of the sponsor of 
this study, Actelion Pharmaceuticals Ltd. It is therefore provided to you in confidence as an investigator, 
potential investigator, or consultant, for review by you, your staff, and an Ethics Committee or Institutional 
Review Board. It is understood that this information will not be disclosed to others without written authorization from Actelion Pharmaceuticals Ltd, except to the extent necessary to obtain informed consent 
from those persons to  whom the study treatment may be administered.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 5/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
INVESTIGATOR SIGNATURE PAGE 
Treatment name / number 
ACT -334441 
Indication Systemic Lupus Erythematosus 
Protocol number, study t itle  
AC-064A201, A multicenter , randomized, double -blind, placebo- controlled, dose -
response study to investigate the biological activity, safety, tolerability, and 
pharmacokinetics of ACT -334441 in subjects with systemic lupus erythematosus. 
I agree to th e terms and conditions relating to this study as defined in this protocol, the 
electronic Case Report Form ( eCRF), and any other protocol -related documents. I fully 
understand that any changes instituted by the investigator(s) without previous agreement with the sponsor would constitute a protocol deviation, including any ancillary studies or 
procedures performed on study subjects (other than those procedures necessary for the wellbeing of the subjects).  
I agree to conduct this study in accordance with the Declaration of Helsinki principles, 
International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, and applicable regulations and laws. I will obtain approval by an Institutional Review Board or Independent Ethics Committee (IRB/IEC) prior to study start and signed informed consent from all subjects included in this study. If an amendment to the protocol is necessary, I will obtain approval by an IRB/IEC and ensure approval by regulatory authorities (if applicable) have been obtained before the implementation of changes described in the amendment. I will allow direct access to source documents and study facilities to sponsor representative(s), particularly monitor(s) and auditor(s), and agree to inspection by regulatory authorities or IRB/IEC representative. I will ensure that 
the study treatment(s) supplied by the sponsor are being used only as described in this protocol. I confirm herewith that the sponsor is allowed to enter and utilize my professional contact details and function in an electronic database for internal purposes 
and for submission to Health Authorities worldwide. 
 Country  Site 
number  Town  Date   Signature  
Site Principal 
Investigator        
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 6/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
 
TABLE OF CONTENTS 
SPONSOR CONTACT DETA ILS ......................................................................................2  
ACTELION CONTRIBUTORS TO THE PROTOCOL  .....................................................2  
MAIN CONTRACT RESEARCH OR GANIZATIONS INFORMAT ION ........................3  
LIST OF ABBREVIATION S AND ACRONYMS  ..........................................................14  
PROTOCOL SYNOPSIS AC -064A201 ............................................................................18  
1 BACKGROUND  .........................................................................................................38  
1.1 Systemic Lupus Erythematosus ....................................................................38  
1.1.1  Clinical manifestations and diagnosis  ...............................................38  
1.1.2  Epidemiology ....................................................................................39  
1.1.3  Current treatments of SLE  ................................................................39  
1.1.3.1  Nonsteroidal anti- inflammatory drugs  ....................................40  
1.1.3.2  Antimalarial drugs  ...................................................................40  
1.1.3.3  Glucocorticoids .......................................................................40  
1.1.3.4  Immunosuppressives ...............................................................41  
1.1.3.5  Biologics  ..................................................................................41  
1.1.4  Unmet needs in SLE .........................................................................42  
1.2 Sphingosine-1-phosphate receptors ..............................................................43  
1.3 ACT -334441 .................................................................................................43  
1.3.1  Nonclinical data  ................................................................................43  
1.3.2  Clinical studies  ..................................................................................44  
1.3.2.1  Clinical pharmacokinetics  .......................................................45  
1.3.2.2  Pharmaco dynamics in humans ................................................45  
1.3.2.3  Safety and tolerability  .............................................................46  
1.4 Purpose and rationale of the study ................................................................47  
2 STUDY OBJECTIVES  ...............................................................................................48  
2.1 Main objectives  .............................................................................................48  
2.2 Exploratory Objectives .................................................................................48  
3 OVERALL STUDY DESIGN AND PLAN  ...............................................................48  
3.1 Study design .................................................................................................48  
3.1.1  Study periods ....................................................................................49  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 7/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
3.1.1.1  Screening period  ......................................................................49  
3.1.1.2  Treatment period  .....................................................................50  
3.1.1.3  Follo w-up period .....................................................................50  
3.1.2  Study duration  ...................................................................................50  
3.2 Study design r ationale  ..................................................................................50  
3.3 Site personnel and their roles ........................................................................52  
3.3.1  Principal investigator  ........................................................................53  
3.3.2  Treating physician  .............................................................................53  
3.3.3  Cardiac safety asses sor .....................................................................53  
3.3.4  Echocardiography specialist .............................................................54  
3.3.5  Clinical coordinator / study nurse .....................................................54  
3.3.6  Ophthalmologist ................................................................................55  
3.3.7  Pulmonary function laboratory technician or expert ........................55  
3.4 Study Committees  .........................................................................................55  
3.4.1  Independent Data Monitoring Committee ........................................55  
3.4.2  Ophthalmology S afety Board ...........................................................56  
4 SUBJECT POPULATION ..........................................................................................56  
4.1 Subject population description .....................................................................56  
4.2 Rationale for the selection of the study population ......................................57  
4.3 Inclusion criteria  ...........................................................................................57  
4.4 Exclusion criteria  ..........................................................................................58  
4.5 Criteria for women of childbearing potential ...............................................61  
4.5.1  Definition of childbearing potential ..................................................61  
4.5.2  Acceptable method s of contraception ...............................................61  
4.6 Medical history  .............................................................................................62  
4.6.1  General medical history  ....................................................................62  
4.6.2  SLE-relevant disease history  ............................................................63  
5 TREATMENTS  ..........................................................................................................65  
5.1 Study treatment  .............................................................................................65  
5.1.1  Investigational treatment: description and rationale  .........................65  
5.1.2  Study treatment administration  .........................................................65  
5.1.3  Treatment  assignment  .......................................................................65  
5.1.4  Blinding ............................................................................................66  
5.1.4.1  Study drug material related blinding  .......................................66  
5.1.4.2  Functional blinding ..................................................................66  
5.1.5  Unblinding ........................................................................................68  
5.1.5.1  Unblinding for final analyses ..................................................68  
5.1.5.2  Unblinding for interim analyses ..............................................68  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 8/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
5.1.5.3  Unblinding before final analyses .............................................68  
5.1.5.4  Unblinding for suspected unexpected serious adverse 
reactions  ...................................................................................68  
5.1.5.5  Emergency procedure for unblinding ......................................68  
5.1.6  Study treatment supply .....................................................................69  
5.1.6.1  Study treatment pac kaging and labeling .................................69  
5.1.6.2  Study treatment distribution and storage .................................69  
5.1.6.3  Study treatment dispensing .....................................................69  
5.1.6.4  Study treatment return and destruction ...................................69  
5.1.7  Study treatment accountability and compliance with study treatment  ...........................................................................................70
 
5.1.7.1  Study treatment accountability  ................................................70  
5.1.7.2  Study treatment compliance  ....................................................70  
5.1.8  Study treatment interruptions  ............................................................71  
5.1.8.1  Between Day 1 and Day 14 .....................................................71  
5.1.8.2  After Day 14  ............................................................................72  
5.1.9  Premature discontinuation of study treatment  ..................................72  
5.1.10  Management of clinical events and study- specific criteria for 
interruption / premature discontinuation of study treatment ............73  
5.1.10.1  Cardiovascular  .........................................................................73  
5.1.10.2  Immune system  ........................................................................74  
5.1.10.3  Respiratory system  ..................................................................75  
5.1.10.4  Pregnancy  ................................................................................76  
5.1.10.5  Liver abnormalities  ..................................................................76  
5.1.10.6  Ocular abnormalitie s ...............................................................77  
5.1.10.7  Infections  .................................................................................77  
5.1.10.8  Premature treatment discontinuation after study treatment interruption, background therapy changes, administration of forbidden therapies, or study drug mis-dispensing ................................................................................78
 
5.2 Previous and concomitant therapy ................................................................79  
5.2.1  Background SLE therapy ..................................................................79  
5.2.1.1  Definition of background SLE therapy ...................................79  
5.2.1.2  Reporting of background SLE therapy in eCRF .....................80  
5.2.2  Previous SLE therapies .....................................................................80  
5.2.2.1  Definition of previous SLE therapies ......................................80  
5.2.2.2  Reporting of previous SLE t herapies in eCRF  ........................80  
5.2.3  Study- concomitant therapy  ...............................................................80  
5.2.3.1  Definition of study-concomitant therapy ................................80  
5.2.3.2  Reporting of study- concomitant therapy in eCRF  ..................81  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 9/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
5.2.4  Allowed concomitant therapy ...........................................................81  
5.2.5  Forbidden concomitant therapy ........................................................82  
6 STUDY ENDPOINTS  ................................................................................................82  
6.1 Pharmacodynamic endpoint s ........................................................................82  
6.2 Safety endpoints  ...........................................................................................83  
6.3 Pharmacokinetic endpoints ...........................................................................83  
6.4 Exploratory disease activity endpoints .........................................................84  
6.5 Quality of life endpoints ...............................................................................84  
6.6 Exploratory biomarker endpoints .................................................................84  
7 STUDY ASSESSMENTS  ...........................................................................................84  
7.1 Screening/baseline assessments  ....................................................................85  
7.1.1  Informed consent (Screening visit) ...................................................85  
7.1.2  Baseline demographics and disease characteristics  ..........................85  
7.1.3  Previous and concomitant therapies .................................................86  
7.2 Safety assessments  ........................................................................................86  
7.2.1  Laboratory assessments  ....................................................................86  
7.2.1.1  Type of laboratory ...................................................................86  
7.2.1.2  Laboratory tests  .......................................................................87  
7.2.2  12-lead ECG  .....................................................................................89  
7.2.3  ECG Holter  .......................................................................................91  
7.2.4  Blood pressure ..................................................................................92  
7.2.5  Echocardiography .............................................................................92  
7.2.6  Spirometry  ........................................................................................93  
7.2.7  Ophthalmological examination  .........................................................94  
7.2.8  Optical coherence tomography .........................................................94  
7.2.9  Chest X -ray .......................................................................................95  
7.2.10  Test for tuberculosis ..........................................................................95  
7.2.11  Weight and height .............................................................................96  
7.2.12  Physical examination  ........................................................................96  
7.3 Pharmacodynamic and pharmacokinetic assessments  ..................................96  
7.3.1  Pharmacodynamic assessments  ........................................................96  
7.3.2  Pharmacokinetic assessments  ...........................................................96  
7.4 Disease activity assessments  ........................................................................97  
7.4.1  Systemic Lupus Erythematosus Activity Index-2000 ......................97  
7.4.2  Physician’s Global Assessment of disease  .......................................97  
7.5 Quality of Life asses sments: 36 -Item Short Form Health Survey v2 ...........98  
7.6 Biomarker assessments  .................................................................................98  
7.7 Total blood volume .......................................................................................99  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 10/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
8 SCHEDULE OF VISITS  ..........................................................................................100  
8.1 Screening period .........................................................................................101  
8.1.1  Visit 1 (Screening)  ..........................................................................101  
8.2 Treatment period  .........................................................................................103  
8.2.1  Visit 2 – Randomization Day 1 .......................................................103  
8.2.1.1  Visit 2 – Day 1 – pre- dose assessment  ..................................103  
8.2.1.2  Visit 2 – Day 1 – Randomization and post-dose 
assessment  .............................................................................104  
8.2.2  Visit 3  – Week 2  .............................................................................104  
8.2.3  Visit 4  – Week 4  and Visit 5 – Week 8  ..........................................105  
8.2.4  Visit 6  – EOT  ..................................................................................106  
8.3 Follow-up period ........................................................................................107  
8.3.1  Visit 7  – EOS  ..................................................................................107  
8.3.2  Visit 8 and Visit 9– follow -up (telephone contact visits) ...............107  
8.4 Unscheduled visits (U1, U2…) ..................................................................108  
8.5 Additional visits for re -initiation of study treatment ..................................109  
9 STUDY COMPLETION AND POST -STUDY TREATMENT  / MEDICAL 
CARE  ........................................................................................................................109  
9.1 Study completion  ........................................................................................109  
9.2 Premature withdrawal from study  ..............................................................110  
9.3 Premature termination or suspension of the study ......................................110  
9.4 Medical care of subjects after study completion  / withdrawal from 
study ............................................................................................................113  
10 SAFETY DEFINITIONS AND REPORTING REQUIRE MENTS  .........................113  
10.1  Adverse events  ............................................................................................113  
10.1.1  Definitions  of adverse events  ..........................................................113  
10.1.2  Intensity of adverse events  ..............................................................114  
10.1.3  Relationship to study treatment ......................................................114  
10.1.4  Adverse events associated to study design or protocol-
mandated procedures ......................................................................115  
10.1.5  Reporting of adverse events ............................................................115  
10.1.6  Follow-up of adverse events ...........................................................115  
10.1.7  Adverse events of special interest  ...................................................115  
10.2  Serious adverse events  ................................................................................115  
10.2.1  Definitions of serious adverse events .............................................115  
10.2.1.1  Serious adverse events  ...........................................................115  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 11/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
10.2.1.2  Serious adverse events associated with the study design 
or protocol- mandated procedures  ..........................................116  
10.2.2  Reporting of serious adverse events ...............................................116  
10.2.3  Follow-up of serious adverse events ...............................................116  
10.2.4  After the 16 -week follow -up period ...............................................116  
10.2.5  Reporting procedures ......................................................................116  
10.3  Pregnancy  ...................................................................................................117  
10.3.1  Teratogenicity  .................................................................................117  
10.3.2  Reporting of p regnancy ..................................................................117  
10.3.3  Follow-up of pregnancy ..................................................................118  
10.4  Study safety monitoring  ..............................................................................118  
11 STATISTICAL METHODS  .....................................................................................118  
11.1  General considerations  ...............................................................................118  
11.2  Analysis Sets  ...............................................................................................119  
11.2.1  Screened Analysis Set .....................................................................119  
11.2.2  PD Analysis Set ..............................................................................119  
11.2.3  Full Analysis Set .............................................................................119  
11.2.4  Per-Protocol S et ..............................................................................120  
11.2.5  Safety Analysis S et .........................................................................120  
11.2.6  PK Analysis Set ..............................................................................120  
11.2.7  Other analysis sets  ..........................................................................120  
11.2.8  Usage of the analysis sets  ...............................................................120  
11.3  Variables  .....................................................................................................120  
11.3.1  Main  pharmacodynamic variable  ....................................................120  
11.3.2  Other pharmacodynamic variables  .................................................121  
11.3.3  Safety variables  ...............................................................................121  
11.3.4  Pharmacokinetic variables  ..............................................................122  
11.3.5  Exploratory disease activity variables  ............................................122  
11.3.6  Quality of life variables  ..................................................................122  
11.3.7  Exploratory biomarker variables ....................................................122  
11.4  Description of statistical analyses  ...............................................................123  
11.4.1  Overall testing strategy  ...................................................................123  
11.4.2  Analysis of the main  pharmacodynamic variable(s)  .......................123  
11.4.2.1  Hypotheses and statistical model ..........................................123  
11.4.2.2  Handling of missing data  .......................................................123  
11.4.2.3  Main analysis  .........................................................................124  
11.4.2.4  Supportive/sensitivity analyses .............................................124  
11.4.2.5  Subgroup analyses .................................................................125  
11.4.2.6  Other pharmacodynamic variables  ........................................125  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 12/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
11.4.3  Analysis of the safety variable(s)  ....................................................125  
11.4.3.1  Adverse events  ......................................................................125  
11.4.3.2  Cardiac safety  ........................................................................126  
11.4.3.3  Pulmonary safety ...................................................................127  
11.4.3.4  Vital signs  ..............................................................................127  
11.4.3.5  Laboratory  endpoints .............................................................127  
11.4.3.6  Ocular safety  ..........................................................................128  
11.4.4  Analysis of the exploratory efficacy variables  ...............................128  
11.4.5  Analysis of other variable(s)  ...........................................................128  
11.4.5.1  Pharmacokinetic endpoints ....................................................128  
11.4.5.2  Exploratory biomarkers .........................................................128  
11.4.5.3  Exploratory analyses  .............................................................129  
11.5  Interim safety review  ..................................................................................129  
11.5.1  Objectives  .......................................................................................129  
11.5.2  Timing  .............................................................................................129  
11.5.3  Unblinded IDMC review ................................................................129  
11.5.4  Variables  .........................................................................................130  
11.6  Sample size  .................................................................................................130  
11.6.1  Sample size justification  .................................................................130  
12 DATA HANDLING  ..................................................................................................131  
12.1  Data collection  ............................................................................................131  
12.2  Maintenance of data confidentiality  ...........................................................132  
12.3  Database management and quality control  .................................................132  
13 PROCEDURES AND GOOD CLINICAL PRACTICE  ...........................................133  
13.1  Ethics and Good Clinical Practice  ..............................................................133  
13.2  Independent Ethics Committee / Institutional Review Board  ....................133  
13.3  Informed consent ........................................................................................133  
13.4  Compensation to subjects and investigators ...............................................134  
13.5  Protoc ol adherence/compliance  ..................................................................134  
13.6  Protocol amendments .................................................................................135  
13.7  Essential documents and retention of documents .......................................135  
13.8  Monitoring ..................................................................................................136  
13.9  Investigator site file  ....................................................................................137  
13.10  Audit ...........................................................................................................137  
13.11  Inspections ..................................................................................................137  
13.12  Reporting of study results and publication .................................................138  
14 REFERENCES  ..........................................................................................................140  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 13/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
 
LIST OF TABLES 
Table 1  Visit and assessment schedule (same for part A and part B)  ........................35  
Table 2  Guidelin es for FEV 1 and/or FVC decrease ...................................................75  
Table 3  Expected total blood volume to be drawn per patient ................................100  
Table 4  Safety areas of interest  ................................................................................112  
Table 5  Thresholds for marked laboratory abnormalities for 
ACT -334441 ...............................................................................................155  
  
LIST OF FIGURES 
Figure 1  AC-064A201 study design ...........................................................................49  
Figure 2  Algorithm for management of study treatment interruptions  .......................72  
Figure 3  Guidance for mo nitoring liver test abnormalities  .........................................76  
Figure 4  Reduction in total lymphocyte count dose-response shapes ......................131  
 
 
LIST OF APPENDICES 
 
Appendix 1  Prohibited anti- arrhythmic or heart rate lowering medications  ..................147  
Appendix 2  List of medications with risk of torsades de pointes ..................................148  
Appendix 3  Adverse events of special interest  ..............................................................149  
Appendix 4  Criteria for discharge from hospital on Day 1 and on the first day of re -initiation following treatment interruptions  ................................150
 
Appendix 5  American College of Cardiology / American Heart Associatio n / 
American College of Physicians Training Requirements for Performance and Interpretation of Adult Transthoracic Echocardiography .......................................................................................151
 
Appendix 6  SLEDAI -2K: DATA COLLECTION SHEET  ...........................................152  
Appendix 7  Notable abnormalities for ECG, BP and laboratory variables ....................154  
Appendix 8  Corticosteroid conversion table ..................................................................158  
Appendix 9  Physician’s Global Assessment Visual Analog Scale  ................................159  
Appendix 10  SF-36v2™...................................................................................................160  
 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 14/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
 
LIST OF ABBREVIATIONS AND ACRONYMS 
 
ACR   American College of Rheumatology  
ADME   Absorption, distribution, metabolism, excretion  
AE  Adverse event  
AESI   Adverse event of special interest  
ALT   Alanine aminotransferase 
ANA   Anti-nuclear antibodies  
ANCOVA   Analysis of covariance  
anti-dsDNA   Anti-double-stranded deoxyribonucleic acid 
anti-Sm  Anti-Smith  
AST   Aspartate aminotransferase 
ATS   American Thoracic Society  
AUC 0-24  Area under  the curve  from 0 to 24 hours  
AV  Atrioventricular  
BAFF   B- cell activating factor  
BLyS   B- lymphocyte stimulator  
BP  Blood pressure  
bpm  Beats per minute  
CD  Cluster of differentiation  
CI  Confidence interval  
Cmax  M aximum observed plasma concentration  
CNS   Central nervous system 
CRA   Clinical research associate  
CRO   Contract Research Organization  
CRP   C- reactive protein  
CSA   Cardiac safety assessor  
CTCAE   Common Terminology Criteria for Adverse Events  
Ctrough  Measured  plasma concentration at the end of one dosing interval 
CTT   Clinical Trial Team  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 15/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
CV  C oeffic ient of variation  
CYP   Cytochrome P450 
CXCL10   C-X-C motif chemokine 10 
CXR   Chest X -Ray 
DBP   Diastolic blood pressure 
DILI  Drug -induced liver injury 
ECG   Electrocardiogram  
EDTA   Ethylenediaminetetraacetic acid  
Emax  Maximum effect  
eCRF   Electronic Case Report Form 
ELISA   Enzyme -linked immunosorbant assay 
EMA   European Medicines Agency 
EOT   End-of-Treatment  
EOS   End-of-Study  
ERS  European Respiratory Society 
EULAR   Europe an League Against Rheumatism  
FAS  Full Analysis Set 
FDA   Food and Drug Administration 
FEV 1  Forced expiratory volume in 1 second  
FSFV   First Subject First Visit 
FVC   Forced vital capacity  
GCP   Good Clinical Practice  
GGT   Gamma glutamyl transferase  
Hb  Hemoglobin  
HIV  Human immunodeficiency virus 
HR  Heart rate  
IB  Investigator’s Brochure  
ICF  Informed Consent Form  
ICH  International Conference on Harmonisation  
IDMC   Independent Data Monitoring Committee 
IEC  Independent Ethics Committee 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 16/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
INR  International normalized r atio 
IRB  Institutional Review Board  
IRT  Interactive response technology 
ISAC   Independent S tatistical Analysis C enter  
ISF  Investigator s ite file 
i.v.  Intravenous 
LSLV   Last Subject L ast Visit 
LT  Liver test 
LOCF   Last observation carried f orward  
MAD  Multiple -ascending dose 
MCP -Mod  Multiple Comparison Procedure and Modelling 
MedDRA   Medical Dictionary for Regulatory Activities  
NSAID   Non-steroidal anti -inflammatory drug  
o.d.  Once daily  
OCT   Optical coherence to mography 
OSB   Ophthalmology Safety Board  
PD  Pharmacodynamic  
PDS  P harmacodynamics Analysis Set 
PFT  Pulmonary funtion test  
PGA  Physician’s Global Assessment  
PK  Pharmacokinetic  
PPS  Per-protocol Set 
QTcB   QT corrected for  heart rate on the basis of Baz ett’s formula  
QTcF   QT corrected for heart rate on the basis of Fridericia’s formula  
RBC   Red blood cells 
S1P  Sphingosine-1-phosphate 
S1P 1  Sphingosine-1-phosphate receptor 1  
SAE   Serious adverse e vent 
SAP  Statistical Analysis Plan  
SBP  Systolic Blood Pressure 
SF-36v2   36-Item Short Form Health Survey v2 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 17/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
SIV  Site initiation visit  
SLE  Systemic lupus e rythematosus 
SLEDAI -2K  Systemic Lupus Erythematosus Disease Activity Index -2000 
SOC   System Organ C lass 
SOP  Standard operating proced ure 
SRBC   Sheep red blood cell 
SUSAR   Suspected unexpected serious adverse r eaction  
t½  Terminal elimination half life  
TB  Tuberculosis  
TBL  Total bilirubin  
ULN   Upper limit of the normal range 
WBC   White blood cells 
WOCBP   Women of childbearing po tential  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 18/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
 
PROTOCOL SYNOPSIS AC-064A201 
TITLE  A multicenter, randomized, double -blind, placebo -controlled, 
dose- response study to investigate the biological activity, 
safety, tolerability, and pharmacokinetics of ACT -334441 in 
subjects with systemic lupus erythematosus.  
OBJECTIVES  Main  objective s 
• To investigate the pharmacodynamics  (PD) of ACT -334441 
in adult subject s with systemic lupus erythematosus  (SLE).  
• To investigate the safety and tolerability of ACT -334441 in 
adult subjects with SLE.  
Exploratory objectives 
• To investigate the pharmacokinetics (PK) of ACT -334441 in 
adult subject s with SLE. 
• To investigate the effect of ACT -334441 treatment on 
disease activity in adult subjects with SLE.  
DESIGN  Prospective, multicenter, multinational, randomized, 
double -blind, placebo- controlled, two- part, dose -response 
Phase 1/2 study.  
This study is divided in two parts:  
• Part A : Four parallel treatment groups (including 
0.5 mg, 1  mg, or 2 mg of ACT -334441 and placebo 
control). 
An interim safety  review will be conducted by the Independent 
Data Monitoring Committee (IDMC) when all subjects enrolled 
into Part A have completed Visit 4, unless prematurely 
discontinued. The IDMC will then evaluate the safety profile of 
ACT -334441 in SLE patients and give a recommendation 
whether or not to continue the study as planned (i.e., proceed to 
Part B ).   
• Part B: Two parallel treatment groups (including 4 mg 
ACT -334441 and placebo control). 
Note: Subjects enrolled in Part A are not eligible to participate 
in Part B.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 19/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
PERIODS  There w ill be three periods in Part A and Part B.  
Screening  period :  
This period starts up to 30 days before randomization and 
includes the Screening visit  and the pre -randomization 
assessments.  
Treatment period :  
The treatment period will last 12 weeks. Visits during the 
treatment period will consist of a Randomization  visit and 
visits at W eeks 2, 4, 8, and 12.  
The End-of-Treatment (EOT) visit will take  place at Week 
12, or earlier in case of premature discontinuation of study 
treatment. In all cases, the EOT v isit should take place 1  day 
after the last dose of study treatment but no later than 7 days 
after the last dose of study treatment.  
Follow- up period:  
Subjects will undergo an End-of-Study (EOS)  Visit 6 weeks 
after the last dose of study treatment.  
Follow- up assessment s via telephone calls will be performed 11 
weeks and 16 weeks  after the last dose of study treatment to 
evaluate potential serious adverse events ( SAEs) and to assess 
pregnancy status (urine test) .    
STUDY TREATMENT 
DISCONTINUATION CRITERIA  AND STUDY -
SPECIFIC CRITERIA 
FOR INTERRUPTION / 
CLINICAL STUDY STOP  Study treatment discontinuation  
At any time during the double -blind treatment period, subjects  
meeting the study -specific criteria for  permanent 
discontinuation of study treatment as descr ibed in 
Sections  5.1.9 and 5.1.10 are to be permanently discontinued 
from study treatment and will perform EOT and EOS visits  and 
will be follow ed up for a total of 16 weeks after last study 
treatme nt intake ( follow-up telephone calls for pregnancy and 
SAEs).  
Study -specific criteria for interruption / stopping of the  
clinical study or Part B  
• Part A: if 12 or more subjects out of the planned 36 
subjects in the combined active treatment groups (0.5, 1,  
or 2 mg) or 6 or more subjects out of the planned 12 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 20/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
subjects in the high dose group (2 mg) have been 
discontinued from study treatment due to meeting any of 
the individual patient’ s stopping rules as defined per 
safety area of interest [see Section 9.3], the entire study 
will be put on hold. A detailed safety signal assessment 
and recommendations from IDMC and Health 
Authorities may allow a potential restart of the study.  
• Part B: if 4 or more subjects out of the planned 
12 subjects in the active treatment group (4 mg) have 
been discontinued study treatment due to meetin g any of 
the individual patient’ s stopping rules as defined per 
safety area of interest [see Section 9.3], all subjects 
included in Part B will stop study treatment. A detailed 
safety signal assessment and recommendations from 
IDMC and Health Authorities may allow a potential 
restart of the Part B.  
PLANNED DURATION Part A: Approximately 11 months from First subject -First visit 
(FSFV) to Last Subject -Last Visit (LSLV).  
Part A and B: Approximately 20 months from FSFV to LSLV.  
SITE(S)  
/ COUNTRY(IES)  Approximately 21 sites notably in the USA , Russia  and Europe . 
SUBJECTS / GROUPS  Part A: Approximately 48 subjects will be randomized 
(1:1:1:1) via an interactive response technology (IRT) system  to 
one of four groups (i.e., 12 subject s in each group; three dose 
levels of 0.5 mg, 1 mg, or 2 mg ACT -334441, or placebo once 
daily [o.d.]). 
 
Part B: Approximately 16 subjects will be randomized (3:1) 
via an IRT system  to one of two groups (i.e., 12 subjec ts 
receiving 4 mg ACT -334441 and 4 receiving placebo o.d.).  
INCLUSION CRITERIA  1. Signed informed consent prior to initiation of any 
study-mandated procedure. 
2. Men or women ≥ 18 and ≤ 65 years of age . 
3. Women of childbearing potential  as defined in 
Section  4.5.1:  
• must have a negative serum pregnancy test at 
Screening and a negative urine pregnancy test at 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 21/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
Randomization  at least 3 weeks apart ; 
• must agree to undertake a urine pregnancy test as 
indicated in Table 1 (bi- weekly/  monthly) during 
the study and up to 16 weeks after study treatment 
discontinuation; 
• must use methods of contraception , as described in 
Section 4.5.2, from the Screening visit until 
16 weeks  after study treatment discontinuation.  
4. Presenting with a diagnosis of SLE  made at least 6 months 
prior to S creening, by fulfilling at least 4 of the 11 criteria 
for SLE , as def ined by the American College of 
Rheumatology (criteria are cumulative  and do not need to 
be present concurrently)  [Tan 1982; Hochberg 1997] . 
5. Presenting with a Systemic Lupus Erythematosus Disease 
Activity Index -2000 ( SLEDAI -2K) score of at least 2 points 
for musculoskeletal or mucocutaneous manifestations (i.e., 
myositis, arthritis, rash, alopecia, mucosal ulcers ) at 
Screening.  
6. History or presence at Screening of positive anti- nuclear 
antibodies (ANA) or anti -double- stranded DNA 
(anti-dsDNA) antibodies. 
7. Currently treated  for at least 30 days prior to Randomization  
with stable doses of  one or more of the following 
background medications: 
• Non-steroidal anti- inflammatory drugs  (NSAIDs) , 
• Corticosteroids (≤ 10 mg/ day p rednisolone or 
equivalent), 
• Anti-malarials (≤ 400 mg/day hydroxychloroquine, 
≤ 500 mg/day chloroquine, ≤ 100 mg/day 
quinacrine)#, 
• Mycophenolate mofetil (≤ 2 g/day)#, 
• Azathioprine (≤ 2 mg/kg/day)#, 
• Methotrexate (≤ 20 mg/week)#. 
 
#Treatment with anti -malaria ls, mycophenolate mofetil, 
azathioprine, or methotrexate must have been started at least 90 days prior to Randomization and must not have been stopped 
within 30 days prior to R andomization.  
EXCLUSION CRITERIA  Pregnancy and b reastfeeding  
1. Breast feeding, pre gnant women or women planning to 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 22/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
become pregnant during the study.  
SLE disease  
2. Subjects with active lupus nephritis (defined by proteinuria 
> 1 g/24 h, or equivalent using spot urine 
protein- to-creatinine ratio)  within 90 days prior to 
randomization; subje cts with central nervous system lupus 
(e.g., aseptic meningitis, seizures, cerebritis, 
polyneuropathy, cerebrovascular disease)  within 90 da ys 
prior to R andomization; subjects with lupus vasculitis  
within 90 days prior to Randomization.  
3. Subjects presenting  with a SLEDAI -2K score > 12 at 
Screening or at Randomization. 
Cardiovascular 
4. History or presence of cardiac rhythm disorders (e.g., 
sinoatrial heart block, second - or third- degree 
atrioventricular  block, symptomatic bradycardia, atrial 
flutter or atrial f ibrillation, ventricular arrhythmias, cardiac 
arrest).  
5. Resting heart rate (HR) < 55 bpm as measured by the 
pre-dose 12- lead electrocardiogram ( ECG ) on Day 1; a n 
increased QT corrected for HR on the basis of Fridericia’s 
formula (QTcF ) interval of > 470 ms (females), > 450 ms 
(males) at Screening, or on Day 1 ECG prior to study 
treatment initiation.  
6. History or presence of ischemic heart disease.  
7. History or presence of myocarditis or endocarditis. 
8. Presence of valvular heart disease associated with 
symptoms or hemodynamic change.  
9. History of syncope associated with cardiac disorders.  
10. History or presence of cardiac failure.  
11. Systemic arterial hypertension not controlled by medication 
according to investigator judgment. 
12. History or presence of vascular thrombosis at  any time or a 
history of pregnancy morbidity in the context of 
anti-phospholipid antibody syndrome within 5 years prior to 
Randomization. 
13. Clinically relevant hypote nsion according to investigator’ s 
judgment or orthostatic hypotension (i.e., > 20 mmHg 
decrease in systolic blood pressure [ SBP] or > 10 mmHg 
decrease in diastolic blood pressure [ DBP ] from supine to 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 23/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
standing position measured between 1 and  3 minutes after 
standing) at Screening . 
14. Known pulmonary arter ial hypertension of functional 
class III or I V.  
Pulmonary 
15. History or presence of severe respiratory disease or 
pulmonary fibrosis, based on medical history, lung function 
and chest X -ray (CXR) performed at Screening or within 3 
months prior to S creening.  
16. Bronchial asthma or chronic obstructive pulmonary disease.  
17. Abnormal pulmonary function tests: forced expiratory 
volume in 1 second (FEV 1) or forced vital c apacity (FVC) < 
70% of predicted normal value; FEV 1/FVC ratio <0.7. 
Treatment s 
18. Treatment or planned treatment with the following 
medications *: 
a. Within 15 days or 5 half-lives of the medication,  
whichever is longer, prior to Randomization: 
o β-blockers, diltiazem, verapamil, digoxin 
or any other anti -arrhythmic or 
HR-lowering systemic therapy ( list of 
drugs provided in Appendix 1) . 
o QT-prolonging drugs with known risk of 
torsades de pointes, for any indication 
(list of drugs provided in Appendix 2) . 
o Short- and long- acting β2 -agonists (e.g., 
albuterol, levalbuterol, formoterol, terbutaline salmeterol) . 
b. Within 30 days or 5 half -lives of the medication, 
whichever is longer, prior to R andomization: 
o Cyclophosphamide, cyclosporine, 
tacrolimus, sirolimus, etc., 
o Pulse methylprednisolone   
o Vaccination with live vaccines . 
c. Within 90 days prior to Randomization: 
o Belimumab, leflunomide, 
o 
Any investigational immunosuppressive 
or immunomodulatory agent (within 
90 days or 5 half-lives of the drug prior 
to start of study treatment , whichever is 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 24/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
longer).  
d. Within 12 months prior to Randomization: 
o B cell -depleting biological agents su ch as 
rituximab or ocrelizumab. 
e. Any time prior to R andomization: 
o Alemtuzumab , sphingosine-1-phosphate 
(S1P) modulators (e.g., fingolimod). 
*For immunosuppressants or anti -inflammatory drugs not listed 
among the fordidden medications, the investigator shoul d 
discuss adequate wash -out time with the sponsor. 
Infection and infection r isk 
19. Active or latent tuberculosis  (TB) , as assessed by CXR  
performed at Screening  or within 3 months prior to 
Screening , and interferon gamma release assay 
(QuantiFERON -TB-Gold®) at Screening , except if there is 
documentation that the subject has completed adequate and 
successful  treatment for latent TB infection or TB disease 
previously. 
20. Ongoing known bacterial, viral or fungal infection that is of 
clinical concern in the judgment of the investigator. 
21. A history of any serious infection, defined as 
life-threatening or requiring intravenous ( i.v.) antibiotics or 
hospitaliz ation, within 30 days prior to Randomization.  
22. Hepatitis B and C, congenital or acquired severe 
immunodeficiency o r known human immunodeficiency 
virus (HIV) infection or positive HIV testing at S creening.  
23. Negative antibody test for varicella -zoster virus at 
Screening.  
Malignancy 
24. History or presence of malignancy (except for surgically 
excised basal or squamous cell sk in lesions), 
lymphoproliferative disease, or history of total lymphoid 
irradiation.  
Transplantation 
25. History or presence of bone marrow or solid organ  
transplantation . 
Opht halmology 
26. Presence of macular edema or active uveitis.  
Metabolic and hepatic  
27. Type 1  or 2 diabetes that is poorly controlled according to 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 25/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
investigator judgment, or diabetes complicated with organ 
involvement such as diabetic nephropathy or retinopathy. 
28. Moderate or severe hepatic impairment defined as Child 
Pugh Score B or C, respectively, based on measurement of 
total bilirubin  (TBL) , serum albumin, international 
normalized ratio , as well as on presence/absence and 
severity of ascites and hepatic encephalopaty . 
29. TBL > 1.5- fold upper limit of normal (ULN; unless in the 
context of known Gilbe rt’s Syndrome).  
30. Alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) > 2 -fold ULN. 
Hematology 
31. Hemoglobin < 9 g/dL. 
32. White blood cell count < 2500/ µL (2.5 ×  109/L). 
33. Lymphocyte count < 800 / µL (0.8 ×  109/L). 
34. Platelets < 75,000/ µL (75 × 109/L). 
Renal 
35. Proteinuria > 1.0 g/24 hour or equivalent using spot urine 
protein- to-creatinine ratio.  
36. Estimated glomerular filtration rate <  60 mL/min/1.73 m2. 
Other categories  
37. History of clinically  significant drug or alcohol abuse. 
38. Known allergy to S1P receptor 1  modulators or any of the 
ACT -334441 formulation excipients. 
39. Any other clinically relevant medical or surgical condition 
that in the opinion of the investigator would put the subject 
at risk if  participating in the study.  
40. Subjects unlikely to comply with protocol, 
e.g., uncooperative attitude, inability to return for follow -up 
visits or likelihood of not completing the study , including 
mental condition rendering the subject unable to understand 
the nature, scope, and possible consequences of the study.  
STUDY TREATMENTS Investigational treatment  
ACT -334441 0.5 mg, 1 mg, 2 mg capsules for Part A, and 4 mg 
capsules for Part B, administered orally o.d. in the morning. 
Placebo  
Placebo matching ACT -334441 c apsules administered orally 
o.d. in the morning.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 26/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
CONCOM ITANT 
THERAPY  Allowed concomitant therapy  
• i.v. atropine in the event of symptomatic bradycardia [ see 
study- specific criteria for permanent discontinuation of study 
treatment in Section  5.1.10] ; 
• Dilating eye drops, mydriatics, i ncluding parasympathetic 
antagonists (e.g., tropicamide) or sympathetic agonists (e.g.,  
phenylephrine) for topical use; 
• Vaccination with non- live vaccines;  
• Stable systemic  corticosteroid therapy; corticosteroids are 
not to be started or stopped during the study, and the dose 
should be kept stable. However , the investigator may see 
reason to initiate or increase the dose of systemic 
corticosteroid  to treat an SLE  flare or another condition. In 
such cases , the dose may be increased  for a period of not 
more th an 14 days up to double the baseline dose or a 
maximum of 20 mg/day  prednisolone or equivalent  (please 
refer to conversion table in Appendix 8) ; 
• Topical treatment therapy including topical use of 
corticosteroid ;  
• Stable antimalarial therapy (e.g., hydroxychloroquine, 
chloroquine, quinacrine ); therapy is  not to be started or 
stopped during the study, and dose should be kept stable; 
• Stable NSAID  chronic therapy. Therapy is not to be started 
or stopped during the study;   
− Temporary use and /or dose change for treatment of 
non-SLE-related conditions (e.g., headache, 
menstrual cramps) is allowed ; 
• Stable immunosuppressant  therapy (i.e., methotrexate, 
azathioprine, or mycophenolate mofetil). Therapy  is not to 
be started or stopped during the study, and dose should be 
kept stable.  
Forbidden concomitant medication 
• Immunosuppressives not listed in allowed concomitant 
medication such as  cyclophosphamide, cyclosporine, 
leflunomide, sirolimus, tacrolimus, etc. ; 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 27/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
• Immunosuppressive or immunomodulatory bio logical agents 
(e.g., belimumab, i.v. immunoglobulin, rituximab , S1P 
modulators other than ACT-334441);  
• β-blockers, diltiazem, verapamil, digoxin, or any other 
anti-arrhythmic or HR -lowering therapy ( as listed in 
Appendix 1) ; 
• QT-prolonging drugs with known risk of torsades de pointes 
(list of drugs provided in Appendix 2);  
• Short- and long -acting β 2-agonists (e.g.,  albuterol, 
levalbuterol, formoterol , terbutaline salmeterol);  
• Vaccination with live vaccines . 
ENDPOINTS Pharmacodynamic endpoint s 
• Change in total lymphocyte count from baseline to  EOT  
• Change in total lymphocyte count from baseline t o each 
post- baseline assessment  
Safety endpoints  
The treatment -emergent period is defined as the time from first 
study treatment intake up to 6 weeks  (inclusive) after last study 
treatment  intake.  
• Treatment -emergent adverse events (AEs),  SAEs, and 
adverse events of special interest (AESI#); 
• AEs leading to premature discontinuation of study treatment; 
• Changes in 12- lead ECG variables  (HR, PR, QRS, QT, QT 
corrected for HR on the basis of Bazzett’s formula [QTcB]  
and QT corrected for HR on the basis of Fridericia’s formula 
[QTcF]), from pre-dose to selected post -dose assessments 
(1 h, 2 h, 3 h, 4 h, 5 h, 6 h) on Day 1 and on day of study 
drug re -initiation ; 
• Occurrence of treatment -emergent 12 -lead ECG outliers 
(e.g., HR, PR, QTc defined in the Statistical Analysis Plan 
[SAP]);  
• Occurrence of treatment -emergent 12- lead ECG 
abnormalities;  
• Occurrence of treatment -emergent ECG -Holter 
abnormalities on Day 1;  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 28/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
• Change in SBP and DBP  from baseline up to EOS;  
• Change in FEV 1 and FVC, expressed in absol ute value (L) 
and percent value from baseline up to EOS; 
• Occurrence of treatment -emergent decrease of FEV 1 or FVC 
> 15% from baseline values;  
• Change in laboratory parameters (hematology, blood 
chemistry, and urinalysis) from baseline up to EOS; 
• Treatment -emergent laboratory abnormalities according to 
CTCAE 2010 v4.03 [CTCAE  2010]  and Food and Drug 
Administration  (FDA ) guidelines [FDA 2009 ] (for 
ALT/AST/TB L); 
• Change in protein- to-creatinine ratio  from baseline to EOT ; 
• Change in body weight from baseline to EOT . 
#AESI considered for the analyses are described in  Appendix 3.  
 
Pharmacokinetic endpoints  
• Ctrough ACT -334441 plasma concentrations prior to dosing at 
Week s 2, 4, 8, and 12 (EOT) or at EOT visit after premature 
study treatment discontinuation (if applicable ); 
• ACT -334441 plasma concentration at EOS (i.e., 6 weeks 
after study treatment discontinuation ). 
Exploratory disease activity endpoints 
• Change in SLEDAI -2K score from baseline to each 
post- baseline assessment ; 
• Change in Physician’s Global Assessment  (PGA) score 
from baseline to each post- baseline assessment;  
• Change in SLEDAI -2K mucocutaneous and/or 
muscoskeletal scorings from baseline to each post -baseline 
assessment . 
Quality of life endpoi nts 
• Change in SF -36v2™ Health Sur vey domain and 
component scores from baseline to EOT.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 29/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
Exploratory biomarker endpoints  
• Change in immunoglobulin serum levels (IgG, IgM, IgA) 
from baseline to each post- baseline assessment;  
• Change in ANA and anti -dsDNA antib ody titers from 
baseline to each post- baseline assessment;  
• Change in serum complement components  C3 and C4, 
C-reactive protein , fibrinogen, B lymphocyte s timulator and 
C-X- C motif chemokine 10 from baseline to each post -
baseline assessment ; 
• Change in blood lymphocyte subsets from baseline to EOT  
and EOS . 
ASSESSMENTS Refer to the schedule of assessments in  Table 1. 
STATISTICAL 
METHODOLOGY  All statistical analyses will be conducted by Actelion or by 
designated Contract Research Or ganizations supervised by 
Actelion.  
The SAP will be finalized  prior to database lock. 
Baseline is defined as the last assessment  prior to initiation of 
the study treatment.  
Analysis sets 
Screened Analysis Set: includes all subjects who were screened 
and re ceived a subject number.  
Safety Analysis Set: includes all randomized subjects who 
received at least one dose of study treatment. Unless otherwise stated, any analysis using the Safety Analysis Set will use all available safety data up to 6 weeks after dis
continuation of 
study treatment. Subjects will be analyzed  based on actual dose 
taken, not the randomized dose. 
PD Analysis Set: includes all subjects who received at least 
3 weeks of study treatment and ha ve at least one lymphocyte 
count measurement  between the Week 4 visit and Week 12 
visit. Subjects will be analyzed according to the treatment they 
received.  
Full Analysis Set (FAS): includes all randomized subjects. 
Subjects will be analyzed according to their randomized 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 30/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
treatment.  
Per-Protocol S et (PPS) : defined as subjects from the FAS 
without any major protocol deviations. Major protocol 
deviations are described in Section  11.2.4.  
PK Analysis Set: includes all randomized subjects who received 
at least one ACT -334441 dose and provided at least one blood 
sample for PK evaluation. Subjects will be analyzed  based on 
actual dose taken, not the randomized dose.  
Pharmacodynamic variable 
The change in lymphocyte count from baseline to EOT  is 
defined as:  
• Total lymphocyte count at EOT  – total lymphocyte 
count at baseline  
Last observat ion carried forward (LOCF; using the Week 4 visit 
or later) will be used  for subjects with a missing EOT  
assessment.   
Exploratory disease activity variables The change from baseline in the SLEDAI -2K (m
odified to 
exclude leukopenia) score at each visit is calculated as : 
• SLEDAI -2K score at each visit – SLEDAI -2K score at 
baseline.  
The change from baseline in PGA score and the SLEDAI -2K 
mucocutaneous and/or muscoskeletal score will be calculated in 
a similar manner.  
Overall testing strategy for the pharmacodynamic endpoint  
An optimized contrast test  according to the Multiple 
Comparison Procedure (MCP) -Mod approach [Bretz 2005] for 
each considered dose -response model will be performed . The 
existence of dose- response effects will be tested using the 
maximum of the model- based contrast tests. Multiplicity 
adjusted p- values will be calculated using the Dunnett -
distribution.  
Pharmacodynamic endpoint analysis 
Null and alternative hypotheses 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 31/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
The null hypothesis is that there is no dose response in terms of 
lowering of lymphocyte count (p, which is a negative value for 
a lowering of the lymphocyte count ) from baseline to EOT , and 
the alternative hypothesis is the existence of a dose response:   
 for all doses d = 0.5, 1, 2, 4 mg 
                                                vs 
 for at least 1 dose d = 0.5, 1, 2, 4 mg 
If Part B of the trial is not performed, the hypothesis will be  
 for all doses d = 0.5, 1, 2 mg 
                                                vs 
 for at least 1 dose d = 0.5, 1, 2 mg 
To meet the objective of demonstrating existence of a dose 
response of ACT -334441 on the lymphocyte count reduction 
from baseline in subjects with  SLE, the null hypotheses must be 
rejected by the test with a one-sided significance level of 5%.  
Main pharmacodynamic analysis  
The MCP -Mod approach consists of a set of optimized contrast 
tests for establishing the existence of dose -response effects. The  
overall strategy is described as follows:  
Definition of a set of likely dose response relations (see sampl e 
size section for more details) : 
• Maximum effect ( Emax) with 50% of the maximum effect 
at dose 0.2 mg 
• Emax with 50% of the maximum effect at dose 0.4 mg 
• Emax with 50% of the maximum effect at dose 1.0 mg 
• Quadratic with maximum effect at dose 3.0 mg  (only if 
the 4 mg dose is studied) 
• Sigmoid -Emax with 50% of the maximum effect at dose 
0.4 mg and 95% of the maximum effect at dose 2.0 mg 
The existence of dose- response effects will be assessed with the 
optimized contrast tests. Dose -response effects are established 
at one sided level α=5%, if the following condition on the p 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 32/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
value holds for at least one contrast i: 
, where 
 describe s the 
Dunnett- distribution with correlation matrix 
 . 
The model with the minimum p-value will be fitted to the data.  
As a sensitivity analysis, all remaining significant models will 
be fitted to the data and model -based dose estimates will be 
calculated.  
Given established dose -response effects with MCP -Mod, PD 
effects will be analyzed based on pairwise comparisons of 
reduction in lymphocyte count from baseline for each active 
dose levels to placebo using an analysis of covariance 
(ANCOVA) model adjusted for baseline lymphocyte counts. 
Testing will be done with a two-sided significance level of 5%. 
The type -1 error will be controlled via a hierarchical ordering of 
the tests: pairwise comparison will be conducted in decreasing 
dose order.  
The dose -response data will be summarized with point -wise and 
model- based estimates, standard deviation and 95% confidence  
intervals (CI) on the reduction in lymphocytes from baseline at 
the examined dose levels. A plot of the estimated dose response curve with 95
% credibility interval limits will be presented 
along with the observed response at each dose.  
This analysis will be performed on the PD analysis set , and a 
supportive analysis will be performed on the FAS and the PPS.  
Exploratory efficacy endpoint analys is 
The exploratory efficacy endpoint change from baseline in 
SLEDAI -2K score at Week 12 will be analyzed  using an 
ANCOVA, with treatment and baseline score as factors. 
Missing values at Week 12 will be imputed using LOCF. The 
mean treatment difference incl uding 95% CI for each 
ACT -334441 dose compared to placebo will be presented. A 
sensitivity analysis will be performed using observed data 
without imputation.  
Other changes from baseline variables will be analyzed in a 
similar manner using an ANCOVA.  
All ex ploratory efficacy endpoints will be analyzed on the FAS 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 33/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
and PP S populations.  
No multiplicity adjustments will be made on exploratory 
efficacy endpoints.  
Safety endpoints  
Safety endpoints will be mainly analyzed descriptively by 
treatment gro up on the Saf ety S et. 
Sample size  
The sample size for the study was determined based on 
simulations.  A maximum % lymphocyte reduction compared to 
baseline of 70% was assumed based on results obtained in 
Phase 1 with ACT -334441 and with other S1P receptor  
modulators. A sample size of 64 subjects (12 in each 
ACT -334441 dose group of 0.5 mg, 1 mg, 2 mg , 4 mg , and 
16 in the placebo group) would provide an average power of at 
least 9 0% to show a significant dose response relationship at a 
one-sided significance level of 5%, under the assumption of a % 
lymphocyte reduction compared to baseline of 0% (mean at 
Week 12 = 2.0 × 109/L) for placebo and a maximum of 70% for 
any ACT -334441 dose (mean at Week 12 = 0.6 × 109/L). The 
pooled SD is assumed to be 0.45 × 109/L. This takes into 
account 10% of subjects being excluded from the PD analysis 
set.  
If Part B is not conducted and the 4 mg dose is not tested, then 
there will be an average power of at least 80% to show a 
significant dose -response relationship with three  dose level s at a 
one-sided significance level of 5%, using the same assumptions 
as above (based on a total sample size of  48 subjects  [12, 12, 12 
and 12 in placebo, 0.5 mg, 1 mg and 2 mg , respectively ]). 
Assumptions on the placebo response rate, maximum effect 
sizes and candidate dose -response models are based on the 
observed lymphocyte count in study AC-064-101. 
STUDY COMMITTEES  Independent Data Monitoring Committee  
An IDMC  has the overall responsibility for safeguarding the 
interests of subjects by monitoring data obtained in the study in 
an unblinded fashion and making appropriate recommendations 
based on the reported data, thus ensuring that the study is being 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 34/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
conducted with the highest scientific and ethical standards. The 
IDMC will be fully operational prior to enrolment of the first 
subject into the study. The IDMC will review unblinded data at 
regular intervals, will provide recommendation to apply study 
stopping rules (if indicated) and in addition wi ll review interim 
safety data collected  when all subjects enrolled into Part A have 
completed Visit 4  (Week 4) , unless prematurely discontinued  
[see Section  11.5] . The composition and operation of the IDMC 
is described in the IDMC charter.  
Ophthalmology Safety Board  
An Ophthalmology Safety Board ( OSB ) composed of two 
independent ophthalmologists will review and evaluate in a 
blinded fashion any new or suspected case of macular edema. The composition and operation of the OSB is described in the 
OSB charter.  
 
ACT -334441  
Systemic lupus e rythematos us 
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 35/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
 Table 1 Visit and assessment schedule  (same for part A and part B) 
Periods  Name  Pre-
randomization  Treatment period  FU Unscheduled  
Duration  Up to 30 days 12 weeks  16 weeks  NA 
Visits   Number  1 2 3 4 5 6 7 8 9 U1, U2,...  I  
Name  Screen ing Randomiz ation 
(15) W2 W4 W8 EOT  EOS  Phone call 
FU  Phone 
call  
FU Unscheduled 
(17)  Re-initiation 
Time  Day −30 to −1  Day 1  Week 2  Week 4  Week 8  Week 12 or 
earlier in 
case of 
premature 
discontinuati
on (16) Last study 
treatment 
intake + 6 
weeks  
 Last study 
treatment 
intake + 11 
weeks   
Last 
study 
treatment 
intake + 
16 weeks  Any day 
between Day 
1 and EOS For study 
treatment 
interruptions 
that started up 
to Day 14  
Visit window    ± 3 days ± 5 days ± 5 days ± 5 days ± 5 days ± 5 days ± 5 days NA 
Informed consent * X           
Inclusion/exclusion criteria * X X          
Demographics * X           
Medical history /smok ing status*  X           
SLE history * (1)  X           
Concomitant medications /SLE 
therapies*  X X X X X X X   X X 
Physical examination* (2)  X X X X X X X   X  
Body weight and height* (3)  X     X      
Disease activity sc ales*:  
SLEDAI -2K, PGA  X X  X X X X   X  
Quality of life questionnaire*:  
SF-36 v2™   X    X      
Chest X -ray (4) X           
SBP/DBP* (5;6)  X X X X X X X   X X 
12-lead ECG** (5) X X X X X X X   X X 
ECG -Holter** ( 7) X X          
Echocardiography*  X     X      
Spirometry** (8)  X  X X X X X     
Ophthalmological examination*  X . X X X X X     
OCT  X     X      
Hematology (9)/ blood 
Chemistry ** X X X X X X X   X  
Pregnancy test  */** (10) X X X X X X X X X X  
Viral serology  / tuberculosis 
test**  X           
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 36/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
Periods  Name  Pre-
randomization  Treatment period  FU Unscheduled  
Duration  Up to 30 days 12 weeks  16 weeks  NA 
Visits   Number  1 2 3 4 5 6 7 8 9 U1, U2,...  I  
Name  Screen ing Randomiz ation 
(15) W2 W4 W8 EOT  EOS  Phone call 
FU  Phone 
call  
FU Unscheduled 
(17)  Re-initiation 
Time  Day −30 to −1  Day 1  Week 2  Week 4  Week 8  Week 12 or 
earlier in 
case of 
premature 
discontinuati
on (16) Last study 
treatment 
intake + 6 
weeks  
 Last study 
treatment 
intake + 11 
weeks   
Last 
study 
treatment 
intake + 
16 weeks  Any day 
between Day 
1 and EOS For study 
treatment 
interruptions 
that started up 
to Day 14  
Visit window    ± 3 days ± 5 days ± 5 days ± 5 days ± 5 days ± 5 days ± 5 days NA 
Additional serum sample for 
viral serology ***  X          
ANA, anti -dsDNA antibodies, 
complement C3 and C4**  X X  X X X X   X  
Exploratory  biomarker s** (10)  X  X X X X     
Lymphocyte subsets *** (11)  X    X X     
Urine protein -to-creatinine 
ratio**  X X    X    X  
Urinalysis (di pstick)*  X X X X X X X   X  
PK sampling  (pre dose)***    X X X X X     
Study treatment  dispensing & 
accountability * (13)  X X X X X     X 
AEs* (14) X X X X X X X   X X 
SAEs* (14) X X X X X X X X X X X 
* Data collected in the eCRF  
** Electronically tran sferred to sponsor  
*** Sample collection d ate recorded  in the eCRF  (for PK samples, time will also be recorded) 
 
Assessments in part A and B are identical . 
Day 1 (date of Randomization visit) is to be used as the reference date for the purpose of calculati ng the subsequent visit dates (and time windows).  
For WOCBP , the serum pregnancy test at Visit 1 must be performed at least 3 weeks before the urine pregnancy test performed at Visit 2  prior to randomization . 
The intervals between Visit 4 (Week 4), Visit 5  (Week 8) and Visit 6 ( EOT ) should not exceed 36 days.   
(1) History of positive  ANA / anti -ds DNA antibodies  will be included . 
(2) Complete physical examination (i.e., inspection, percussion, palpation and auscultation) will be performed at Visit 1 ( Screen ing) and Visit 6 (EOT). A symptom -driven, 
abbreviated physical examination will be performed at all other visits in order to capture assessments needed for the SLEDAI -2K 
(3) Height only at Screening.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 37/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 
(4) A chest X -ray that has been performed within 3 mont hs prior to Screening  can be used (in this case, no need to repeat chest X -ray at Screening ). 
(5) On Day 1 and at re -initiation, SBP/DBP  assessment and 12 -lead ECG will be done pre -dose and hourly until 6 h post- dose; after 6  h, subjects may be discharged from the hospital 
if they meet the discharge criteria, otherwise SBP/ DBP  assessments and 12 -lead ECG will be performed hourly until discharge criteria are met. If discharge criteria are not met after 
12 h, the subject must be permanently discontinued. At a ll other visits , only pre -dose SBP/ DBP  assessments and 12 -lead ECG  will be performed .  
(6) At Screening , SBP/DBP  will be assessed  in supine position and after 1 to 3 minutes in standing position to assess orthostatic hypotension. At all other visits, SBP/D BP will be 
assessed in supine position.  
(7) At Screening , 24 hour ECG -Holter will start before 12:00. On Day 1 , 24 hour ECG -Holter will start immediately before dosing.   
(8) Two spirometry assessments will be performed at Visit 1 ( Screening ). The assessmen ts should be at least 5 days apart. The last assessment will count as baseline.  
(9) H ematology assessments including coagulation tests  will be performed at each visit until EOS  
(10) Serum pregnancy tests will be performed at Screening  and EOS. Urine pregna ncy tests  will be performed at all other visits (including telephone call s FU, 11 weeks and 16 weeks 
after study treatment  discontinuation).  
(11) IgM, IgG, IgA, CRP, fibrinogen , and BLyS will be measured in serum. At Randomization visit only, anti -Smith, anti-cardiolipin, and anti -ribosomal P will also be measured . 
EDTA plasma sample s will be shipped via central laboratory  to Actelion for analysis of CXCL10 and other soluble biomarkers potentially related to SLE and/or S1P 1 modulation . 
(12) Blood samples w ill be shipped via central laboratory to Actelion for lymphocyte subset s analysis.  
(13) No study drug dispensing at V3 and re -initiation visit  
(14) All AEs and SAEs that occur after signing the Informed Consent Form and up to 6 weeks (AEs) or 16 weeks (SAE s) after study treatment  discontinuation must be reported.  
(15) Prior to randomization, the following central lab oratory  results must be available to confirm eligibility: ANA, anti -dsDNA, Hepatitis B surface antigen, Hepatitis C, HIV1 and 
HIV2, varicella-z oster virus, urine protein -to-creatinine ratio, ALT/AST/TBIL, pregnancy test (if applicable) .  
(16) EOT visit should preferably take place 1 day after last study treatment  dose, and  no later than 7 days.  
(17) Unscheduled visits may be performed at any time  during the study . Recording of changes in concomitant medications and background SLE therapies since last visit  needs to be 
performed at each unscheduled visit. Further assessments including 12-lead ECG, SBP/DBP, SLEDAI -2K, PGA,  laboratory assessments for  SLEDAI -2K scoring (i.e., 
hematology/blood b iochemistry , urinalysis,  anti-dsDNA, complement C3 and C4 ) may be performed  at the discretion of the investigator . 
 
AE = adverse event; ALT = alanine aminotransferase; ANA = anti-nuclear antibodies ; anti-dsDNA  = anti-double -stranded DNA ; AST = aspartate aminotransferase; BLyS = 
B lymphocyte stimulator ; CRP = C -reacti ve protein; CXCL10 = C-X- C motif chemokine 10; ECG = electrocard iogram; eCRF = electronic Case Report Form; EDTA= 
ethylenediaminetetraacetic acid ; DBP  = diastolic blood pressure; EOS = End- of-Study; EOT = End -of-Treatment; FU = follow -up; HIV = human immunodeficiency virus; NA = not 
applicable; OCT = optical coherence tomography; PGA = Physician’s Global Assessment; PK = pharmacokinetic; SAE = serious a dverse event ; S1P 1 = sphingosine -1-phosphate 
receptor 1 ; SBP = systolic blood pressure; SF -36 = Short- Form 36; SLE = systemic lupus erythematosus; SLEDAI -2K = Systemic Lupus Erythematosus Disease Activity Index -2000; 
TBIL = total bilirubin; WOCBP = women o f childbearing potential . 
 
 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 38/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
 PROTOCOL 
1 BACKGROUND  
1.1 Systemic Lupus Erythematosus 
Systemic Lupus Erythematosus  (SLE) is a complex and heterogeneous  autoimmune 
disease of unknown etiology , characterized by the production of pathogenic 
autoantibodies, tissue deposition of immune complexes, and tissue damage across 
multiple organ systems.  The adaptive T and B cells and the innate immune system are 
considered to play a major pathophysiological role in this disease . 
SLE is primarily a disease of young women with a peak incidence between the ages of 
15 and 40 years [Borchers 2010; Pons- Estel 2010]  and a n estimated male to female ratio 
of 1:7 to 1:10 [Govoni 2006] .  
The natural history of  SLE is  characterized by relapses or flares, alternated  with periods 
of remission . The outcome is highly variable , ranging from p rolonged remission to high 
morbidity with progression of organ damage and death.  
Clinical manifestations of SLE include rash, arthritis, anemia, thrombocytopenia, 
serositis, nephritis, seizures, and psychosis among others [Rahman 2008].  Current 
treatment of SLE is based on the use of anti -inflammatory and immunosuppressive 
therapies. With improved diagnosis and tre atment, the life expectancy of SLE patients 
has improved from an approximate 4- year survival rate of 50% in the 1950s to a 15- year 
survival rate of 80% [ Abu-Shakra 1995] . 
1.1.1 Clinical manifestations and diagnosis  
The clinical presentation of SLE is highly heterogeneous and includes a constellation of signs and symptoms involving various organs with an undulating course and accumulation of organ involvement over time [Boumpas 1995a ; Boumpas 1995b] .  
The more commonly involved organ systems are mucocutaneous, musculoskeletal, renal, nervous, cardiovascular, pleura, and lungs. The mucocutaneous and musculoskeletal systems are involved in over 75% of SLE patients. While these common manifest ations 
are debilitating  and negatively impact the patients’ quality of life, the y are generally not 
fatal.  
Renal involvement occurs in one -half to two -thirds of patients and is associated with a 
poor outcome and mortality. Neuropsychiatric manifestations occur in about two-thirds of patients with varying manifestations, such as mood disorders, anxiety, and psychosis. Central nervous system ( CNS ) vasculitis and transverse myelitis are less common but 
serious acute manifestations. Most patients with SLE also  have general constitutional 
symptoms including fatigue, malaise, fever, anorexia, and weight loss.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 39/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The unifying laboratory abnormality of SLE is the presence of circulating autoantibodies 
including anti-nuclear antibodies  (ANA) . The American College of R heumatology 
(ACR) has designated 11 classification criteria incorporating major clinical features (mucocutaneous, articular, serosal, renal, and neurologic) and laboratory findings (hematologic and immunologic) , which have been recently validated for the d iagnosis of 
SLE [Petri 2012; Tan 1982; Hochberg 1997].  The presence of four or more criteria 
occurring either simultaneously or in succession is strongly suggestive of the diagnosis of 
SLE.   
1.1.2 Epidemiology 
Epidemiological studies of incidence and prevalence of SLE have shown large 
differences  in different regions of the world and within the same country. Of note, 
diagnostic criteria have been updated in 1997, and many  of the available epidemio logical  
studies are based on previous criteria . 
Recent publications (applying the most updated diagnostic criteria) reported overall prevalence rates (per 100,000 inhabitants) ranging from 45.3 in Australia to 100 in USA [Bossingham 2003; Lerang 2012; Chiu 2010; Mok 2011; Helmick 2008 ; Furst 2013] . 
Overall incidence rates (per 100,000 person- year) range from 3 in Norway to  7.2 in USA 
and 8.1 in Ta iwan [Lerang 2012; Chiu 2010; Furst 2013].  There are great differences in 
prevalence and incidence based on race: most of the studies indicate that SLE more frequent ly affects non -Caucasian individuals (e.g., in USA, the occurrence of SLE was 
three to four times higher among African -American than Caucasian women 
[Alarcón  2002; Danchenko 2006] ). 
Categorized as a fatal condition in the beginning of the last century, patients with SLE now live years if not decades after diagnosis. Since the mid -1970s, most studies in 
Europe, the U SA, Canada, and Latin America have demonstrated 5- year survival rates 
among newly diagnosed patients of over 90%, and 15- to 20- year survival rates of around 
80% [Mok 2011; Pons- Estel 2010] . In addition to failure of control ling renal and 
neurologic disease, infections and thrombosis are  the leading cau ses of death in SLE 
patients [Kataoka 2004; Cervera 2009; Ward 2006 ]. 
1.1.3 Current treatment s of SLE  
The current standard of care for treatment of SLE includes the use of non- steroidal 
anti-inflammatory drugs  (NSAIDs) , antimalarials,  glucocorticoids , and 
immunosuppressive drugs such as cyclophosphamide, m ycophenolate mofetil, 
azathioprine, or methotrexate . Guidelines for the pharmacological treatment of SLE were 
developed by the ACR in 1999 [ACR 1999] and the EULAR task force in 2008 [Bertsias 
2008] . 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 40/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The choice of therapy is highly individualized and depends on symptom manifestations, organ involvement, and disease severity. Life-threatening or organ -threatening 
manifestations of SLE, such as those involving the kidneys, CNS , or blood vessels are 
treated with high -dose corticosteroids, immunosuppressive drugs, and biologics. 
Prednisone, hydroxychloroquine, and belimumab are approved therapies for SLE; other 
therapies including immunosuppressive drugs, rituximab, and intravenous (i.v.) 
immunoglobulins are used off -label [Yildirim- Toruner 2011] . Management of disease 
refractory to standard treatments, especially nephritis, cutaneous and neuropsychiatric 
manifestations  as well as the prevention of disease flares , remain unsatisfactory and new 
therapeutic options are needed.  
This study will require patients to receive stable doses of at least one standard SLE therapy , which ma y include NSAIDs, antimalarials, glucocorticoids, methotrexate, 
azathioprine, or mycophenolate mofetil.  
1.1.3.1 Nonsteroidal anti- inflammatory d rugs  
NSAIDs  are commonly used to relieve SLE manifestations including arthralgia, 
inflammation, sero sitis, and fever. They can be used in combination with low doses of 
steroids or antimalarial agents  [Gurevitz 2013] .  
1.1.3.2 Antimalarial drugs  
Chloroquine- based antimalarial drugs such as chloroquine and hydroxychloroquine, often 
in combination with NSAID s, are generally used as a first -line treatment for patients with 
mild SLE. Hydroxychloroquine (Plaquenil
®) is approved for the treatment of SLE in the 
USA [FDA Plaquenil]  and in some European countries including United Kingdom, 
France and Belgium . 
Antimalarials were found to prevent lupus flares and increase long- term survival of 
patients with SLE [Ruiz- Irastorza 2010] . Antimalarials are most useful for constitutional 
symptoms (e.g., fatigue and fever), musculoskeletal, and skin manifestations. 
Antimalarials have also possible cardioprotective and thromboprotective effects  
[Jung 2010] . Common adverse effects  are gastrointestinal discomfort and dermatological 
reactions. Rarely, retinal toxicity has been reported , and regular eye examinations are 
recommended.  
1.1.3.3 Glucocorticoids 
Glucocorticoids rapidly relieve inflammation and modulate the immune system. The dose of glucocorticoid treatment depends on the severity and organ involvement in SLE.  
Low doses of oral prednisone (e.g., 0.1–0.2 mg/kg/ day) can be used for the treatment of 
cutaneous or musculoskeletal manifestations not responding to other treatments  and can 
help to prevent flares in clinically stable but serologically active patien ts [Gurevitz 2013; 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 41/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Amissah -Arthur 2010] . A medium dose of oral prednisone (e.g.,  0.5 mg/ kg/day) can be 
used for moderate SLE with cardiopulmonary or hematological involvement. Finally, a  
high dose of oral prednisone (e.g., 1 mg/kg/day) or pulse methylprednisolone i.v. is used 
to treat severe disease with major organ involvement including the kidneys, CNS , or 
blood vessels , often in conjunction with immunosuppressive agents such as 
cyclophosphamide or mycophenolate mofetil [Kalunian 2009].  
Long -term treatment with glucocorticoids  can have several adverse effects including 
hyperglycaemia, osteoporosis, hypertension , glaucoma, gastrointestinal discomfort, 
myopathy, and accelerated atherosclerosis for which patients should be monitored. The lowest dose and shortest effective duration of treatment should be used. 
1.1.3.4 Immun osuppressives  
Treatment with immunosuppressive s is reserved for patients with severe manifestations. 
These drugs usuall y include methotrexate, cyclophosphamide, mycophenolate mofetil, 
and azathioprine. Cyclosporine, tacrolimus, and leflunomide are used less frequently. 
Methotrexate has anti -inflammatory effects and can be beneficial in patients with 
articular and cutaneous  involvement, decreasing SLE activity and allowing the use of 
lower glucocorticoi d dose  [Fortin 2008; Yildirim- Toruner 2011] . Adverse effects include 
stomatitis, bone marrow suppression, hepatotoxicity, alopecia, and pneumonitis. Cyclophosphamide has a cytotoxic effect on lymphocytes. In conjunction with 
glucocorticoids, cyclophosphamide is the standard of care for treatment of severe 
organ- threatening manifestations including lupus nephritis , neuropsyc hiatric lupus, and 
systemic vasculitis [Kalunian 2009] . Adverse effects include cystitis, infertility, alopecia, 
malignancies, and infections.  
Mycophenolate (the active metabolite of mycophenolate mofetil ) blocks the proliferation 
of lymphocytes. M ycophenolate mofetil  is often used instead of cyclophosphamide in 
combination with glucocorticoids for the treatment of lupus nephritis. Mycophenolate 
mofetil can be used for  maintenance of renal response in patients with lupus nephritis  
[Dooley 2011] . Adverse effects include nausea, abdominal pain, diarrhea, bone marrow 
suppression, and infections. 
Azathioprine blocks lymphocyte proliferation. It is effective for treatment of articular and 
cutaneous manifestations  and is frequently used to manage mild lupus nephritis and as a 
steroid -sparing agent [Yildirim- Toruner 2011].  Adverse effects include bone marrow 
suppression, gastrointestinal intolerance, and hepatotoxicity. 
1.1.3.5 Biologics 
Belimumab is a human IgG1λ monoclonal antibody that inhibits B -cell activating factor 
(BAFF), also known as B- lymphocyte stimulator (BLyS) . 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 42/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Belimumab (Benlysta®) was approved by the FDA in 2011 for use in adult patients with 
active, autoantibody -positive SLE who are receiving standard therapy  [FDA Benlysta ] 
[Furie 2011; Navarra 2011] . In the EU , belimumab is approved as add -on therapy in adult 
patients with active, autoantibody -positive SLE with a high degree  of disease activity 
(e.g., positive anti-double- stranded DNA [anti-dsDNA] and low complement) despite 
standard therapy  [EMA Benlysta ]. Adverse effects observed in the clinical studies were 
mainly injection reactions.  Biologics have  reported therapeutic effects in SLE clinical 
studies. Rituximab depletes CD20+ B cells including autoreactive B  cells 
[Yildirim- Toruner 2011] . Although placebo -controlled trials in SLE failed to demonstrate 
clinical improve ment with rituximab, a number of small studies have suggested 
therapeutic benefit , and the drug is often used for treatment of severe refractory SLE 
especially lupus nephritis. Adverse effects include lymphopenia, neutropenia, and severe infections. 
Small clinical trials have reported beneficial effects of i.v. immunoglobulins, and this is 
sometimes used to treat refractory SLE. Other biologics with immunomodulatory 
activity , including abatacept (an inhibitor of T -cell activation), epratuzumab (a 
monoclonal antibody to CD22), blisibimod (a peptide inhibitor of BAFF) , have reported 
potential beneficial effects , and clinical studies are ongoing to confirm preliminary 
findings [Ding 2013].   
1.1.4 Unmet needs in SLE  
Despite the significant improve ments in diagnosing and managing the disease, treatment 
of SLE remains an area of significant unmet need. With the exception of belimumab, no 
new drug has received an approval for treatment of SLE in the last 50 years. Therapies for SLE consist of relatively non- specific immunosuppressive and anti -inflammatory 
drugs that are not effective in some patients and can be associated with significant side 
effects. Novel treatment options are needed for patient s with severe disease, especially 
renal and CNS manifes tations , and for patient s with disease refractory to conventional 
therapies. Although approved for treatment of SLE, belimumab has shown modest 
efficacy and slow onset of effect and is not approved for treatment of lupus nephritis or CNS lupus.  
There is a  great need for effective and safe steroid -sparing therapies that can help reduce 
toxicity from long -term use of high -dose glucocorticoids. Accelerated atherosclerosis and 
cardiovascular disease represent significant burden for patients with SLE that may b e 
exacerbated by chronic use of glucocorticoids. Fatigue is a very common symptom of 
SLE that negatively affects quality of life in the majority of SLE patients; none of the 
currently available treatments has shown significant effects on fatigue.  Furthermo re, the 
prevention of disease flares re presents also a high medical need.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 45/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The study has recently been completed , and main  findings of t he study are  summarized in 
the next section s. More detailed information can be found in the Investigator's brochure 
[ACT -334441 IB]. 
1.3.2.1 Clinical pharmacokinetics 
Followin g administration of single doses to male healthy subjects , the PK profile of 
ACT -334441 was characterized by low inter -subject variability (coeffic ient of variation 
[CV] < 30%  for area under the curve, maximum observed plasma concentration [ Cmax], 
and half life [ t½]). C max was achieved within 5 –6 h after dosing and t ½ was between 170 
and 199 h (~ 7–9 days). 
Following administration of multiple once daily ( o.d.) doses, steady -state conditions were 
attained between 20 –32 days of treatment , and the t ½ after the last administration was 
between 12 –22 days. ACT -334441 accumulated in plasma, with 5- to 9- fold higher C max 
and area under the curve  from 0 to 24 hours ( AUC 0-24) at steady -state when compared to 
the first day of treatment. C max and AUC 0- 24 were shown to be dose  proportional across 
the 0.5–4 mg dose range.  
The effect of food on the PK of a single 1 mg dose was investigated in study 
AC-064- 101. No relevant effect of food on the PK parameters of ACT -334441 was 
observed. Only limited  clinical data are currently available regarding the metabolism of 
ACT -334441. N o informat ion is available regarding the effects of disease (e.g., renal or 
hepatic impairment), age, or ethnicity on the PK of ACT -334441. Only limited data are 
available on the effects of sex on the PK of ACT -334441 (examination of the data from 
the 2 female subjects who received ACT -334441 suggest that the PK profile is not 
influenced by sex).  
1.3.2.2 Pharmacodynamics in humans 
Effect on lymphocyte count  
Oral administration of ACT -334441 at single doses ≥ 3 mg reduced lymphocyte count in 
humans. The extent of lymphocyte count reduction was dose  dependent. A reduction 
from baseline of approximately 76% was achieved after the highest single dose of 25 mg. 
The nadir in lymphocyte count was attained within 16 h following a given dose. After a single dose of ACT -334441, the lym phocyte count generally returned to normal range 
within 6 days.  
Repeated o.d. dosing of ACT -334441 (0.5 mg, 1 mg, 2 mg, or 4 mg) for 35 days led to a 
gradual, dose -dependent reduction in absolute lymphocyte count. Compared to baseline, 
multiple doses of A CT-334441 induced a decrease ranging from 34% to 64%  with doses 
from 0.5 mg to 4 mg . The time the mean lymphocyte counts  return ed to within normal 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 46/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
range (i.e., ≥ 1 × 109 cells/L) dose dependen tly increased  and was 28 days for the 4 mg 
dose group. 
No relevant differences in the effect on lymphocyte count reduction were seen after 
single -dose administration of 1 mg ACT-334441 in the fed and fasted states. 
1.3.2.3 Safety and tolerability  
Single doses of 1 mg, 3 mg, 10 mg, and 25 mg were evaluated in healthy subjects. The 
10 mg dose was identified as the maximal tolerated single dose of ACT -334441. In the 
25 mg group , a serious life -threatening event of hypotensive shock (preferred term: 
circulatory collapse) was reported. Per study stopping criteria, dose escalation wa s halted 
after the 25 mg dose group. One event of non -serious syncope of moderate intensity was 
also reported in the 10 mg treatment group.  
Multiple doses of 0.5 mg, 1 mg, 2 mg, and 4 mg ACT -334441 were administered o.d. for 
up to 35 days. All doses were found to be well tolerated, with no serious adverse events 
(SAEs ) and no adverse events ( AEs) leading to treatment discontinuation. The most 
frequently reported AEs in the active treatment groups were headache (37.5%) , chest pain 
(all combined chest pain, chest discomfort, musculoskeletal chest  pain, non -cardiac chest 
pain; 33.3%), followed by nasopharyngitis (16.7%), and dizziness (16.7%). 
Effect on heart rate 
In the single -ascending dose part of the study, a transient decrease in heart rate ( HR) was 
obser ved as the most frequent drug -related effect with ACT -334441, with maximal 
reduction reached approximately 4 h post-dose and resolved within 12 h after dosing. 
In the multiple -ascending dose (MAD) part of the study, a transient decrease in HR was 
observed on Day 1 following treatment with ACT -334441 in all dose groups, when 
compared to placebo. The HR changes from baseline were not clinically significant, did 
not increase with dose, and were followed by a return to baseline over time (between 
7 and 14 days of treatment), with repeated administration of ACT -334441. 
In Part D of study AC -064- 101, repeated administration of 2 mg ACT -334441 o.d. 
reduced the effect on HR of subsequent administration of 10 mg ponesimod, another 
S1P 1 modulator with first -dose effect on HR. This shows that chronic o.d. administration 
of a 2 mg ACT-334441 dose can lead to desensitization of S1P 1.  
Effect on blood pressure 
Blood pressure (BP) reduction was observed following a single high- dose administration 
(10 mg and 25 mg) , with a maximal reduction reached approximately 6 –8 h post -dose. In 
the MAD study, no relevant changes in BP were observed in the 0.5–4 mg dose groups 
following multiple o.d. dosing of ACT-334441. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 47/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Effect on liver enzyme elevations  
A transient increase in alanine aminotransferase ( ALT ) and/or aspartate aminotransferate 
(AST ) and/or gamma glutamyl transferase ( GGT ) was observed in 8 subjects on active 
treatment  after multiple doses of ACT -334441 (Part B) . These changes were transient and 
not accompanied by an increase in bilirubin. No relevant changes in other clinical 
chemistry variables were observed.  None of the out -of-normal- range values in ALT 
and/or AST and/or GGT were  considered as clinically significant , therefore  none were 
reported as an AE . 
Effect on pulmonary function test 
No relevant effects on mean forced expiratory volume in 1 second ( FEV 1) and forced 
vital capacity ( FVC ) were observed . 
1.4 Purpose and rationale of the study 
The central role of S1P 1 in T and B lymphocyte trafficking and the ability of an S1P 1 
modulator to reduce the availability of circulating lymphocytes create a promising 
therapeutic approach for several autoimmune diseases  including SLE. S1P modulation  
has been proven effective for the treatment of multiple sclerosis [Kappos 2010]  and has 
recently been shown to have therapeutic potential also in psoriasis [Vaclavkova 2014] .  
S1P 1 modulators, including fingolimod (non- selective), ponesimod and KRP203 (both 
selective for S1P 1), have shown benefi cial effects  in mouse model s of SLE. Positive 
effects have been observed on kidney disease, serological abnormalities, and survival 
[Okazaki 2002; Ando 2010; Alperovich 2007; Wenderfer 2008] . Based on these data, it is 
plausible to hypothesize a therapeutic effect of ACT -334441 in patients with SLE. 
Patients with SLE have a number of immune system abnormalities , with the disease 
involving multiple organs and systems. The complexity and heterogeneity of SLE manifestations make it important to initially characterize the safety and biological activity 
of a potential novel treatment. For these reasons, the main purpose of this study is to 
investigate the dose  response for lymphocyte count reduction and the safety and 
biological activity of ACT -334441 in SLE patients.  
Data from the non -selective S1P modulator fingolimod have shown that a 70% decrease 
in lymphocyte count compared to baseline is associated with efficac y in multiple 
sclerosis. Other selective S1P
1 modulators such as siponimod and ponesimod have also 
shown that a lymphocyte count reduction of 60– 70% from baseline is associated with a 
plateau of efficacy in  multiple sclerosis, while a 20 –30% reduction in lymphocyte counts 
is associated with minimal efficacy [Olsson 2014; Selmaj 2013].  
The dose levels of 0.5 mg, 1 mg, 2 mg, and 4 mg of ACT -334441 planned for this study 
were well tolerated and have shown lymphocyte count reduction from baseline in the 
range 34 –64% in healthy subjects in Phase 1. This approach is expected to allow the 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 48/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
characterization of the safety and biological activity for a range of potentially efficacious doses of ACT -334441 in SLE patients, and to possibly enable the selection of dose(s) for 
subsequent studies. 
2 STUDY OBJECTIVES 
2.1 Main objectives 
• To investigate the PD of ACT -334441 in adult subject s with SLE.  
• To investigate the safety and tolerability of ACT -334441 in adult subjects with SLE.  
2.2 Exploratory Objectives 
• To investigate the PK of ACT -334441 in adult subject s with SLE. 
• To investigate the effect of ACT -334441 treatment on disease activity in adult 
subjects with SLE.  
3 OVERALL STUDY DESIGN AND PLAN  
3.1 Study design  
This is a prospective, multicenter, multinational, randomized, double -blind, 
placebo -controlled, two -part, dose- response Phase 1/2 study.  
This study is divided in two parts:  
Part A  
Part A will consist of four parallel treatment groups  (including 0.5 mg, 1 mg, or 2 mg of 
ACT -334441 and placebo control). 
Approximately 48 subjects will be randomized (1:1:1:1)  via an interactive response 
technology (IRT) system  to one of four groups (i.e., 12 subject s in each group; three dose 
levels of 0.5 mg, 1 mg, or 2 mg ACT-334441, or placebo o.d.). 
Interim safety review  
An interim safety review will be conducted by the Independent Data Monitoring 
Committee (IDMC) when all subjects enrolled into Part A have completed Visit 4  
(Week  4), unless prematurely discontinued. The IDMC will then evaluate the sa fety 
profile of ACT -334441 in SLE patients and give a recommendation whether or not to 
continue the study as planned (i.e., proceed to Part B ) [see Section  11.5].  
Part B   
Part B  will consist of  two parallel  treatment groups (in cluding 4 mg ACT -334441 and 
placebo control). 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 49/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Approximately 16 subjects will be randomized (3:1) via an IRT system to one of two groups (i.e., 12 subjects receiving 4 mg ACT -334441 and 4 receiving placebo o.d.). 
Subjects enrolled in Part A are not eligible  for Part B.  
The overall study design is shown in Figure 1. 
Figure 1 AC-064A201 s tudy design 
  
 
 
EOT = End -of-Treatment; EOS = End -of-Study; FU = follow -up; IDMC= Independent Data Monitorin g 
Committee.   
3.1.1 Study periods  
There will be three periods in Part A and Part B: 
3.1.1.1 Screening  period  
This period starts up to 30 days before Randomization at the time of the Informed 
Consent Form (ICF) signing and ends with subject randomization. I t includes the 
Screening  visit and the pre- randomization assessments.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 50/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
3.1.1.2 Treatment  period  
The treatment period will last 12 weeks. Visits during the treatment period will include 
the post- randomization assessments of the Randomization visit and  visits at Weeks 2, 4, 
8, 12.  
The End-of-Treatment  (EOT) visit will take place at Week 12 or earlier in case of 
premature permanent discontinuation of study treatment. In all cases, the EOT visit 
should take place 1 day after the last dose of study treatment intake but no later tha n 
7 days after the last dose of study treatment  intake. 
3.1.1.3 Follo w-up period  
This period starts immediately after the last dose of study treatment intake and ends 
approximately 16 weeks after the last dose of  study treatment  intake. The End-of-Study 
(EOS ) visit will take place 6 weeks after the last dose of study treatment intake. 
After EOS , the subject will be followed up for an additional 10 weeks and will  be 
contacted by telephone for follow-up 11 weeks and 16 weeks after last dose of study drug  
intake for SAEs and pregnancy status assessments . 
3.1.2 Study duration 
The planned  study duration for Part A is a pproximately 11 months from 
First subject -First Visit (FSFV) to Last Subject -Last Visit (LSLV)  and approximately 
20 months until LSLV  from Part B .  
3.2 Study design rationale 
This Phase 1/2 study is the first ACT -334441 study in SLE patients and the first study of 
an S1P 1 modulator in SLE. The study has been designed to investigate the dose response 
for lymphocyte count reduction, and the safety, tolerability, PK, and biological activity of 
ACT -334441 in subjects with SLE who have at least one mucocutaneous and/or 
musculoskeletal manifestation despite receiving standard therapy. Because side effects of ACT -334441 may overlap with major organ involvement in SLE, patients with renal, 
cardiac, CNS, lung, and liver involvement are excluded. Patients with high disease 
activity (SLEDAI -2K >  12) will not be allowed to enter the study . (For the rationale of 
the study population, see Section  4.2.) 
A randomized, placebo -controlled, double -blind approach is used to eliminate bias in 
reporting safety and biological activity data. During the study , several decisions and 
assessments will have to be performed. In order to limit the risk of bias , specific 
measures are implemented to reduce the risk of unblinding . These measures include 
preventing access  to results of white blood cell (WBC) and lymphocyte counts to the 
study site personnel and sponsor’ s team , and preventing access of first -dose HR data 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 51/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
(12-lead electrocardiogram [ ECG ] on Day 1 and day of re -initiation and 24-hour Holter 
ECG on Day 1) to the the investigator, unless deemed necessary for patient  safety.  
The use of ACT -334441 as adjunctive therapy to the standard of care is  a suitable 
approach  that enables evaluation of ACT -334441 in the context of commonly used SLE 
medications. Background standard therapy for SLE is allowed to ensure feasibility and 
representativeness of the real -life setting , but the type and dose of background therapies 
are limited and required to be stable to avoid confounding the evaluation of safety and 
biological activity of ACT -334441.  
A 12-week treatment duration is considered adequate for the initial evaluation of 
potential risks associated with ACT -334441 treatment. Twe lve weeks is a sufficient time 
for ACT -334441 to reach steady -state concentration and is expected to allow an 
evaluation of  biological activity (e.g., lymphocyte count reduction) , an assessment  of 
acute effects on HR and atrioventricular ( AV) conduction, a s well as of potential effects 
on pulmonary function. A 6-week follow -up period is considered adequat e based on 
results from the  Phase 1 study in healthy volunteers , in which the lymphocyte count  
normalized within 28 days for the 4 mg dose group. Additiona l 11- week and 16-w eek 
follow-up telephone call s are implemented to further increase patients’ safety.  
The dose levels of 0.5 mg, 1 mg, 2 mg, and 4 mg of ACT -334441 planned for this study 
have shown a dose response for lymphocyte count reduction, with a dec rease in the range 
from −34 to −64% from baseline  in healthy subjects in Phase 1, and are expected to be 
efficacious doses  of ACT -334441 in SLE patients . 
The study will be performed in two parts . The first part (P art A) consists of a 
parallel -group treatment period, in which approximately 48 patients are randomized in a 
1:1:1:1 ratio to receive 0.5, 1, 2 mg ACT -334441 or placebo for 12 weeks. The second 
part ( Part B) consists of a parallel -group treatment period , in which approximately 
16 patients are rando mized in a 3:1 ratio to receive 4 mg ACT -334441 or placebo for 
12 weeks. For safety reasons, the second part testing the highest dose of 4 mg will commence only after an interim safety review of data from Part A is completed by the 
IDMC. This interim safety review will take place once all patients randomized in Part A 
have completed the Week 4 visit, unless prematurely discontinued. Four weeks of 
treatment are selected for this interim review  as, based on observations in healthy 
subjects, this is a sufficie nt time to approach a plateau in the reduction of lymphocyte 
counts and to detect the main adverse effects of ACT -334441 treatment , including acute 
effects on HR and AV conduction.  
Study- specific stopping rules will be applied separately for the first part (Part A) and the 
second part (Part B). For Part A, if 12 or more subjects out of the planned 36 subjects in 
the combined active dose groups (0.5, 1, or 2 mg), or 6 or more subjects out of the 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 52/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
planned 12 subjects in the 2 mg dose group, have been discontinued study treatment due to meeting any of the individual patient’s stopping rules as defined per safety area of interest [see Section  9.3], the entire study will be put on hold. A detailed safety signal 
assessment and recommen dations from IDMC and Health Authorities may allow a 
potential restart of the study.  
For Part B, if 4 or more subjects out of the planned 12 subjects in the active dose group (4 mg), have been discontinued study treatment due to meeting any of the individual 
patient’s stopping rules as defined per safety area of interest [see Section  9.3], all subjects 
included in P art B will stop study treatment. A detailed safety signal assessment and 
recommendations from IDMC and Health Authorities may allow a potential restart of the 
Part B.  
This study has been designed in accordance with the FDA guidance [FDA 2010] , draft 
EMA guidelines [EMA 2013]  and EULAR recommendations [Bertsias 2008]  for clinical 
investigations in SLE . 
3.3 Site personnel and their roles 
In order to maintain the blind throughout the study [see Section  5.1.5]  and to facilitate the 
performance of assessments required by the protocol , it is essential that: 
• the site personnel have the appropriate medical expertise to perform these assessments; 
• the roles are defined clearly upfront . 
 
It is recommended that the designated personnel remain unchanged throughout the entire course of the study  and that an adequately trained back -up is designated in case of 
absence of any of the staff listed below.  
At each site, the study staff will consist of: 
• A principal investigator; 
• A treating physician  (the principal investigator may be acting as treating 
physician);  
• A cardiac safety assessor (CSA) responsible for close cardiac monitor ing of the 
subject  on Day 1 after dosing and at study treatment re -initiation visits, as well as 
at other visits as needed  (for a given subject, the roles of treating physician and 
CSA  are irreconcilable and must be assumed by two distinct physicians); 
• An echocardiography specialist responsible for echocardiographies; 
• A clinical coordinator/study nurse (if required); 
• An ophthalmologist  responsible for the ophthalmological assess ments (incl. 
optical coherence tomography  [OCT] ); 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 53/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• A pulmonary function laboratory technician or expert responsible for spirometry. 
3.3.1 Principal investigator 
The principal investigator is responsible for the overall conduct of the study at the clinical 
site. I t is her/his responsibility to assign appropriate personnel to the protocol -requested 
assessments (including safety and efficacy) and to define their roles. The principal investigator oversees the accrual of appropriate subjects, the conduct of the study according to the trial protocol, and the collection of the required data. 
3.3.2 Treating physician 
The treating physician can be a rheumatologist or a physician with specific training and 
experience in the management of patients with SLE.  The principal investigat or may act as 
the treating physician .  
It is the responsibility of the treating physician to explain the study in all its aspects to the subject and to obtain her/his informed consent.  
The treating physician will be responsible for subject clinical care a nd management, e.g., 
eligibility evaluation, supervision of study drug administration, reporting of disease 
activity , safety monitoring (including recording and treating of AEs, SAEs, physical 
examination, and routine laboratory results) , and concomitant m edications  monitoring 
and reporting.  
The treating physician will be responsible for complet ing the Systemic Lupus 
Erythematosus Disease Activity Index -2000 ( SLEDAI -2K) and the Physician’s Global 
Assessment ( PGA). She/he must be trained to use the the SLED AI-2K. 
The treating physician can consult the CSA and/or a cardiologist for interpretation of 
12-lead ECG and 24-hour ECG assessments made at Visit 1 (Screening) and Visits 3 to 7 . 
The same physician must maintain the role of the treating physician for a g iven subject 
throughout the study. A back -up treating physician may conduct a subject study visit only 
if the primary treating physician is not available.  
3.3.3 Cardiac safety assessor 
The CSA  must be a physician adequately trained and experienced in cardiology or a 
physician who is experienced in making health care decisions based on ECG 
interpretation reports  that may be provided by another cardiologically experienced  
person. She/he can support the principal investigator  / treating physician  in making a 
decisio n on eligi bility of the subject prior to randomization, and in providing adequate 
treatment in case of cardiac events.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 54/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The CSA will be responsible to perform all BP, 12- lead ECGs and 24- hour Holter ECG 
assessments at Visit 2 ( Day 1) or at study treatment r e-initiation  as requested by the 
protocol [see Sections  7.2.2, 7.2.3, and 7.2.4] . This includes the hourly 12 -lead ECGs and 
systolic BP ( SBP) / diastolic BP ( DBP ) assessments during the first 6 hours a nd up to 
12 hours following the first study treatment  intake. She/he will independently assess the 
subject’ s eligibility for discharge [see  Appendix 4]  or study drug discontinuation [see  
Section s 5.1.9 and 5.1.10].   
While the exams themselves may be performed by a delegate (e.g., study nurse), the review and/or interpretation of 12- lead ECGs  and Holter ECG reports must be performed  
by the CSA only. T he reporting of BP and dates and time of ECG assessments will be  
performed  by a delegate (e.g., main study nurse  or clinical coordinator ) in the electronic 
Case Report Form  (eCRF) . 
Reports and alerts from 12- lead ECGs performed at Visit 2 (Day 1) or at study treatment 
re-initiation and from 24-hour Holter ECG performed at Visit 2 (Day 1)  will be sent only 
to the CSA and must not be shared with the treating physician.  
At Visit 2 (Day 1) or at study treatment re -initiation, significant fin dings (e.g., new ECG 
abnormalities, bradycardia), which in the view of the CSA meet the definition of an AE, 
must be reported to the primary investigator  / treating physician and recorded on an A E 
page of the eCRF. Any treatment administered by the CSA (if  applicable) will be 
reported to the primary investigator  / treating physician and recorded as concomitant 
medication in the eCRF.  
3.3.4 Echocardiography specialist 
The physician conducting  and interpreting  Standard 2D/Doppler echocardiography must 
have qualific ations equivalent at least to those defined for Level 2 training by the 
American College of Cardiology Board / American Heart Association clinical 
competence statement on echocardiography  [see Appendix 5; Quiñones 2003] . In case a 
sonographer conducts the examination, the physician must review and interpret  the 
results.  
3.3.5 Clinical coordinator / study nurse  
Depending on the organization of the investigational site, a clinical coordi nator / study 
nurse may be required to assist the principal investigator / treating physic ian in all aspects 
of subject management. She/he will be responsible for scheduling visits and assessments as planned in the study protocol, recording concomitant medications, maintaining source documentation, and transcription of data into the eCRF. She/he will instruct the subjects 
on study drug administration, and collect, process, and send all blood and urine samples 
to the central laboratory. Additionally, she/he may be responsible for coordinating the pulmonary function tests (PFTs), ophthalmological and cardiac examinations, and the  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 55/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
36-Item Short Form Health Survey v2 ( SF-36v2™) questionnaire. In the absence of a 
clinical coordinator  / study nurse, the above tasks will be performed by the principal 
investigator.  
Important note: A person supporting the principal investigator / treating physician in 
performing or reporting study assessments cannot be delegated by the CSA to conduct 12-lead ECG and Holter ECG at Day  1 or study re- initiation with unblinding potential. 
3.3.6 Ophthalmologist 
The ophthalmologist will review and interpret the ophthalmological examinations 
including OCT assessments as scheduled in the study protocol [ see Section s 7.2.7 and 
7.2.8] . In the event of findings observed at any visit during the study, the ophthalmologist 
will conduct further examination, as per local standard practice, to rule out or confirm the diagnosis, and the treating physician will be notified for reporting any AEs  or SAEs . 
3.3.7 Pulmonary function laboratory technician or expert  
Spirometry testing will be performed by a PFT technician, respiratory therapist or expert, or by a person with qualification s equivalent to those defined for a Registered Pulmonary 
Function Technologist  and/or Registered Respiratory Therapist  by the American 
Thoracic Society (ATS ) / European Respiratory Society (ERS) guidelines [Miller  2005a] . 
Minimum requirements include sufficient  education and  training to assure that the 
technician understands the fundamentals  of the tests, the common signs of pulmonary 
diseases  and the management of the acquired pulmonary function data [ Miller  2005a]  . 
To the extent logistically feasible, attempts should be made to have the same tester throughout the study for a subject. Back- up testers (PFT technician, respiratory therapist 
or expert , or an equally experienced  person according to the ATS/ERS guidelines 
[Miller  2005a ] may conduct spirometry if the primary tester is not available. All PFT 
technicians or other  experienced  persons participating in the study will be trained before 
study start on the specific study requirements and if compliance issues are identified. 
3.4 Study Committees  
3.4.1 Independent  Data Monitoring Committee 
An IDMC  has overall responsibility for safeguarding the interests of subjects by 
monitoring safety data obtained in the study in an unblinded fashion and making appropriate recommendations based on the reported data, thus ensuring that the study is being conducted with the highest scientific and ethical standards. The IDMC will be fully operational prior to enrolment of the first subject into the study. The IDMC will review 
unblinded safet y data at regular intervals, including frequency of AE s, adverse events of 
special interest  (AESI s), SAEs, AEs leading to treatment  discontinuation (by  dose and 
safety area of interest  dependent manner ). The IDMC will provide recommendation to 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 56/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
apply study stopping rules (if indicated [see S ection 9.3]). In addition, the IDMC  will 
review interim data from Part A when all subjects enrol led into Part A have completed 
Visit 4  (Week 4) , (unless prematurely discontinued) [see Section 11.5]  and will 
recommend  whether or not to continue the study as planned (i.e., proceed to P art B) . 
The composition and operation of the IDMC is described in the IDMC charter. 
3.4.2 Ophthalmology S afety  Board 
An Ophthalmology S afety  Board ( OSB) composed of two independent ophthalmologists 
will review and evaluate in a blinded fashion any new or suspected case of macular 
edema. The composition and operation of the OS B is described in the OS B charter.  
4 SUBJECT POPULATION 
4.1 Subject populati on description 
This Phase 1/2 study will enroll adult patients with a  confirmed diagnosis of SLE 
≥ 6 months, as defined by the 1997 update of the 1982 ACR revised criteria for 
classification o f SLE [Hochberg 1997; Tan 1982] . Per the classification, patients will 
have fulfilled ≥ 4 of the 11 ACR diagnostic criteria , either serially or simultaneously.  
Presence of at least one mucocutaneous or musculoskeletal manifestation including myositis, arthritis, rash, alopec ia, mucosal ulcers  will be required at Screening  [see 
Appendix 6] . A positive serum antibody test ( ANA or anti -dsDNA) at Screening  or a 
documented history of positive test will also be needed to ensure correct SLE diagnosis. 
Background therapies for SLE are allowed and at least one background therapy is required, with ACT-334441 used as adjunctive treatment.  This defines a target population 
with remaining active disease and an unmet need for additional treatment despite standard therap y. Concomitant background therapy for SLE is permitted if treatment has 
been stable for 30 days prior to randomization and will have to include at least one of the following: NSAID s, glucocorticoids , anti -malarials (hydroxychloroquine, chloroquine, 
quinacr ine), mycophenolate mofetil, azathioprine, or methotrexate. T he dose of these 
medications will be required not to exceed certain thresholds [see Section  4.3] and will be 
kept stable during the study.  
Patients with underlying pulmonary, cardiac or liver disease as well as patients with 
severe lupus (SLEDAI- 2K score > 12 points) will be excluded. Subjects with active lupus 
nephritis, as proteinuria > 1.0 g/24 h, or equivalent using spot urine protein- to-creatinine 
ratio or subject s with CNS lupus (e.g., aseptic meningitis, seizures, cerebritis,  
polyneuropathy, cerebrovascular disease) within 90 days prior to Randomization will be 
excluded from the study. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 57/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Please refer to Sections 4.3 and 4.4 for a complete listing of the inclusion/exclusion 
criteria for the study.  
4.2 Rationale for the selection of the study population 
Clinical manifestations of SLE are highly heterogeneous , ranging from fatigue, 
arthralgia,  oral ulcerations, skin rash to life -threatening renal, hematological, and 
neurological disease. Current treatments remain inadequate, with many patients having an incompletely controlled disease and suffering from debilitating side effects of therapies. Patients with active disease receiving standard therapies represent  a significant unmet 
need for new therapeutic options.  
Involvement of skin and/or joints is present in over 75% of SLE patients [see 
Section  1.1.1] . Inclusion of patients with muscul oskeletal  or mucocutaneous 
manifestations at Screening  ensures the inclusion of subjects representative of the major 
SLE population.  
Subjects  with severe SLE, active lupus nephritis and CNS lupus  are excluded due to 
potential increased risk for end -organ damage . In addition, subjects presenting organ 
manifestations (i.e., pulmonary, cardiac or liver disease) that could overlap with potential 
toxicities of ACT -334441 will be excluded. This approach is intended to minimize the 
risk of adverse effects and to  limit the type and dose  of glucocorticoids and 
immunosuppress ive therapies  that can confound the evaluation of safety, tolerability, and 
biological activity of ACT -334441. 
4.3 Inclusion criteria 
For inclusion in the study, all of the following inclusion criteria must be fulfilled. It is not permi ssible  to waive any of the criteria for any subject:  
1. Signed informed consent prior to initiation of any study-mandated procedure. 
2. Men or women ≥ 18 and ≤ 65 years of age . 
3. Women of childbearing potential (WOCBP) as defin ed in S ection  4.5.1:  
• must have a negative serum pregnancy test at Screening and a negative urine 
pregnancy test at Randomization at least 3 weeks apart ; 
• must agree to undertake a urine pregnancy test as indicated in Table 1 
(bi-weekly/ monthly) during the study and up to 16 weeks after study 
treatment discontinuation; 
• must use methods of contraception  as described in Section  4.5.2 from the 
Screening visit until 16 weeks afte r study treatment discontinuation.  
4. Presenting with a diagnosis of SLE  made at least 6 months prior to Screening, by 
fulfilling at least 4 of the 11 criteria for SLE as defined by the ACR  (criteria are 
cumulative  and do not need to be present concurrently)  [Tan 1982; Hochberg 1997] . 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 58/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
5. Presenting with a SLEDAI -2K score of at least 2 points for musculoskeletal or 
mucocutaneous manifestations (i.e., myositis, arthritis, rash, alopecia, mucosal ulcers ) 
at Screening.  
6. History or presence at Screening of positive ANA or anti- dsDNA antibodies. 
7. Currently treated  for at least 30 days prior to R andomization  with stable doses of  one 
or more of the following background medications: 
• NSAID s; 
• Corticosteroids (≤ 10 mg/day prednisolone or equivalent), 
• Anti-malarials (≤ 400 mg/day hydroxychloroquine, ≤ 500 mg/day 
chloroquine, ≤ 100 mg/day quinacrine)#, 
• Mycophenolate mofetil (≤ 2 g/day)#, 
• Azathioprine (≤ 2 mg/kg/day)#, 
• Methotrexate (≤ 20 mg/week)#. 
 
#Treatment with anti- malarials, mycop henolate mofetil, azathioprine, or methotrexate 
must have been started at least 90 days prior to Randomization and must not have been stopped within 30 days prior to Randomization. 
4.4 Exclusion criteria 
Subjects must not fulfill any of the following exclusion  criteria. It is not permissible to 
waive any of the criteria for any subject:  
 
Pregnancy and Breastfeeding  
1. Breast feeding, pregnant women or women planning to become pregnant during the 
study.  
SLE disease  
2. Subjects with active lupus nephritis (defined by proteinuria > 1 g/24 h, or equivalent 
using spot urine protein- to-creatinine ratio)  within 90 days prior to R andomization; 
subjects with CNS lupus (e.g., aseptic meningitis, seizures, cerebritis, 
polyneuropathy, cerebrovascular di sease) within 90 days prior to R andomization; 
subjects with lupus vasculitis within 90 days prior to Randomization.  
3. Subjects presenting with a SLEDAI- 2K score > 12 at Screening or at Randomization.   
Cardiovascular 
4. History or presence of cardiac rhythm disorders (e.g., sinoatrial heart block, second or 
third degree AV block, symptomatic bradycardia, atrial flutter or atrial fibrillation, 
ventricular arrhythmias, cardiac arrest).  
5. Resting HR < 55 bpm as measured by the pre -dose 12- lead ECG on Day 1; a n 
increased QT corrected for heart rate on the basis of Fridericia’s formula (QTcF ) 
interval of > 470 ms (females), > 450 ms (males) at Screening, or on Day 1 ECG prior to study treatment initiation.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 59/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
6. History or presence of ischemic heart disease.  
7. History or presence of myocarditis or endocarditis.  
8. Presence of valvular heart disease associated with symptoms or hemodynamic change.  
9. History of syncope associated with cardiac disorders.  
10. History or presence of cardiac failure.  
11. Systemic arterial hypertension not controlled by medication according to investigator 
judgment. 
12. History or presence of vascular thrombosis at any time or a history of pregnancy morbidity in the context of anti -phospholipid antibody syndrome within 5 years prior 
to Randomization. 
13. Clinically relevant hypote nsion according to inve stigator’ s judgment or orthostatic 
hypotension (i.e., > 20 mmHg decrease in SBP or > 10 mmHg decrease in DBP from supine to standing position measured between 1 and  3 minutes after standing) at 
Screening . 
14. Known pulmonary arterial hypertension of functional c lass III or IV .  
Pulmonary 
15. History or presence of severe respiratory disease or pulmonary fibrosis, based on 
medical history, lung function and chest X -ray (CXR) performed at Screening or 
within 3  months prior to S creening.  
16. Bronchial asthma or chronic obstructive pulmonary disease.  
17. Abnormal PFTs: FEV
1 or FVC < 70% of predicted normal value; FEV 1/FVC ratio 
< 0.7. 
Treatment s 
18. Treatment or planned treatment with the following medications *: 
a. Within 15 days or 5 half-lives of the medication,  whichever is longer , 
prior to Randomization: 
o β-blockers, diltiazem, verapamil, digoxin or any other 
anti-arrhythmic or HR-lowering systemic therapy ( list of drugs 
provided in Appendix 1) . 
o QT-prolonging drugs with known risk of torsades de pointes, for 
any indication (list of drugs provided in Appendix 2) . 
o Short- and long- acting β2 -agonists (e.g., albuterol, levalbuterol, 
formoterol, terbutaline salmeterol) . 
b. Within 30 days or 5 half -lives of the medication, whichever is longer, 
prior to Randomization: 
o Cyclophosphamide, cyclosporine, tacrolimus, sirolimus, etc.,  
o Pulse methylprednisolone , 
o Vaccination with live vaccines . 
c. Within 90 days prior to Randomization: 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 60/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
o Belimumab, leflunomide  
o Any investigational immunosuppressive or immunomodulatory 
agent (within 90 days or 5 half-lives of the drug prior to start of 
study treatment, whichever is longer).  
d. Within 12 months prior to Randomization: 
o B cell -depleting biological agents such as rituximab or 
ocrelizumab.  
e. Any time prior to R andomization: 
o Alemtuzumab , S1P modulators (e.g., fingolimod). 
*For immunosuppressants or anti -inflammatory drugs not listed among the fordidden 
medications, the investigator should discuss adequate wash-out time with the sponsor. 
Infection and i nfection Risk  
19. Active or lat ent tuberculosis  (TB) , as assessed by CXR  performed at Screening  or 
within 3 months prior to Screening , and interferon gamma release assay 
(QuantiFERON -TB-Gold®) at Screening , except if there is documentation that the 
subject has completed adequate and suc cessful  treatment for latent TB infection or 
TB disease previously. 
20. Ongoing known bacterial, viral or fungal infection that is of clinical concern in the 
judgment of the investigator. 
21. A history of any serious infection, defined as life -threatening or requiring i.v. 
antibiotics or hospitaliz ation, within 30 days prior to Randomization.  
22. Hepatistis B, C, congenital or acquired severe immunodeficiency or known human 
immunodeficiency virus (HIV) infection or positive HIV testing at Screening.  
23. Negative antibody test for varicella -zoster virus at S creening.  
Malignancy 
24. History or presence of malignancy (except for surgically excised basal or squamous 
cell skin lesions), lymphoproliferative disease, or history of total lymphoid irradiation.  
Transplantation 
25. History o r presence of bone marrow or solid organ  transplantation. 
Opht halmology 
26. Presence of macular edema or active uveitis.  
Metabolic and hepatic  
27. Type 1 or 2 diabetes that is poorly controlled according to investigator judgment, or 
diabetes complicated with org an involvement such as diabetic nephropathy or 
retinopathy. 
28. Moderate or severe hepatic impairment defined as Child Pugh Score B or C, 
respectively, based on measurement of total bilirubin  (TBL) , serum albumin, 
international normalized ratio (INR) , as well as on presence/absence and severity of 
ascites and hepatic encephalopaty . 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 61/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
29. TBL > 1.5- fold upper limit of normal (ULN; unless in the context of known Gilbert’s 
Syndrome). 
30. ALT or AST > 2 -fold ULN. 
Hematology 
31. Hemoglobin (Hb) < 9 g/dL. 
32. WBC  count < 2500/ µL (2.5 ×  109/L). 
33. Lymphocyte count < 800 / µL (0.8 ×  109/L). 
34. Platelets < 75,000/ µL (75 × 109/L). 
Renal  
35. Proteinuria > 1.0 g/24 hour or equivalent using spot urine protein- to-creatinine ratio.  
36. Estimated glomerular filtration rate < 60 mL/min/1.73 m2. 
Other categories  
37. History of clinically significant drug or alcohol abuse. 
38. Known allergy to S1P 1 modulators or any of the ACT -334441 formulation excipients  
[see Section 5.1.1] . 
39. Any other clinically relevant medical or surgical condition that in the opinion of the 
investigator would put the subject at risk if participating in the study.  
40. Subjects unlikely to comply with protocol, e.g., uncooperative attitude, inability to 
return for follow -up visits or likelihood of not completing the study including mental 
condition rendering the subject unable to understand the nature, scope, and possible consequences of the study. 
 
4.5 Criteria for women of childbearing potential 
4.5.1 Definition of childbearing potential  
A woman is considered to be of childbearing potent ial unless she meets at least one of the 
following criteria:  
• Previous bilateral salpingectomy, bilateral salpingo -oophorectomy or 
hysterectomy.  
• Premature ovarian failure confirmed by a specialist.  
• XY genotype, Turner syndrome, uterine agenesis. 
• Postmenopaus al, defined as 12 consecutive months with no menses without an 
alternative medical cause (ICH M3 definition).  
4.5.2 Acceptable methods of contraception  
WOCBP  [see Section 4.5.1]  must use one of the following methods of contraception 
from  Visit 1 (Screening)  up to at least 16 weeks  after study treatment discontinuation: 
i. Two methods of contraception, one from Group 1 and one from Group 2, defined as follows: 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 62/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
o Group 1: Oral, implantable, transdermal, or injectable hormona l contraceptives 
or intrauterine devices. If a hormonal contraceptive is chosen from this group, it 
must be taken for at least 1 month prior to Randomization. 
o Group 2: Female or male condoms, diaphragm or cervical cap .  
OR 
ii. Sterilization of the male partner  with documented post -vasectomy confirmation of 
the absence of sperm in the ejaculate. 
OR 
iii. Permanent female sterilization (tubal occlusion/ligation at least 6 weeks prior to Screening).  
OR 
iv. True abstinence from intercourse with a male partner only when this is in line with 
the preferred lifestyle of the subject.  
Rhythm methods or the use of a condom by a male partner alone are not considered acceptable methods of contraception for this study. 
The methods of contraception used (including non- pharmacological methods) must be 
recorded in the eCRF.  
4.6 Medical history 
4.6.1 General medical history  
Relevant medical history , as defined below, must be recorded in the eCRF : 
• Chronic medical conditions including cardiac, cardiovascular, pulmonary, CNS, liver 
function, renal function, eye disorder, and skin conditions a t any time in the past  
• New acute medically relevant  conditions including any serious infection, defined as 
life-threatening or requiring i.v.antibiotics or hospitalization in the past 6 months 
• Exposure to healthcare  settings in the past 3 months  (e.g., hospitalization, em ergency 
care admissions, visit to emergency medical services facility ) 
• Pregnancy morbidity (e.g., fetus loss, spontaneous abortion, premature birth) 
• Previous and concomitant baseline therapy [s ee Section 5.2]  
• History of chemotherapy , radiotherapy, operations, immunosuppression or any other 
relevant medical treatment 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 63/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
4.6.2 SLE- relevant disease  history  
SLE disease characteristics  as defined below , evidenced by documentation in the subject 
charts , will be recorded on the SLE history page of the eCRF:  
• Date of first SLE symptoms  
• Date of SLE diagnosis 
• SLE symptoms according to ACR criteria [ ACR 1997]  
1. Malar rash  Fixed erythema, flat or raised, over the malar 
emin ences, tending to spare the nasolabial folds  
2. Discoid rash  Erythematous raised patches with adherent 
keratotic scaling and follicular plugging; atrophic 
scarring may occur in older lesions  
3. Photosensitivity  Skin rash as a result of unusual reaction t o 
sunlight, by patient history or physician 
observation  
4. Oral ulcers  Oral or nasopharyngeal ulceration, usually 
painless, observed by physician  
5. Noner osive arthritis  Involving 2 or more peripheral joints, 
characterized by tenderness, swelling, or eff usion  
6. Pleuritis or Pericarditis  1. Pleuritis --convincing history of pleuritic pain or 
rubbing heard by a physician or evidence of 
pleural effusion OR  
2. Pericarditis --documented by electrocardigram 
or rub or evidence of pericardial effusion  
7. Renal disorder  1. Persistent proteinuria > 0.5 grams per day 
or > than 3+ if quantitation not performed 
OR 
2. Cellular casts --may be red cell, hemoglobin, 
granular, tubular, or mixed  
8. Neurologic Disorder  1. Seizures --in the absence of offending drugs or 
known metabolic derangements; e.g., uremia, 
ketoacidosis, or electrolyte imbalance  
OR  
2. Psychosis --in the absence of offending drugs or  
or known metabolic derangements, e.g., uremia, 
ketoacidosis, or electrolyte imbalance  
9. Hematologic Disorder  1. Hemolyti c anemia --with reticulocytosis  
OR 
2. Leukopenia --< 4,000/mm3 on ≥ 2 occasions  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 64/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
OR 
3. Ly mphopenia --< 1,500/ mm3 on ≥ 2 occasions 
OR 
4. Thrombocytopenia --<100,000/ mm3 in the 
absence of offending drugs  
10. Immunologic Disorder  1. Anti -DNA: antibody to native  DNA in 
abnormal titer  
OR  
2. Anti -Sm: presence of antibody to Sm nuclear 
antigen 1.  
OR  
3. Positive finding of antiphospholipid antibodies on:  
1. an abnormal serum level of IgG or IgM 
anticardiolipin antibodies,  
2. a positive test result for lupus anti coagulant 
using a standard method, or  
3. a false- positive test result for at least 6 
months confirmed by Treponema pallidum 
immobilization or fluorescent treponemal 
antibody absorption test  
11. Positive Antinuclear 
Antibody An abnormal titer of antinucle ar antibody by 
immunofluorescence or an equivalent assay at any 
point in time and in the absence of drugs  
 
In the eCRF, the date of first documented appearance and duration of the above ACR 
criteria will be recorded (when applicable).  
• History of detectabl e ANA or anti-dsDNA testing.  
o ANA  
 Date of testing  
 Titer value  
 Reference range  
 Test kit (e.g., Hep- 2 titer, ELISA)  
 Testing laboratory 
o Anti-dsDNA  
 Date of testing  
 Titer value  
 Reference range  
 Test kit (e.g., Far assay , ELISA)  
 Testing laboratory 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 65/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Important notes: If, at the Screening visit , ANA and anti -dsDNA results are negative per central laboratory 
testing, a positive historical test must be recorded  to assess patient eligibility  [see 
Section  4.3, inclusion criteri on 6] . A hi storical testing is considered positive  if ANA 
and/or anti -dsDNA antibodies was/were measured above the detection limit of the 
specific test kit used . The elevated ANA and/or anti -dsDNA should unequivocally be due 
to SLE in the opinion of the investigator. 
5 TREATMENTS 
5.1 Study treatment  
Study treatments include ACT -334441 and matching placebo, whi ch are administered 
during a 12-week double-blind treatment period. 
5.1.1 Investigational treatment: description and rationale 
ACT -334441 is supplied as capsules at the doses of 0.5 mg, 1 mg, 2 mg, or 4 mg. The 
matching placebo is supplied as identical capsules  formulated with the same excipients 
but without the active ingredient, ACT -334441. 
The four treatment doses  of 0.5 mg, 1 mg, 2 mg, or 4 mg were selected based on  PK, PD, 
safety, and tolerability results  from the Phase 1 study, where such doses were 
administered o.d. up to 35 days in healthy subjects [see Section  1.3.2] .  
Inactive ingredients of ACT -334441 formulation are: methycellulose, sodium lauryl 
sulfate, mannitol, colloidal silicon dioxide and dipalmitoylphosphatidylcholine ; the 
capsule shell contains  hydroxypropylmethylcellulose and titanium dioxide.  
5.1.2 Study treatment administration  
One capsule of ACT -334441 or placebo will be taken ora lly irrespective of food intake.  
The capsule will be swallowed as a whole. It is preferable that the capsule be taken each 
day at approximately the same time (preferably each morning).  
On the day of the study visits, study drug must be taken only after the com pletion of the 
pre-dose safety assessments ( SBP, DBP , ECGs, PFTs, laboratory tests) and PK sampling. 
5.1.3 Treatment assignment  
In Part A, a  total of 48 eligible subjects will be randomized in a 1:1:1:1  ratio to  
ACT -334441 0.5 mg, 1 mg, and 2 mg  or placebo . In Part B, a total of 16 eligible subjects 
will be randomized in a 3:1 ratio to  ACT -334441 4 mg or placebo.  
Each of the clinical study sites will be assigned a unique site number . At Visit 1  
(Screening ), all screened subjects will be assigned a study -specific subject number by the 
IRT system, which identifies the subject throughout the study. After having confirmed 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 66/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
the eligibility of the subject and prior to the start of study treatment, the investigator/delegate contacts the  IRT system  at Visit 2 to randomize  the subject. The 
IRT system  assigns a randomization number to the subject and assigns the bottle number 
that matches the treatment arm assigned by the randomization list to the randomization 
number. 
The randomization list is generated by the independent I RT provider  and is kept strictly 
confidential. 
5.1.4 Blinding  
5.1.4.1 Study drug material related blinding  
This study will be performed in a double -blind fashion. The investigator and study staff, 
the subjects, the clinical research associates ( CRAs ), all Clinical Trial Team (CTT) 
members at Actelion and Contract Research Organizations (CROs) involved in the 
conduct of the study will remain blinded to the treatment allocation until study closure. 
Actelion staff responsible for clinical trial supply will need to be unblinded to ensure 
adequate distribution of study treatment. These persons will be clearly identified, their 
unblinding will be documented in the trial master file , and they will not take part in any 
CTT meeting s after the study set -up has been completed. 
Until the time of unblinding for final data analysis, the randomization list is kept strictly 
confidential and accessible only to authorized persons who are not involved in the conduct and analysis of the study  [see Section 5.1.5] . A sealed randomization code is 
kept by Actelion Global Quality Management in a safe cabinet. A second set will be provided to the statistician of the Independent Statistical Analysis Center ( ISAC ) for the 
production of unblinded IDMC statistical outputs. 
The investigational treatment and its matching placebo are indistinguishable , and all 
bottles will be packaged in the same way.  
5.1.4.2 Functional blinding  
First-dose effects on HR  and AV conduction and lymphocyte  counts reduction have been 
identified as potentiall y unblinding information. Access to this information by the site’s 
staff and sponsor’s study team will be restricted.   
The following measures will be taken to ensure that the  main site staff and the Actelion 
study team will remain blinded to lymphocyte counts and that the medical review of 
cardiac safety assessments with unblinding potential will be performed without 
introducing bias:  
• Results of the total WBC count and total lymphocyte count will not be 
communicated to the sites, sponsor, and CRO unless  a total lymphocyte count 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 67/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
< 200 cells/ µL at any study visits until EOT or < 800 cells/  µL at EOS, is 
recorded by the central laboratory . In these events  an alert will be sent to the 
principal investigator and to the sponsor including lymphocyte  count results . 
Follow-up monitoring must be provided as described in Section 5.1.10.2. 
• Blood samples for lymphocyte subset exploratory analysis will be analyzed by the 
sponsor within 6 days after sampling. In order to avoid potential unblindi ng, the 
blood sam ples will be shipped to Actelion  via the central laboratory with 
scrambled identification number s. The Actelion team performing the analysis will 
be separated from the Actelion study team and will not have access to the subject 
number , date and time of the sampling (i.e., baseline or EOT ) prior to database 
lock. 
• At the site level: 
o  A CSA will perform and evaluate the cardiac safety assessments on Day 1 
(Randomization) and on days of study treatment re- initiation . 
o The subject will be instructed not to discuss any results r elated to the 
first-dose administration (i.e., ECG results)  with the principal investigator  
/ treating physician  or any other blinded site personnel.  
o The central reading reports on 12-lead ECG  and 24-hour Holter ECG  
perfo rmed after first dosing will be sent to the CSA  only and must not be 
shared with the principal investigator  / treating physician.  
o The principal investigator  / treating physician and the CSA  must not 
discuss any issues related to subject  care and management o n Day 1 or 
first day of study drug re -initiation, unless mandated for subject safety  
reasons . The principal investigator should not access the blinded ECG 
results , unless medically mandated to ensure subject’s safety . 
• At the sponsor level : 
o  The medical rev iew of all first-dose data assessed on Day 1 
(Randomization) or on days of study treatment re -initiation (including 
hourly post -dose 12- lead ECGs and 24- hour Holter ECG data with 
unblinding potential , as well as  other relevant data) will be performed by a 
first-dose monitor . He/she will only discuss the first- dose data with the 
CSA, the site CRA and/or IDMC members . Further details on the role of 
the first -dose monitor are described in the first -dose monitor charter. 
o Other sponsor team members involved in t he medical review of other 
study data will not have access to first-dose data.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 68/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
5.1.5 Unblinding  
5.1.5.1 Unblinding for final analyses 
Full randomization information will be made available for data analysis only after 
database closure in accordance with Actelion  standar d operating procedures ( SOPs). 
5.1.5.2 Unblinding for interim analyses 
An I SAC, not otherwise involved in the design, conduct and analysis of the study, will 
have access to the randomization code in order to prepare the interim analysis reports and 
unblinded periodic reports for review by the IDMC  during the course of the trial. The 
randomization code will be made available to the ISAC in accordance with the sponsor’s 
SOPs . 
5.1.5.3 Unblinding before final analyses 
The randomization code will be made available to the PK bioanalytic laboratory in 
accordance with the sponsor’s SOPs.  
5.1.5.4 Unblinding for suspected unexpected serious adverse reactions  
When a suspected unexpected serious adverse reaction (SUSAR ) occurs for a subject 
participating in the study, Actelion Global Drug Safe ty will request the unblinding of the 
treatment assignment. The randomization code will not be communicated to the site staff or to the Actelion study team; unblinded SUSAR information will be anonymized and provided to Actelion Global Drug Safety, respective health authorities and Institutional 
Review Boards (IRBs) / Independent Ethics Committees (IECs), and the IDMC . SUSARs 
will be reported to investigators in a blinded fashion. 
5.1.5.5 Emergency procedure for unblinding  
The investigator, study staff and sponsor staff must remain blinded to the subject’s 
treatment assignment. The identity of the study treatment may be revealed only if the 
subject experiences a medical event, the management of which would require knowledge of the blinded treatment assignment. In this case, the investigator can receive the unblinded randomization code for study treatment allocation through the IRT system . In 
these situations, the decision to unblind resides solely with the investigator. Whenever it is possible and if it does not interfere with (or does not delay) any decision in the best interest of the subject, the investigator should discuss the intended code break with the 
sponsor. 
The occurrence of any code break during the study must be clearly justified and 
explained by the inve stigator. The investigator must not disclose the unblinded treatment 
in the eCRF or to the sponsor or its delegates. In all cases, the sponsor must be informed 
as soon as possible before or after the code break.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 69/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The circumstances leading to the code break must be documented in the site study file 
and e CRF.  
Refer to the IRT system  guidelines for complete information regarding the IRT system  
procedures for randomization, study drug assignment, and unblinding. 
5.1.6 Study treatment supply  
Manufacture, labeling, pack aging and supply of study treatments will be  conducted 
according to Good Manufacturing Practice, Good Clinical Practice ( GCP ) and any local 
or national regulatory requirements. 
All treatment supplies are to be used only in accordance with this protocol  and not for 
any other purpose. 
5.1.6.1 Study treatment packaging and labeling 
5.1.6.1.1 Study treatment packaging and preparation 
Study treatment (ACT -334441 or placebo) is provided as capsules  and is  supplied in 
childproof bottles . 
5.1.6.1.2 Study treatment labeling 
Study treatment is labeled to comply with the applicable laws and regulations of the 
countries in which the study sites are located.  
The batch number and the retest date (or expiry date) will be given on the study treatment 
labels .  
5.1.6.2 Study treatment distribution and storage  
Treatment supplies must be kept in an appropriate, secure area and stored according to 
the conditions specified on the medication labels.  
5.1.6.3 Study treatment dispensing  
The subjects will receive sufficient study treatment to cover the period up to the next 
scheduled visit. Subjects are asked to return all used, partially used and unused study 
treatment bottles  at each visit. The protocol -mandated study drug dispensing/return 
procedures may not be altered without prior written approval from the sponsor . An 
accurate record of the date and amount of study treatment dispensed to each subject must be available for inspection at any time.  
5.1.6.4 Study treatment return and destruction  
On an ongoing basis and/or upon termination of the study, the CRA  will collect used and 
unused subject kits, which will be sent to the warehouse, where the sponsor  or a 
representative will check treatment reconciliation. In certain circumstances, used and 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 70/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
unused treatment bottle s may be destroyed at the site once treatment accountability is 
finalized and checked by the sponsor  or a representative, and written permission for the 
destruction has been obtained from the sponsor 
If the CRA  is not able to reconcile the treatment due to lost or prematurely destroyed 
bottles prior to destruction, the site is to provide detailed documentation that describes the 
loss or premature destruction to justify treatment accountability.  
5.1.7 Study treatment  accountability and compliance  with study treatment  
5.1.7.1 Study treatment accountability  
The inventory of study treatment dispensed and returned (i.e., study treatment accountability) must be performed by the study staff on the day of the subject visit and before providing further study treatment. It is recorded on the investigational medic inal 
product dispensing and accou ntability log and in the eCRF and checked by the CRA  
during site visits and at the end of the study. The study treatment accountability log in the eCRF will include at least the following information for each study treatment bottle  
dispensed to the subject : 
• Dispensed bottle number 
• Date dispensed / number of  capsules  dispensed (pre-populated in e CRF)  
• Date returned  / number of capsules  returned  
All study treatment supplies, including partially used or empty  bottles , must be retained 
at the site for review by the CRA.  
If the subject forgets to bring the remaining study treatment to a study visit, he/she must be instructed to not take any tablet/capsules from the remaining s tudy treatment and to 
bring it to  the next visit.  
5.1.7.2 Study treatment compliance  
Treatment compliance will be assessed based on study treatment accountability: 
Accountability based compliance =  
[(number of capsules  dispensed at Visit n − number of capsules  returned at Visit n+1) / 
number of capsules  that should have been taken during the period*] × 100 
*The period is defined as the number of days elapsed between the respective visits.  
During the study, study treatment compliance based on accountability  is expected to be 
above 80%. If below 80% , without a medical  justification  (e.g., adverse even t), this will 
be considered as a protocol deviation. The investigator must check with the subject the 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 71/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
reasons for this non- compliance and discuss actions to be taken to avoid re -occurrence at 
the next visit.  If the subject forgets to bring the remaining st udy treatment to a study visit, 
he/she will be asked to bring it to  the next visit.  
At Visit 3 and re -initiation visits , a compliance review based on study drug 
accountability, will be performed by the investigator  (or delegate) and recorded in the 
eCRF.  
5.1.8 Study treatment interruptions  
Study treatment should not be interrupted. If study treatment intake is interrupted by the 
subject  for a day or more for any reason, she/he must immediately inform the principal  
investigator  / treating physician.  If a subject f orgets to take study treatment in the 
morning, s he/he should take it on the same day and resume regular dosing the next 
morning. 
The following guidance is provided for re -initiation of study treatment after study 
treatment interruptions.   
Note that under no circumstances  should a subject take more than one capsule per day. 
5.1.8.1 Between Day 1 and Day 14 
• If the subject misses to take the dose for 1 day or more , he/she must interrupt the 
treatme nt and immediately inform the principal investigator / treating physician. A 
re-initiation visit should take place within 7 days  after the first dose  was missed . 
Re-initiation of study treatment must be monitored on site following the cardiac 
assessment schedule and applying the discharge criteria as on Day 1.  
• If the study tr eatment cannot be re- initiated within 7 days after the treatment 
interruption, the subject should be permanently discontinued. (Note that re -initiation 
visits may be performed after Day 14 if initial mis sed dosing occurred between 
Day 7–14) 
• If, at any visi ts (scheduled or unscheduled) , the subject reports to the investigator 
having missed to take the dose for one or more days during  the initial 2 weeks of 
treatment (Day 1 to Day 14) but has then resumed  study treatment without reporting 
promptly the interruption to the investigator, information on any event potentially 
related to the interruption should be collected and the subject should be  counselled  on 
the risks of non- compliance. Based on the information available, the investigator may 
decide to permanen tly discontinue the subject or to continue study treatment as 
planned. No re-initiation should be performed  in such a case. 
Note that a  subject can be re- initiated only once during the study duration. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 72/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
5.1.8.2 After Day 14 
• If the subject missed doses for less than 7 consecutive days: 
o Regular dosing should be continued with the morning dose on the following 
day. 
o Subjects must be instructed to contact the investigator immediately if they experience any symptoms of bradycardia (e.g., dizziness, vertigo, syncope).  
• If the subject missed doses for more than 7 consecutive days: 
o The subject should be permanently discontinued. 
A schematic overview is provided in Figure 2. 
Figure 2 Algorithm for management of study treatment interruptions  
 
5.1.9 Premature discontinuation of study treatment  
The decision to prematurely discontinue study treatment may be made by the subject, the investigator , or Actelion.  The main reason and whether discontinuation of st udy 
treatment is the decision of the subject, the investigator, or Actelion must be documented in the e CRF.  
A subject has the right to prematurely discontinue study treatment at any time by withdrawal from study treatment only or by withdrawal from any further participation in 
the study (i.e., prema ture withdrawal from the study  [see Section  9.2]). 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 73/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The investigator should discontinue study treatment for a given subject if, on balance,  
she/he believes that continued administratio n would be contrary to the best interests of 
the subject.  Study treatment may be discontinued in response to an AE, lack of efficacy 
(including disease progression, treatment failure, worsening of subject  condition), a 
protocol deviation (including not mee ting eligibility criteria , non- compliance with study 
requirements, such as non- compliance with study treatment intake or visit attendance), or 
if the subject is lost to follow -up. Study -specific criteria for discontinuation of study 
treatment are described  in Section  5.1.10. 
Premature discontinuation of study treatment may also result from a decision by Actelion, e.g., in case of premature termination or suspension of the study [see Section  9.3].  A subject who prematurely discontinues study treatment is not considered as 
withdrawn from the study , provided that the subject’s consent for this limited 
participation in the study has not been withdrawn. Subjects who prematurely discontinue 
study treatment will be asked to return for an EOT visit within 7 days of last study 
treatment intake,  to attend a n EOS  Visit 6 weeks after the last dose of study treatment and 
will be followed -up for a total of 16 weeks after last study tr eatment intake ( telephone 
call follow-up for pregnanacy and SAEs). 
A subject who prematurely discontinues study treatment and withdraws consent to participate in any further study assessments is considered as withdrawn from the study. Subjects who die or a re lost to follow -up are also considered as withdrawn from the 
study. Withdrawal from the study and follow-up medical care of subjects withdrawn from the study is described in Sections  9.2 and 9.4,  respectively . 
5.1.10 Management of clinical events and s tudy -specific criteria for interruptio n / 
premature discontinuation of study treatment  
5.1.10.1 Cardiovascular 
Subjects must be permanently discontinued from study treatment if any of the following 
occurs:  
• HR < 40 bpm at two consecutive hourly 12- lead ECG post -dose on Day 1 (or on 
days of re -initiation following study treatment interruptions), or 
• SBP < 90 mmHg at two consecutive hourly BP measurements post- dose on Day 1 
(or on days of re-initiation following study treatment  interruptions ), or 
• The subject does not meet the criteria for discharge from the hospital on Day 1 (or 
on days of re -initiation following study treatment interruptions) after 12 -hour 
post-dose monitoring [see Appendix 4] , or 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 74/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• QTcF > 500 ms is observed at any time throughout the study, as documented by 
12-lead ECG.  
In addition, the investigator should consider permanent discontinuation of study 
treatment if a subject reports at any time symptomatic  bradycardia or hypotension (e.g., 
syncope).  
Follow- up monitoring will have to be provided until the event resolves, the condition is 
stable, or the change is regarded as no longer clinically relevant.  
Continuous ECG monitoring is recommended for subjects  who meet study treatment  
discontinuation criteria related to bradycardia or other arrhythmia. Subjects who are permanently discontinued should not be discharged from the monitored setting before vital signs return to near baseline values and until there is no persisting ECG abnormality (e.g., QT prolongation, AV block second degree or higher) or ongoing AE requiring (continued) hospitalization, or until medically indicated. Any clinically relevant finding s 
meeting the definition of an AE will be recorded a ccordingly in the eCRF.  
In case of any signs and symptoms of bradycardia or other arrhythmia (e.g., syncope, palpitations,  dizziness ) at any time during the study treatment, the  CSA  should be 
consulted. In case a cardiac origin of any event is suspected, p ermanent discontinuation 
of study treatment should be considered. 
In case subjects develop new  or worsening of pre -existing hypertension during the course 
of the treatment with the study treatment that in the opinion of the investigator cannot be 
adequatel y controlled by medications, study treatment should be permanently 
discontinued.  
5.1.10.2 Immune system  
Subject s must be permanently discontinued from study treatment at any time throughout 
the study in the event of: 
• Confirmed total lymphocyte count < 200 cells/ µL 
Confirmation will be done as follows: 
Whenever a total lymphocyte count < 200 cells/ µL, is recorded by the central laboratory, 
an alert will be sent to the principal investigator and the sponsor. The primary 
investigator will immediately contact the subje ct and ask her/him to return to the site 
within 48 hours at the latest to repeat the test at trough level (pre -dose) by the central 
laboratory (unless the clinical situation mandates an immediate local testing) . If the 
repeat test confirms a total lymphocy te count < 200 cells/ µL, the study treatment must be 
discontinued, and lymphocyte counts must be monitored on a  regular basis (e.g., every 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 75/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
2 weeks) at least until the EOS visit (6 weeks after study drug discontinuation).  If 
lymphocyte count is still < 800 cells/µl at the EOS visit, monitoring should continue on a 
regular basis (e.g., every 2 weeks) by the local laboratory until the lymphocyte count has 
returned to ≥ 800 cells/ µL or until medically indicated.  
In the event that clinically relevant, persistent blood cell count abnormalities  (e.g., a 
marked abnormal low value for neutrophils , RBC  or platelets flagged “LLL” ; see 
Appendix 7) are observed, the investigator should consider permanent discontinuation of 
study treatment and/or discontinuation of concomitant immunosuppressive medications. 
5.1.10.3 Respiratory system  
In case of abnormal spirometry results or persistent respiratory symptoms (e.g., dyspnea) , 
the subject will be closely observed, spirometry  assessments will be repeated, and study 
treatment must be permanent ly discontinued, according to the guidance provided in 
Table 2 and below. Table 2 Guidelines for FEV
1 and/or FVC decrease  
 
Item  Parameter  Guideline  
1 If FEV 1 and/or FVC > 15% decrease from the study 
baseline.  Repeat spirometry assessments 
preferably within 1 week  
See item 1a, 1b.  
1a If at repeat spirometry  assessment : 
FEV 1 and/or FVC > 15% decrease from the study 
baseline.  Permanently discontinue study 
treatment  and perform FU 
spirometry  assessments . 
1b If at repeat spirometry  assessment : 
FEV 1 and/or FVC ≤ 15% decrease from the study 
baseline.  Resume regular spirometry assessment 
schedule.  
If at any other scheduled assessment 
FEV 1 and/or FVC > 15% decrease 
from  the study baseline: 
permanently discontinue study 
treatment and perform FU 
spirometry  assessment . 
FEV 1 = forced expiratory volume in 1 second; FVC = forced vital capacity ; FU = follow -up. 
 
If clinically significant, persistent respiratory AEs (e.g., dysp nea) are reported , PFTs  must 
be performed and study treatment must be permanently discontinued. Further diagnostic 
work -up and consultation with a pulmonologist or other specialist should be considered 
according to local practice and the clinical situation .  
In all cases of permanent study treatment discontinuation, follow-up monitoring must be 
provided until respiratory AEs  are resolved and changes in pulmonary function are no 
longer clinically relevant  or until medically indicated . 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 76/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
5.1.10.4 Pregnancy 
If a subject  becomes pregnant while on study treatment, study treatment must be 
permanently discontinued. 
If a subject has a positive urine pregnancy test, study treatment must be interrupted 
immediately. A serum pregnancy test must be performed as soon as possible. If  the 
pregnancy is confirmed, study treatment must be permanently discontinued (apart from study drug , also some co-medications may have to be considered for discontinuation). If 
the result of the serum pregnancy test is negative, study drug may be re -initiated as 
indicated in study treatment interruptions section  [see Section  5.1.8] .  
5.1.10.5 Liver abnormalities 
In case of abnormal liver tests (LTs) or signs and symptoms  suggestive of drug-induced 
liver injury (DILI), the subject will b e closely observed, LTs will be repeated, and study 
treatment must be permanent ly discontinued, according to the guidance provided in 
Figure 3. 
Figure 3 Guidance for monitori ng liver test abnormalities 
 
* Symptoms includ e unusual lethargy or fatigue, nausea, vomiting, right upper quadrant pain or tenderness, jaundice, 
anorexia, dark urine, fever, rash, itching and/or eosinophilia (>5 %) ; ** Investigator may consider permanent  
discontinuation  
AST = aspartate aminotransferase, ALT= alanine aminotransferase, INR = international normalized ratio, LT = Liver 
test, TBL = total bilirubin, ULN = upper limit of normal.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 77/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
When  marked abnormalities levels for AST, ALT, TBL or INR are reached as indicated 
in Figure 3, an alert will be sent by the central laboratory , to the principal investigator and 
the sponsor, as defined in Appendix 7. The sponsor will contact the principal i nvestigator 
to ensure that she/he will immediately contact the subject to enquire about symptoms and 
ask her/him to return to the site within 72  hours at the latest to repeat the test by the 
central laboratory (unless the clinical situation mandates immediate local testing). In the case of repea ted abnormal LFTs within 72 hours, the subject will be closely observed and 
liver enzyme and bilirubin tests will be repeated by the central laboratory or locally  
according to the scheme illustrated in  Figure 3. Further diagnostic work- up and 
consultation with a hepatologist or other specialist should be considered according to local practice and the clinical situation.  
In all cases of permanent study treatment discontinuation, follow-up monitoring must be 
provided until signs and symptoms  have resolved and changes in liver function 
abnormalities  are no longer clinically relevant  or until medically indicated . 
5.1.10.6 Ocular abnormalities 
Subject s with suspected macular edema or retina l vasculitis should be confirmed by 
diagnostic work-up as recommended by local guidelines  (e.g., OCT, fluorescence 
angiography) . The O SB will receive all  information related to suspected cases of macular 
edema and will perform a review  of OCT results and the subject ’s data. In case of 
confirmed macular edema, study treatment must be permanently discontinued and the 
subject must be followed up until resolution or until medically indicated . 
5.1.10.7 Infections  
Infections are a leading cause for morbidity and mortality  in subjects with SLE 
[Danza 2013] . Bacterial infections are most frequent , followed by viral and fungal 
infections. Disease activity, disease duration, leukopenia, use of glucocorticoids and immunosuppressives have been linked to increased risk of infections in SLE patients , in 
particular in the respiratory system and urinary tract as well as in the skin and soft tissues.  
Diagnosis of infections may be delayed because they may mimic an SLE flare, therefore the investi gator needs to maintain a high level of vigilance  [Mosca 2010] .  
TB infection in SLE is mainly localized to the lung with upper lobe infiltrates, miliary 
lung disease, and pleural effusions , and may be confused with pulmonary lupus 
manifestations.  Opportunistic infections caused by the reactivation of human herpes 
viruses (herpes simplex viruses, varicella -zoster virus, Epstein- Barr virus, 
cytomegalovirus) may be associated with cutaneous and neurological symptoms. The 
neurotropic herpes viruses (herpes simplex and varicella -zoster) are frequent human 
pathogens, and their reactivation can cause serious infections of the CNS , such as 
encephalitis and meningitis  [Steiner 2007] . The m ost frequent characteristics of these 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 78/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
infections are of acute onset, associated with fever, headache, confusion, personality changes, and disorientation. These symptoms may be difficult to distinguish from CNS 
lupus manifestations, therefore heightened vig ilance is required.  Particular vigilance is 
required for rare and unusual neurological symptoms, as their recognition is crucial for the early diagnosis of neurotropic herpes viruses infections and progressive multifocal leucoencephalopathy, caused by reac tivation of John Cunningham virus [ Nived  2008] .  
The physical examination and blood tests on the routine visits should be focused on any potential sign of skin, mucosal surfaces, lung, gastrointestinal tract, liver, CNS, 
hematological abnormality and organ dysfunction suggesting a potential opportunistic 
infection.  
Subjects should be advised to be pro -active and alert in reporting any unusual 
neurological symptoms and any signs and symptoms indicative of systemic infec tions, 
such as fever, malaise and fatigue. 
In the event of a suspected clinically relevant infection (e.g., serious infection, 
opportunistic infection), the subject should be treated as clinically indicated and study treatment must be permanently discontinued. Concomitant  immunomodulatory 
medications may also be discontinued at the discretion of the investigator
. The decision 
to permanently discontinue study treatment will be made after evaluation of all available 
information concerning all potential causes  of infection  and the clinical status of the 
subject. Further diagnostic work- up and consultation with a n infectious disease specialist  
or other specialist should be considered according to local practice and the clinical situation . 
 
In the event of perman ent discontinuation from study treatment due to infection, adequate 
treatment needs to be provided, and the subject must be monitored until complete resolution of the infection. Furthermore, in the event of permanent discontinuation from study treatment du e to any reason, subjects should not receive any of the prohibited 
systemic immunosuppressive treatment during the follow -up period of 16 weeks after last 
study drug intake , unless clinically indicated and j ustifiable in the opinion of the 
investigator . 
5.1.10.8 Premature treatment discontinuation after study treatment interruption , 
background therapy changes , administration of forbidden therapies, or study 
drug mis -dispensing 
A subject must be permanently discontinued from study treatment if study treatment has 
been interrupted between Day  1 and Day  14 and not re -initiated within 7 days after 
treatment interruption [see Section 5.1.8.1]  or the subject missed doses for more than 
7 consecutive days after Day  14 [see Section  5.1.8.2] .  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 79/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
In case of disease progression, treatment failure, worsening of subject condition requiring 
changes in the dose of background therapy outside of protocol- specified levels  [see 
Section 5.2.4] , the subjec t may  be permanently discontinued from the study treatment at 
the discretion of the investigator and after discussion with the sponsor. In case of need to administer forbidden concomitant therapies, the subject must be permanently discontinued from the study treatment [see Section  5.2.5] . 
In case of study drug mis-dispensing (incorrect kit dispensed) and incorrect study drug 
intake, the subject  must be permanently discontinued. 
Furthermore, in the event of permanent discontinuation from study treatment due to any reason, subjects should not receive any of the prohibited systemic immunosuppressive treatment or other forbidden therapies during the follow -up period of 16 weeks after last 
study drug intake , unless clinically indicate d and j ustifiable in the opinion of the 
investigator . Also, the allowed concomitant therapies should stay within the 
protocol- defined ranges during the follow -up period of 16 weeks after last study drug 
intake, and may only be changed if clinically indicat ed and justifiable by the investigator.  
5.2 Previous and concomitant therapy 
5.2.1 Background SLE therapy  
5.2.1.1 Definition  of background SLE therapy 
In order to be eligible for the study, subjects must currently receive at least one of the below background treatments for SLE.   
• NSAIDs  
o Aspirin (acetylsalicylic acid)  
o Ibuprofen 
o Naproxen  
o Celecoxib  
o Others  
• Corticosteroids (≤ 10 mg/day prednisolone or equivalent ; see Appendix 8)  
o Prednisolone 
o Prednisone 
o Methylprednisolone 
o Dexamethasone  
o Betamethasone  
o Hydrocortisone  
o Triamcinolone  
o Cortisone  
o Others  
• Anti-malarials  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 80/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
o Hydroxychloroquine (≤ 400 mg /day)  
o Chloroquine (≤ 500 mg/day)  
o Quinacrine (≤ 100 mg/day) 
• Mycophenolate mofetil (≤ 2 g/day) 
• Azathioprine (≤ 2 mg/kg/day) 
• Methotrexate (≤ 20 mg/week) 
 
Note:  
All background SLE therapies must have been started at least 30 days prior to randomization with stable doses. Treatment with anti- malarials, mycophenolate mofetil, 
azathioprine, or methotrexate must have been started at least 90 days prior to randomization and must not have been stopped within 30 days prior to randomization. 
5.2.1.2 Reporting of background S LE therapy in eCRF  
All background SLE therapies ongoing at baseline or started during the study will be 
reported in the background SLE therapies pages of the eCRF. 
The generic name, start/end dates of administration, route, dose  and change in dose, 
frequen cy of administration, and reason for discontinuation will be recorded in the eCRF. 
5.2.2 Previous SLE therapies  
5.2.2.1 Definition of previous SLE therapies  
A previous SLE therapy is any treatment administered for SLE and/or SLE 
manifestations for which the end date is prior to the start of the study (i.e., signing of 
ICF).  
5.2.2.2 Reporting of previous SLE therapies in eCRF 
All previous SLE therapies administered within 24 months prior to Screening will be reported in the previous SLE therapies pages of the eCRF. 
The generic name, start/end dates of administration, route, dose, frequency, and reason 
for discontinuation will be recorded in the eCRF.  
5.2.3 Study -concomitant therapy 
5.2.3.1 Defin ition of study-concomitant therapy  
A study -concomitant therapy is any treatment (including methods of contraception  and 
traditional and alternative medicines, i.e., plant -, animal -, or mineral -based medicines) 
given for any reason except SLE that is either ongoing at the start of study treatment or is 
initiated during th e study treatment period, or durin g the follow -up period up to V isit 7 
(EOS).  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 81/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
5.2.3.2 Reporting of study-concomitant therapy in eCRF  
All study -concomitant therapies administered for non- SLE reasons will be reported in the 
concomitant medications pages of the eCRF.  
The generic name, start/end dates  of administration (as well as whether it was ongoing at 
start of treatment and/or EOS), route, dose, frequency, and indication will be recorded in 
the eCRF.  
5.2.4 Allowed concomitant therapy  
• i.v. atropine in the ev ent of symptomatic bradycardia (see study -speci fic criteria for 
permanent discontinuation of study treatment in  Section  5.1.10) ; 
• Dilating eye drops, mydriatics, including parasympathetic antagonists (e.g., 
tropicamide) or sympathetic agonists (e.g., phenylephrine) for topic al use; 
• Vaccination with non- live vaccines  (Note: although nonclinical data indicate no 
significant impairment of antibody response to immunization,  no clinical data is 
currently available on vaccination efficacy under ACT -334441 treatment , therefore it 
is suggested that all planned/indicated vaccinations are completed more than 30 days 
before the start of treatment  and, in case of vaccination during the study, titer control 
is recommended .); 
• Stable systemic corticosteroid therapy; corticosteroids are not to be started or stopped 
during the study and the dose should be kept stable. However, t he investigator may 
see reason to initiate or increase the dose of systemic corticosteroid  to treat an SLE  
flare or another condition. In such cases, t he dose may be inc reased for a period of not 
more than 14 days up to double the baseline dose or a maximum of 20 mg/day 
prednisolone or equivalent (please refer to conversion table in Appendix 8) ; 
• Topical treatment therapy including  topical use of cort icosteroid is allow ed.  
• Stable antimalarial therapy (e.g., hydroxychloroquine, chloroquine, quinacrine);  
therapy is not to be started or stopped during the study , and dose should be kept 
stable ; 
• Stable NSAID  chronic therapy. Therapy is not to be started or  stopped during the 
study;   
− Temporary use and/or dose change for treatment of non- SLE related 
conditions (e.g., headache, menstrual cramps) is allowed;  
• Stable immunosuppressant  therapy (i.e., methotrexate, azathioprine, or mycophenolate 
mofetil) . Therapy  is not to be started or stopped during the study, and dose should be 
kept stable;  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 82/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Background medications must be kept stable until the end of the follow -up period 
(16 weeks after the last study treatment intake) unless clinically indicated and justifiable 
in the opinion of the investigator . In case of changes in the dose of background 
medications outside protocol -specified levels, discontinuation of study treatment may be 
considered on a case- by-case basis and after discussion with the sponsor. 
5.2.5 Forbidden concomitant therapy  
• Immunosuppressives not listed in Section 5.2.4 such as  cyclophosphamide, 
cyclosporine, leflunomide, sirolimus, tacrolimus, etc.; 
• Immunosuppressive or immunomodulatory biological agents (e.g., belimumab, i.v. 
immunoglobulin, rituximab, S1P modulators other than ACT-334441);  
• β-blockers, diltiazem, verapamil, digoxin, or any other anti -arrhythmic or 
HR-lowering therapy (as listed in  Appendix 1);  
• QT-prolonging drugs with known risk of torsades de pointes (list of drugs and specific 
rules provided in Appendix 2) ; 
• Short- and long -acting β2-agonists (e.g.,  albuterol, levalbuterol, formoterol,  
terbutaline , salmeterol);  
• Vaccination with live vaccines.  
The forbidden concomitant therapies are not allowed during the study until the end of the follow- up period (16 weeks after the last study treatment intake) unless clinically 
indicated and justifiable in the opinion of the investigator. 
In case of significant SLE worsening or significant disease flare requiring the 
administration of prohibited immunosuppressives or immunomodulatory biological agents, study treatment should be permanently discontinued. For guidance on the use of allowed concomitant medications following EOS , see Section  5.2.4.  
If patients require treatment with any of the  forbidden concomitant therapie s or need to 
receive a live vaccine, study treatment should be permanently discontinued and patients 
should be followed up as clinically indicated.  
6 STUDY ENDPOINTS 
6.1 Pharmacodynamic endpoints 
• Change in total lymphocyte count from baseline to EOT ;  
• Change in  total lymphocyte count from baseline to each post- baseline assessment.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 83/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
6.2 Safety endpoints 
Treatment -emergent period is defined as the time from first study treatment intake up to 
6 weeks  (inclusive) after last study treatment intake.  
• Treatment -emergent AEs, SAEs, and AESI s#; 
• AEs leading to premature discontinuation of study treatment; 
• Changes in 12- lead ECG variables  (HR, PR, QRS, QT, QT corrected for heart rate on 
the basis of Bazzett’s formula [QTcB]  and QT corrected for heart rate on the basis of 
Frideric ia’s formula [QTcF]), from pre -dose to selected  post- dose assessments (1 h, 
2 h, 3 h, 4 h, 5 h, 6 h) on Day 1 and on day of study drug re- initiation ; 
• Occurrence of treatment -emergent 12 -lead ECG outliers ( e.g., HR, PR, QTc defined in 
the Statistical Analysis Plan [SAP]);  
• Occurrence of treatment -emergent 12- lead ECG abnormalities ; 
• Occurrence of treatment -emergent ECG -Holter abnormalities on Day 1;  
• Change in SBP and DBP  from baseline up to EOS; 
• Change in FEV 1 and FVC, expressed in absolute value (L) and percent value from 
baseline up to EOS; 
• Occurrence of treatment -emergent decrease of FEV 1 or FVC >  15% from baseline 
values;  
• Change in laboratory parameters (hematology, blood chemistry, and urinalysis) from 
baseline up to EOS; 
• Treatment -emergent lab oratory abnormalities according to CTCAE 2010 v4.03 
[CTCAE  2010 ] and FDA guidelines [FDA 2009]  (for ALT/AST/TB L); 
• Change in protein- to-creatinine ratio  from baseline to  EOT ; 
• Change in body weight from baseline to EOT. 
#AESI considered for the analyses are described in  Appendix 3.  
6.3 Pharmacokinetic endpoints  
• Ctrough ACT -334441 plasma concentrations prior to dosing at Weeks 2, 4, 8, and 12 
(EOT)  or at EOT visit after premature study treatment discontinuation (if applicable) . 
• ACT -334441 plasma concentration at EOS (i.e., 6 weeks after study treatment 
discontinuation). 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 84/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
6.4 Exploratory disease activity endpoints 
• Change in SLEDAI -2K score (modified to exclude leukopenia) from baseline to each 
post- baseline assessment ; 
• Change in PGA score from baseline to each post- baseline assessment ; 
• Change in SLEDAI -2K mucocutaneous and/or muscoskeletal scorings from baseline 
to each post- baseline assessment . 
6.5 Quality of life endpoints 
• Change in SF -36v2™ Health Survey domain and component scores  from baseline to 
EOT . 
6.6 Exploratory biomarker endpoints 
The following exploratory biomarkers will analyzed, but the analysis is not limited to 
these markers:  
• Change in immunoglobulin serum levels (IgG, IgM, IgA)  from baseline to each 
post- baseline assessment;  
• Change in ANA and anti -dsDNA antibody titers from baseline to each post -baseline 
assessment;  
• Change in serum complement components C3 and C4, C-reactive protein ( CRP ), 
fibrinogen, BLyS and C-X- C motif chemokine 10 ( CXCL10 ) from baseline to each 
post- baseline assessment.  
• Change in blood lymphocyte subsets from baseline to EOT  and EOS. 
7 STUDY ASSESSMENTS  
All study assessments are performed by a n experienced  study staff member: medical, 
nursing, or specialist technical staff, and are recorded in  the eCRF, unless otherwise 
specified. Study assessments performed during unscheduled visits will also be recorded in the e CRF.  
If the principal investigator delegates any study procedure/assessment for a subject, e.g., 
ECG, OCT , blood sampling etc., to an external facility, he/she should inform the sponsor  
to whom these tasks are delegated. The set -up and oversight will be agreed upon with the 
sponsor . The supervision of any external facilities remains under the responsibility of the 
principal investigator. 
Calibration certificates for the following devices used to perform study assessments must be available at the clinical site prior to the randomization of the first subject:  
• Temperature measurement devices for study medication storage area and freezer.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 85/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• Spirometer; in addition, a copy of the calibrations check (syringe check) of the  
day of measurement  must be stored and a log of calibration check results must be  
maintained at the site [see Section  7.2.6] . 
• 12-lead ECGs  and 24-hour Holter ECG . 
• BP monitoring device. 
 
Calibration certificates for echocardiography and OCT devices should be available as 
indicated in  Section s 7.2.5 and 7.2.8. 
7.1 Screening/baseline assessments 
7.1.1 Informed consent (Screen ing visit)  
Prior to performi ng any study -specific procedure or assessment , the subject must provide 
written informed consent to participate in the study. If the signing of informed consent 
and performance of the first study -specific procedures or assessments take place on the 
same day, it must be clear from the source documents that informed consent was obtained prior to any study -specific procedures being performed (i.e., time of procedures 
documented). If a study -specific procedure or assessment has been performed as part of 
routine assessments and the results are available prior to the subject’ s signing of informed 
consent (e.g., SLE -relevant disease history, CXR; see Sections 4.6.2 and 7.2.9) , such 
procedure or assessment may be used to assess eligibility and does not have to be repeated. In such cases, it must be clear from the source document when and for which reason  the assessment was done prior to the signing of the informed consent. It is the 
responsibility of the principal investigator  / treating physician  to explain the study in all 
its aspects to the subject and obtain her/his informed consent. T he informed consent 
process will be documented in the investigator site file . The language used in the oral and 
written information about the trial, and including the informed consent form , will be 
provided in a language that is fully understandable to the subject.  
7.1.2 Baseline demographics and disease characteristics  
At Visit 1 (Screening) , the below data are to be recorded in the eCRF.  
• Baseline demographics (sex, age, race/ethnicity , body weight and height). 
• Complete, clinically relevant medical history and current conditions, as well as 
smoking status. 
• SLE-relevant disease history , ACR criteria [see Section 4.6.2]  and SLE 
assessments (i.e., SLEDAI -2K and PGA) [see Section 7.4].  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 86/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
7.1.3 Previous and concomitant therapies  
All background/previous SLE therapies, as well as all study-conc omitant therap ies [see 
Section  5.2], will be reported in the corresponding eCRF pages [see Section  5.2]. 
7.2 Safety assessments 
The definitions, reporting and follow-up of AEs and SAEs are described in Section  10. 
7.2.1 Laboratory assessments 
7.2.1.1 Type of laboratory 
A central laboratory (see central laboratory manual for contact details ) will be used for all 
protocol- mandated laboratory tests, including re -tests due to laboratory abnormalities and 
laboratory tests performed at unscheduled visits. Central laboratory data will be 
automatically transferred from the central laboratory database to the sponsor ’s clinical 
database.  Analysis of lymphocyte subsets  will be performe d by the sponsor [ see 
Section  7.6]. 
In exceptional cases (e.g., subject is hospitalized in a different hospital from the study center due to a medical emergency, or missing central laboratory values) , local laboratory 
results ( with the corresponding normal ranges) will be entered into the clinical database 
via dedicated eCRF pages . Testing of WBC and total lymphocyte counts at a local 
laboratory should not  performed  unless deemed absolutely necessary by the investigator  
to ensur e subject’s safety. In this particular case, the local results of WBC and total 
lymphocyte counts will be recorded in the eCRF. 
In case a central laboratory sample is lost or cannot be analyzed for whatever reason, the 
investigator will collect an addition al sample as soon as possible for repeat analysis, 
unless a local laboratory sample was collected within the same time  window and these 
test results are available.  
Central laboratory reports will be sent to the investigator. In case of specific (pre -defined) 
laboratory abnormalities, the central laboratory will alert the sponsor and the concerned 
clinical site. Values that will trigger such alert notification are displayed in Appendix 7.  
All laboratory reports must be signed and dated by the primary investigator or delegate 
within 3 working days of receipt and filed with the source documentation. The 
investigator/delegate must indicate on the laboratory report whether abnormal values are considered clinically relevant or not . Clinically  relevant laboratory findings that are 
present at the time of signature of informed consent must be recorded on the medical history page of the eCRF. Any clinically relevant laboratory abnormalities detected after 
signature of informed consent must be reported as an AE or SAE as  appropriate [see 
Section  10] and must be followed until the value returns to within the normal range or is 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 87/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
stable, or until the change is no longer clinically relevant. Further laboratory  analyses 
should be performed as indicated and according to the judgment of the investigator. 
Details about the collection, sampling, storage, shipment procedures, reporting of results 
and abnormal findings can be found in the laboratory manual. 
7.2.1.2 Laboratory tests  
Blood samples will be drawn at all scheduled  visits . At unscheduled visits , blood samples 
will be collected at the investigator’s  discretion. Sample collection date s will be recorded 
in the eCRF.  
Hematology  
• Hb  
• Hematocrit , MCH, MCV , and MCHC 
• Erythro cyte count ( reticulocyte  count) 
• Leukocyte count with differential counts* 
• Platelet count  
*For the purpose of func tional blinding  [see Section 5.1.4.2] , the WBC  and the 
lymphocyte counts will not be available to sites and the sponsor during the study. This 
data will be available only after database lock.  Non-lymphocyte differential counts will 
be available during the course of the study  as specified in the lab oratory manual . If a 
lymphocyte count <  200 cells/µl is recorded by the central laboratory, an alert including 
lymphocyte count results will be sent to the investigators and to the sponsor  at any study 
visits until EOT . If lymphocyte count  < 800 cells/µl at EOS visit, an alert including 
lymphocyte count results will be sent to the investigator and to the sponsor’ s team , and 
lymphocyte count  should be monitored on a regular basis  (e.g., every 2 weeks) by the 
local laboratory until the lymphocyte count has returned to ≥ 800 cells/ µL or  until 
medically indicated . 
Clinical chemistry  
• Aminotransferases (AST/ALT), alkaline phosphatase, total and direct bilirubin, 
lactate dehydrogenase  
• Creatinine  
• Blood urea nitrogen 
• Uric acid  
• Glucose 
• Cholesterol, triglycerides  
• Sodium, potassium, chloride, calcium 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 88/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• Protein, albumin 
Test for tuberculosis 
• An interferon gamma release assay  will be performed at Visit 1 ( Screening) to screen 
for active or latent TB [see Section  7.2.10] . 
Coagulation tests  
• Prothrombin time and INR 
• Activated partial thromboplastin time 
Pregnancy test  
A serum pregnancy test for WOCBP  will be performed at Visit 1 ( Screening ) and Visit 7 
(EOS), and if pregnancy is suspected during the study. Urine pregnancy  tests will be 
performed at all other visits .  
In order to be randomized in the study, WOCBP  must have a confirmed negative serum 
pregnancy test at Visit 1 ( Screening ) and a second confirmed negative  urine pregnancy 
test prior to Randomization. The two tests must be performed a minimum of 3 weeks 
apart.  
At Visit 7 (EOS) , two urine pregn ancy test kit s will be dispensed to WOCBP  to perform 
the test at their home 1 –2 days before the planned follow-up telephone call s (11 weeks 
and 16 weeks after study drug discontinuation). The result of the test s (positive/negative) 
will be communicated to the treating physician during the follow-up telephone call s. 
Serum pregnancy test results data will be automatically transferred from the central 
laboratory database to the sponsor ’s clinical database. Urine pregnancy testing results 
will be recorded in th e eCRF  (except for the follow-up telephone call s). In case of 
pregnancy up to the follow -up telephone call s, a Pr egnancy Form must be completed [ see 
Section  10.3.2] .  
Virus serology  
• Hepatitis B surface antigen, Hepatitis C antibodies, HIV1 and HIV2 antibodies, 
varicella -zoster virus  IgG antibodies will be assessed in serum at Visit 1 ( Screening ) 
(a confirmatory test might be required in case of positive testing results [e.g., positive 
Hepatitis C antibodies ]). 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 89/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Additional analyses in the event of infections 
• A serum sample will be taken at Visit 2 ( Randomization ) and stored at the central 
laboratory for potential retrospective analyses of viral serology titers in the event of infections (e.g., suspected opportunistic infection) during the study. 
Urinalysis   
Including but not limited to : 
• pH 
• Glucose 
• Proteins 
• Blood 
• Leukocytes  
A midstream urine sample (approximately 30 mL) will be obtained, in order to avoid contamination with  epithelial cells and sediments . Urine dipsticks provided by the central 
laboratory will be used to perform the urinalysis  at all visits . The test will be performed 
and analyzed at the site, and the results will be recorded in the eCRF. 
If the dipstick results are positive for protein, leukocytes, or blood, the urine sample will be subject to further analysis as clinically indicated (i.e., microscopic analysis of WBC, red blood cells  [RBC ], casts, and protein quantification). The results of any further 
analysis must be documented in the source documents / subject charts and can be used for 
assessment of the SLEDAI -2K score.  
Urine protein- to-creatinine ratio  
At Visit 1 (Screening), Visit 2 (Randomization) and Visit 6 (EOT) , urine samples will be 
collected and sent to the central laboratory for protein and creatinine m easures , and 
determination of the protein- to-creatinine ratio.  
7.2.2 12-lead ECG  
Digital 12 -lead ECG devices will be provided to each site by the central ECG laboratory 
for the duration of the study. 
Digital ECG recording will be performed for all subjects at all scheduled study visits with 
the subject in a fully rested supine position after the subject has been allowed to rest for a 
minimum of 5 minutes prior to the measurement. Pre -dose ECGs also need to be 
performed at unscheduled visits (U1, U2, etc.)  to the study protocol schedule. During the 
treatment period , 12-lead ECGs must be performed prior to dosing. The data records  (i.e., 
flashcards)  will be sent to the evaluation center for central reading . 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 90/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Details will be provided in the 12- lead ECG laboratory manual.  
The following parameters will be evaluated: HR (bpm), PR (ms), QRS (ms), QT (ms), 
QTc (ms), and any ECG findings. QTc (ms) will be calculated according to Bazett’s and 
Fridericia’s formula (QTcB = QT/(RR) 0.5 and QTcF = QT/(RR)0.33, respectively).  
ECG printout tracings must be reviewed, signed and dated by the physician responsible 
for the performance (i.e., principal investigator  / treating physician or CSA) as soon as 
possible after the examinations; a copy of the tracing should be made and both origi nal 
and copy will be kept in the subject file. The tracings  signed by the CSA will be kept in a 
separate file and will not be made accessible to the principal investigator  / treating 
physician .  
All ECG reports (received from central reader) must be signed  and dated by the primary 
investigator  / treating physician or CSA  within 3 calendar days of receipt and filed with 
the source documentation. The investigator  / treating physician  or CSA must indicate on 
the ECG  report whether abnormal values are considered clinically relevant or not. 
Clinically relevant ECG findings that are present at the time of signature of informed consent must be recorded on the medical history page of the eCRF. Any clinically relevant ECG abnormalities detected after signature of informed consent must be 
reported as an AE or SAE as  appropriate [see Section  10] and must be followed until the 
value returns to within the normal range or is stable, or until the change is no longer clinically re levant . 
At all visits , except at Visit 2 (Randomization) and study treatment re-initiation  visits  
(see below ), the 12- lead ECGs will be performed under the responsibility of the treating 
physician  who may consult the CSA.  
At Visit 2 (Randomization  / Day 1)  and at study treatment re -initiation visits where 
post-dose monitoring is  required, the pre - and post-dose 12- lead ECG assessments will be 
performed under the responsibility of the CSA  who will interpret the re sults.  
The pre -dose 12- lead ECG interpretat ion (before Randomization) provided by the CSA  
will support the subject’ s final eligibility decision made by the principal investigator  / 
treating physician according to the inclusion/exclusion criteria.   
The post -dosing 12- lead ECGs will be performed together with BP assessments  hourly 
until 6 hours post -dose. At this time, subjects may be discharged from the hospital if they  
meet the discharge criteria [ see Appendix 4] , otherwise 12 -lead ECG and BP will be 
assessed hourly until discharge criteria are met . If the subject does not meet the defined 
discharge criteria at 12 hours post -dose, the subject will be permanently discontinued 
from the study treatment  and will be kept in the hospital for observation.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 91/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The CSA must ensure that the main study team  at site  including the principal investigator  
/ treating physician, clinical coordinator  / study nurse, and other personnel involved in  
subject s’ clinical care and management do not access first-dose ECG data with 
unblinding potential , inclu ding hourly post-dose 12-lead ECGs  and 24- hour Holter ECG 
data of D ay 1 or at re- initiation (e.g., central reading reports, tracings). 
7.2.3 ECG Holter  
ECG Holter monitoring will be performed for 24 hours at  Visit 1 (Screening ) and Visit 2 
(Randomization). Testi ng at Visit 1 (Screening) can be performed at any time  during the 
Screening  period. 
Digital ECG Holter devices will be provided to the sites for the duration of the study. The 
data records will be sent to the ECG  Holter core laboratory for central reading.   
At Visit 1 (Screening), the 24- hour ECG Holter will be performed under the 
responsibilit y of the principa l investigator  / treating physician. The performance of the 
assessment may be delegated to the CSA. The recording must be initiated before 12 pm (noon) and must be obtained for 24 hours.  
At Visit 2 (Randomization  / Day 1), the 24- hour ECG Holter will be performed under the 
responsibility of the CSA. The recording must be initiated immediately  before  first 
dosing. The subject will be allowed to leave the clinic with the Holter and to perform 
her/his usual daily activities. The recording will be stopped 24 hours post -dose. It is 
essential to have uninterrupted recording during the 24 hours (including sleep hours).  The central reading results (including alert notifications in case of specific findings) of 
the ECG  Holter performed at Visit 1 (Screening) will be sent to the principal investigator  
/ treating physician and to the CSA . The central reading results (including alert 
notifications in case of speci fic findings) of the Holter performed at Visit 2 
(Randomization) will be sent only to the CSA. 
The ECG Holter reports must be signed and dated by the primary investigator  / treating 
physician (Visit 1) or the CSA (Visit 2)  within 3 calendar days of receipt  and filed with 
the source documentation. The ECG Holter reports signed by the CSA will be kept in a 
separate file. The physic ian signing the ECG Holter report must indicate on the report 
whether abnormal values are considered clinically relevant or not. C linically relevant 
ECG Holter findings that are present at the time of signature of informed consent must be 
recorded on the medical history page of the eCRF. Any clinically relevant ECG  Holter 
abnormalities detected after signature of informed consent mus t be reported as an AE or 
SAE as  appropriate [see Section 10] and must be followed until the value returns to 
within the normal range or is stable, or until the change is no longer clinically relevant.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 92/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
7.2.4 Blood pr essure 
BP measurements include SBP and DBP. BP will be assessed at all scheduled visits.  
BP assessment  will be performed using the same type of device throughout the study on 
the same arm with the subject in a fully rested supine position after the subject  has been 
allowed to rest for a minimum of 5 minutes prior to the measurement. At each pre -dose 
assessment, SBP and DBP will be measured twice. The two obtained measurements  (i.e., 
two SBP measurements and two DBP measurements) and the position and arm us ed are 
to be recorded in the eCRF. The means of the two obtained measurements will be 
calculated by the eCRF. Any clinically relevant BP abnormalities detected after informed 
consent signature  must be reported as an AE or SAE as appropriate [see Section  10]. 
At all visits , except at Visit 2 (Randomization) and study treatment re -initiation visits 
(see below ), the SBP/DBP assessments will be performed under the responsibility of the 
treating physician , who may consult the CSA.  
At Visit 1 (Screening) , SBP and DBP will be measured sequentially once in supine and 
once in standing position to determine the presence of orthostatic hypotension (i.e., 
> 20 mmHg decrease in SBP or > 10 mmHg decrease in DBP from supine to standing positio n, measured between 1 and 3 minutes after standing; see exclusion criteria 13.) 
At Visit 2 (Randomization  / Day 1)  and visits for re -initiation of study treatment when 
post- dose monitoring will be required, the SBP/DBP assessments will be performed 
under the responsibility of the CSA who will interpret the results.  
The pre- and post- dose SBP/DBP assessments will be performed in parallel to 12 -lead 
ECG s until subject discharge.  
The hourly post -dose assessments will only be measured once at each hourly timep oint. 
Single SBP measurement s will be used for determining discharge criteria. 
7.2.5 Echocardiography 
Echocardiography will be performed at Visit 1 (Screening ) and Visit  6 (EOT)  using the 
equipment present at the clinical site . 
Standard 2D/Doppler echocardiography should assess regional wall abnormalities, aortic 
valve morphology and function, mitral valve morphology and function, and left ventricular ejection fraction. The echocardiography equipment needs to be maintained and calibrated according to the manufacturer’s recommendations . A copy of the 
calibration certificate s done before the day of assessment must be stored as source 
documents at the site . 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 93/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The physician conducting and interpreting standard 2D/Doppler echocardiography must 
have a level of experience equivalent to at least a Level 2 training , as defined in the 
American College of Cardiology Board / American Heart Association clinical 
competence statement on echocardiography [Quiñones 2003].  In case an expert 
sonographer is conducting the examination, the  physician must review and interpret the 
echocardiography results.  
In the eCRF , the date of the echocardiography performance will be recorded. 
Echocardiography results will be documented in the patient charts but will not be 
reported in the eCRF. The presence/absence (i.e., Yes/No) of any abnormality will be 
entered  in the eCRF. Clinically relevant echocardiography  findings that are present at the 
time of signature of informed consent must be recorded on the medical history page of 
the eCRF. Any clinically relevant echocardiography  abnormalities detected after 
signature of informed consent must be reported as an AE or SAE as appropriate [see 
Section  10] and must be followed until the value returns to wi thin the normal range or is 
stable, or until the change is no longer clinically relevant.  
7.2.6 Spirometry  
Spirometry will be performed at all scheduled visits except  Visit 2  (Randomization).  
Spirometry at Visit 1 (Screening) will consist of two assessments per formed at least 
5 days apart during the Screening period. Spirometry at Visit 3 (Week 2) can be 
performed up to 3 days prior to or after the visit date. Spirometry from Visit 4 (Week 4) 
to Visit 7 (EOS) can be performed up to 5 days prior to or after the visit date.  All 
spirometry assessments should preferably be performed in the morning  at approximately 
the same time to avoid diurnal variation, and prior to study drug intake. 
Spirometry testing will assess FVC and FEV 1. 
A central reader will provide equipm ent and a PFT manual with detailed instructions for 
the procedures , calibration and validation of spirometers. All recorded spirometry values 
will be transmitted to the centralized provider, and will be reviewed by independent 
central readers. Quality of t he assessments will be evaluated for compliance with 
ATS/ERS criteria [Miller  2005a, Miller 2005b] , and queries may be sent to the sites for 
clarification. If quality issues are identified, additional trainin g will be provided. The 
selection of the highest (largest) FEV 1 and FVC values to be used for the main endpoint 
derivations will be validated by the independent central readers prior to being 
electronically transferred to the sponsor. No data will be repor ted in  the eCRF.  
PFT values that trigger study drug discontinuation will be flagged and sent to the sites 
and the sponsor. Any clinically relevant PFT  abnormality detected after signature of 
informed consent must be reported as an AE or SAE as appropriate [see Section  10] and 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 94/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
must be followed until the value returns to within the normal range or is stable, or until the change is no longer clinically relevant . 
The predicted normal values for FEV
1 and FVC used to determine the exc lusion and 
discontinuation criteria [see Section  5.1.10.3] will be those as defined by  the European 
Community for Coal and Steel including ethnic group adjustments [Quanjer 1993] . 
7.2.7 Ophthalmological examination 
An ophthalmological examination will be performed by an ophthalmologist at any time  
during the Screening  period. Examination at Visit  3 can be performed up to 3 days prior 
to or after the visit date. Examinations  from Visit 4 (Week 4) to Visit 7 (EOS ) can be 
performed up to 5 days prior to or after the visit date.  
The ophthalmological examination should include previous eye history and ophthalmic 
condition, any new or current ophthalmological symptoms, assessment of best corrected 
visual acuity ( Early Treatment Diabetic Retinopathy Study  charts), measurement of 
Goldmann applanation tonometry  (recommended, if not available other applanation 
tonometer allowed ), slitlamp examination of the anterior segment, and dilated indirect 
funduscopy. While the visual acuity  and measurement of applanation tonometry  exams 
may be performed by a delegate (e.g., experienced  technician, optometrician ), the review 
and interpretation must be performed by the ophthalmologist. Conduct, review, and 
interpretation of all other ophthalmological exams must be performed by the 
ophthalmologist. 
The purpose of the assessment prior to randomization is to exclude subject s with macular 
edema or active uveitis  from the study  and to document a baseline assessment. 
Assessments at each visi t will ensure that any new ophthalmological abnormality is 
detected and treated at an early stage.  
In the eCRF , the date of the o phthalmological examination  will be recorded. The results 
will be documented in the patient charts but will not be reported in the eCRF. The 
presence/ absence of any abnormality (i.e., Yes/No) will be recorded  in the e CRF. 
Clinically relevant findings that are present at the time of signature of informed consent 
must be recorded on the medical history page of the eCRF. Any clin ically relevant 
ophthalmological abnormalities (inclu ding OCT findings  [see Section 7.2.8] ) detected 
after signature of informed consent must be reported as an AE or SAE as appropriate [see Section  10] and must be followed until the value returns to within the normal range or is 
stable, or until the change is no longer clinically relevant. 
7.2.8 Optical coherence tomography 
OCT will be assessed at Visit 1 (Screening ) and Visit  6 (EOT). Testing  at Visit 1 can be 
perfo rmed at any time  during the Screening  period. At Visit 6 (EOT ), testing may be 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 95/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
performed up to 7 days prior to the visit date  but no later than 7 days after the 
discontinuation of  study drug . In addition, unscheduled OCT examination will have to be 
assessed in the event of visual symptoms  or findings suggestive of macular edema  
according to  the opht halmologist’ s decis ion or in case of active uveitis diagno sed during 
the study. While the OCT exam may be performed by a delegate (e.g., experienced  
technician, optometrician ), the review and interpretation must be performed by the 
ophthalmologist.   
The purpose of the assessment prior to randomization is to exclude subjects with macular edema or active uveitis  from the study, and to document a baseline ass essment. The site 
will use the OCT device available locally and must ensure it is working properly . A copy 
of the calibration certificate s done before the day of assessment must be stored as source 
documents at the site . To the extent that is logistically feasible, the same OCT machine is 
to be used for each individual subject  throughout the study.  
In the eCRF , the date of the OCT assessment will be recorded. The results will be 
documented in the patient charts but will not be reported in the eCRF. The presence/absence of any abnormality (i.e., Yes/No) will be recorded in the eCRF.  Any 
clinicall y relevant abnormalities detected after signature of informed consent must be 
reported as an AE or SAE as appropriate [see Section  10]. 
The OSB will receive all information related to suspected cases of macular edem a and 
will perform a central, blinded review of OCT images  and subjec t’s data of suspected 
cases of macular edema. 
7.2.9 Chest X -ray 
A CXR  will be performed at Visit 1 ( Screening ) and  assessed by the local radiologist in 
order to exclude any subject with findings suggestive of active or latent TB. Any CXR 
that had been performed within 3 months prior to Screening  can be used; if available, 
there is no need to repeat CXR at Screening . The report of the CXR must be recorded in 
the patient file.  
7.2.10 Test for tuberculosis  
An interferon gamma release assay  (QuantiFERON- TB-Gold
®) will be performed at 
Visit 1 ( Screening ) to screen for active or latent TB. The test will be analyzed and 
interpreted at the central laboratory and electronically transferred to the eCRF database.  
Only subjects with a negative test at Screening  and without C XR findings [ see 
Section  7.2.9]  at Screening  or within the previous 3 months suggestive of active or latent 
TB can be included in the study. If the test result is positive, subjects must not be 
included in the study, except if there is documentatio n that the subject has completed 
adequate and successful  treatment for  TB previously . If the test result is inconclusive 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 96/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
(invalid, indeterminate, or borderline), the test may be repeated one time and a negative result must be obtained prior to randomization in order to include the subject. If the result 
of the repeated test is inconclusive, subjects must not be included in the study. 
Details on the performance of the test for TB will be provided in the specific central 
laboratory manual.  
7.2.11 Weight and height  
Height will be measured at Visit 1 ( Screening ). Body weight (in underwear) will  be 
measured at  Visit 1 ( Screening) and at Visit 6 (EOT) .  
7.2.12 Physical examination 
Complete p hysical examination (i.e., inspection, percussion, palpation and auscultation)  
will be performed at Visit 1 ( Screening)  and Visit 6 (EOT) . A symptom -driven, 
abbreviat ed physical examination will be performed at all other visits in order to capture 
assessments needed for the SLEDAI -2K scoring  (note: SLEDAI- 2K not assessed  Visit 3) . 
The observations should be reported according to body system in the eCRF as either 
normal or abnormal. If an abnormality is found, it should be specified on the 
corresponding eCRF  page, describing the signs related to the abnormality (e.g., systolic 
murmur) and not the diagnosis (e.g., mitral valve  insufficiency). Clinically relevant 
findings that are present at study start (i.e. , before signing of informed consent) must be 
recorded on the Medical History or SLE -relevant disease history eCRF page.  Physical 
examination findings made after study start  that meet the definition of an AE /SAE  [see 
Section s 10.1.1 and 10.1.2]  must be recorded by the principal investigator / treating 
physician  on an AE page of the eCRF  and must be reported to Actelion Global Drug 
Safety department  (SAEs only). 
7.3 Pharmacodynamic and pharmacokinetic assessments 
7.3.1 Pharmacodynamic assessments 
The PD marker is total lymphocyte counts, which will be measured as part of the 
hematology tests [ see Section  7.2.1.2] . 
7.3.2 Pharmacokinetic a ssessments  
PK samples will be collected pre-dose ( except EOT and EOS ) at all visits from V isit 3 
(Week 2) to Visit 7 (EOS).  
The date and the time of blood sample collection will be entered in the eCRF. The date 
and time of the last study treatment dosing before blood draw will be entered in the 
eCRF.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 97/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The site staff will ship the plasma samples to the central laboratory. The central 
labora tory will ship the samples to  the CRO in charge of the PK analysis (see page  3 for 
contact  details ).  
7.4 Disease activity assessments 
7.4.1 Systemic Lupus Er ythematosus Activity Index -2000 
The SLEDAI -2K will be assessed by the treating physician  at all visits ex cept Visit 3 
(Week 2)  [see Appendix 6] .  
The original SLEDAI is a valid ated tool for global measure of disease activity introduced 
in 1985 [Bombardier 1992] . The SLEDAI -2K is an updated version of the original 
SLEDAI. It has been validated as a measure of global disease activity and is suitable for use in clinical trials [Gladman 2002].  
The treating physician  will p erform physical examinations as required [see 
Section  7.2.12] , question the subject on her/his current state and about any potential SL E 
symptoms and/or manifestation that may have occurred during the past 10 days, and 
collect all lab oratory  parameter s relevant to the scoring (e.g., protein- to-creatinine ratio, 
anti-dsDNA titer , dipstick urinalysis). If the dipstick results are positive , urine sample 
will be further analy zed as clinically indicated (i.e., microscopic analysis of WBC, RBC, 
casts, and  protein quantification). 
All relevant data will be entered in  the SLEDAI -2K form of the eCRF  [see Appendix 6] . 
In case o f musculoskeletal symptoms, the number of affected joints will be assessed. 
Important note: 
Reduction in WBC  count (lymphocytes) is the main PD effect of S1P 1 modulators 
including ACT -334441. Therefore, leukopenia is not assessable in the present study and  
will be excluded from the SLEDAI-2K scoring.  
7.4.2 Physician’s Global Assessment of disease  
The PGA will be assessed by the treating physician  at all visits except Visit 3 (Week 2) . 
The PGA is a visual 100 mm analog scale for assessment of disease activity by the 
physician ranging  from 0 to 3 [see Appendix 9] . The scale is anchored at 0= “None ”, 
1=“mild”, 2=“ moderate”, 3=“ severe”  [Petri 2005].  
Paper sheets  will be provided to clinical sites . The treating physician will rate the overall 
state of the subject  and make a vertical mark on  the scale. Only original sheets should be 
used (i.e., no photocopies). A metric  ruler will be used to measure the length  between 
0 and the vertical mark.  The length will be entered into the  eCRF.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 98/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
7.5 Quality of Life assessments: 36-Item Short Form Health Survey v2 
The SF -36v2™ questionnaire  (SF-36v2™ Health Survey© 1996, 2000 by Medical 
Outcomes Trust and Quality Metric Incorporated ) [see Appendix 10]  is used to assess the  
subject’s quality of life. The SF -36v2™ will be completed by the subject at V isit 2 
(Randomization) and Visit 6 (EOT) . Preferably, the SF -36v2™ questionnaire will be 
completed by the subject in the morning prior to any other protocol assessment and prior 
to any other discussion with the investigator or treating physician. 
In the SF -36v2™ questionnaire, subjects are instructed to rate their health and capacity to 
perform daily living activities in eight domains including physical functioning, physical 
role limitations, bodily pain, general health, vitality, social functioning, emotional role 
limitations, and mental health during the last 4 weeks. Raw domain scores are determined and transformed to a 0– 100 scale as described in the SF -36v2™ manual , and i ndividual 
domain scores are used to determine the physical and mental component summary scores as described in the SF -36v2™ manual [Maruish 2011] .  
The standard SF -36v2™ considering the past 4- week period will be used. A sample of 
the SF -36v2™ (in English) is provided in Appendix 10. The s ubject will complete the 
questionnaire in local language on a validated paper  form that will be collected and 
transcribed in the eCRF.  
Actelion has been granted a license agreement  for the use of the SF -36v2™ 
questionnaire. 
7.6 Biomarker assessments 
Serum and ethylenediaminetetraacetic aci d (EDTA) plasma  samples will be drawn at 
indicated visits and will be tested by the central laboratory  (except lymphocyte subsets , 
which will be analy zed by the sponsor ). Sample collection date will be recorded in the 
eCRF.  
Details of the collection, labeling and shipment of the samples can be found in the 
laboratory manual provided to the investigator. The tubes and labels for the samples will 
be provided to the investigator and/or staff by the sponsor or the central laboratory. 
ANA, anti -dsDNA, complement factors and exploratory biomarkers 
ANA and anti-dsDNA are a hallmark of SLE , and titers of these autoantibodies have 
been found to correlate with cli nical disease activity and the response to therapy 
[Ravirajan 2001] . Low C3 and C4 complement have also been found to correlate with 
clinical disease activity  [Swaak 1986] . Immunoglobulins may be elevated in SLE 
patients , and cytokines and other soluble factors have been found to be elevated in serum 
of SLE patients.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 99/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The following biomarkers as indicated below (but not limited to) will be measured at 
baseline and during the course of study treatment in order to support the SLE diagnosis of 
involved subjects, to explore their predictive value for treatment response and to explore changes in response to ACT-334441 treatment. 
• ANA, anti -dsDNA, complement C3 and C4 (all visits except Visit 3)  
• IgM, IgG, IgA, CRP, fib rinogen, and BLyS (Visit 2 and Visits 4 to 7)  
• anti-Smith, anti- cardiolipin  (IgA, IgG, IgM) , anti-ribosomal P, (Visit 2 only). 
• CXCL10  (EDTA -plasma; Visit 2 and Visits 4 to 7 ) 
At Visit 1 (Screening), ANA and/or anti -dsDNA antibody testing should be positive in 
order to fulfill inclusion criterion 6 [ see Section 4.3] unless a documented historical 
positive testing is  available to confirm the subject’ s eligibility [see Section  4.6.2].  
Aliquots of the EDTA  plasma samples will be transferred to the sponsor  for exploratory 
analysis of new soluble biomarkers potentially related to SLE and/or S1P
1 modulation. 
Frozen samples will be kept for a maximum duration of 15 years and will be destroyed thereafter.  
Blood lymphocyte subsets 
S1P 1 modulators such as ACT -334441 reduce total lymphocyte counts (T and B 
lymphocytes) in healthy  subjects. T and B  cells consist of different subsets with potential 
distinct functions in SLE disease manifestation and progression. Specific subsets of B 
and T cells such as recently activated short -lived plasma cells  are increased in the 
circulation of SLE patients  [Grammer 2003a ; Grammer 2003b; Klinman 1991] . Analysis 
of specific blood lymphocyte subsets may provide a better understanding of the 
immunomodulatory effect of ACT -334441 in SLE patient s. 
Blood samples for lymphocyte subset  analysis  will be taken at Visit 2 ( Randomization) , 
Visit 6 (EOT)  and Visist 7 (EOS). 
The site staff will ship the blood samples to the central laboratory. The central laboratory will then ship the samples to the sponsor  for analysis . B and T cell subsets will be 
analyzed  using a combination of cell surface markers  (e.g., CD3, CD4, CD 19, CD 20). 
7.7 Total blood volume 
The expected total blood volume to be drawn per subject during the entire course of the 
study is described in  Table 3. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 100/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Table 3 Expected total blood volume to be drawn per patient  
Test Number 
of tests  Volume 
per test  Total volume per 
scheduled study visits  
Viral serology at screening  (including test confirmation)  1  9 mL 9 mL 
Interferon gamma release assay for tuberculosis at screening  1 3 x 1 mL   3 mL  
Serum sample at randomization1 1  5 mL   5 mL  
Hematology  (including coagulation)  7 6 mL 42 mL 
Blood chemistry2 7 7.5 mL  52.5 mL 
ACT -334441 PK 5 3 mL  15 mL  
Complement C3/C4, ANA, anti -ds DNA  6 7.5 mL 45 mL 
Exploratory biomarkers (serum)  5 5.5 mL 27.5 mL 
Expl oratory biomarkers (plasma)  5 5 mL  25 mL  
Lymphocyte subsets  3 5 mL  15 mL  
Total blood volume drawn at scheduled study visits: 239 mL3 
1. To be stored at the central laboratory for potential retrospective analyses of viral serology titers in the event of infections.  
2. Includes serum pregnancy.  
3. Total blood volume may vary depending on re -test and unscheduled samples  
ANA = anti -nuclear antibodies; anti- ds DNA = anti -double -stranded  DNA ; PK = pharmacokinetic. 
 
8 SCHEDULE OF VISITS 
To ensure compliance, at each visit, the study personnel must remind WOCBP  to use the 
methods of contraception defined for this study. The reminders must be documented in 
the hospital chart. 
A tabulated summary of all visits and assessments described in the following sections is 
provided in Table 1. The schedule of visit dates should be established at the time of 
Screening . It is recommended that subjects adhere to the established visit schedule. 
The timepoint for every visit is defined taking as a referenc e Day 1 ( Visit 2), which is the 
day of randomization.  
When scheduling the different assessments for a subject visit, the following should be 
taken in to account:  
• The subject must come to the clinic in a fasted condition for all visits, and, when 
applicable, before administration of study drug.  
• The intervals between all visits following Visit 4 (Week 4) and up to EOT 
(Week  12) visit should not exceed 36 days.  
• At Visit 2 ( Randomization; Day 1) and on the days of re -initiation of study drug 
(if applicable), the assessments during the visits will be divided into two parts: 
before (pre -dose) and after (post -dose) the administration of the study drug, which 
will be taken at the site.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 101/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• At other visits, ECGs, SBP/DBP, spirometry, blood drawings for hematology and 
biochemistry, along with all other assessments, are to be performed at pre-dose.  
• All PK sampling should be done at pre-dose ( except EOT and EOS ). 
• Resting time: 
o When the subject is to go to another department within the hospital for a 
specific test, suffici ent time should be allowed for the subject to rest prior 
to the examination.  
o Sufficient time between blood drawing and cardiac assessments (i.e., ECGs and/or BP  measurement) is to be allowed.   
Re-screening  
It is permitted to re -screen subjects once, if the  reason for non- eligibility was transient 
(e.g., abnormal laboratory test, insufficient wash -out period of a forbidden medication, 
etc.), provided that documented authorization has been received from Actelion. Subject s 
who were not eligible due to  a negative test  for varicella zoster antibodies may also be 
re-screened once after having been vaccinated. All pre-randomization assessments should 
then be repeated at the time of re- screening  (with the exception of CXR  evaluation). 
A subject who failed the screen ing for Part A may be re -screened for Part A or screened 
for Part B.  
8.1 Screening  period 
The Screening  period must take place within 3 0 days prior to Randomization and include 
the Visit 1 ( Screening) and the pre- dose assessments of Visit 2 (Day 1).  
The start  of the Screening  period is defined as the  day of the first Screening  assessment 
(i.e., signature of informed consent). 
8.1.1 Visit 1 (Screening)  
Visit 1 will be performed up to 3 0 days prior to Randomization. Visit 1 date is defined as 
the date of the first ass essment performed for the study (i.e., informed consent signature).  
During this visit, subject informed consent will be obtained, and the assessments required 
for subject eligibility will be performed. These assessments may generally be performed 
on separate days within the Screening  period .  
Visit 1 includes: 
• After discussing the study with the investigator and after agreeing to participate, the 
subject must sign the ICF . It is the responsibility of the investigator to obtain written 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 102/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
informed consent prior to any screening assessment.  Subjects will be assigned a 
subject number by the IRT provider , for identification throughout the study . In case 
of re -screening, t he subject number assigned during the first screening procedure will 
be retained.  
• Recording of  demographics, medical history, smoking status, and disease history 
(including documented history of ANA, anti-dsDNA antibodies) 
• Review of SLE diagnosis and ACR criteria  
• Recording of previous SLE therapies, concomitant medications and background SLE 
therapies  
• Complete physical examination  
• Body weight, and height 
• SLEDAI -2K and PGA 
• CXR  (any CXR  performed within 90 days prior to Screening  can be used). In case of 
re-screening, CXR does not need to be repeated. 
• SBP/DBP  (including supine and standing position to assess orthostatic hypotension; 
see excluion criterion  13) 
• 12-lead ECG  
• 24-hour ECG-Holter (starting before 12:00) 
• Echocardiography (under the responsibility of the echocardiography specialist) 
• Spirometry  (under the responsibility of the pulmonary function laboratory technician 
or expert ) 
• Ophthalmological examination ( under the responsibility of the ophthalmologist) 
• OCT ( under the responsibility of the ophthalmologist) 
• Hematology  (including coagulation tests), blood chemistry, and serum  pregnancy test 
for WOCBP  
• Viral serology  
• TB test  
• ANA, anti -dsDNA antibodies, complement C3 and C4 
• Urine protein- to-creatinine ratio  
• Urinalysis (dipstick)  
• Recording of AEs/SAEs: all AEs/SAEs occurring after signing of the ICF are to be 
reported in the eCRF and on an SAE form, i f applicable.   
The principal investigator  / treating physician  must check inclusion/exc lusion criteria. 
The next visit  (Visit 2) will only be scheduled if the subject meets all the eligibility 
criteria. Date of screen failure will be collected in the IRT s ystem and in the eCRF; 
additionally, t he reasons for screen failure are documented in the eCRF (screening 
information is collected for all screen failure subjects).  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 103/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
8.2 Treatment period  
The treatment period consists of Visits 2 to 6 (Randomization – Day 1, Wee ks 2, 4, 8,  
and 12 (EOT).  
8.2.1 Visit 2 – Randomization Day 1 
Visit 2 corresponds to the start of the treatment period (Day 1 of the study). The ECGs 
(pre- and post -dose), BP (pre- and post -dose), and first -dose administration must be 
performed on the same day and define the date of the visit. This date should preferably correspond to the date of randomization in the IRT system. The assessments during this 
visit will be divided  into two parts: before (pre -dose) and after study drug administration 
(post-dose). 
Important note: For WOCBP, the serum pregnancy test at Visit 1 (Screening) must be 
performed at least 3 weeks before the urine pregnancy test  performed at Visit 2 prior to 
Randomization. 
8.2.1.1 Visit 2 – Day 1 – pre- dose assessment  
The principal investigator  / treating physician must check all inclusion/exclusion criteria. 
Pre-dose assessments include:  
• SF-36v2™ questionnaire  (to be completed prior to any other assessment)  
• Recording of change in concomitant medications and background SLE therapies since 
Visit 1  
• Recor ding of methods of contraception (for WOCBP ) 
• Abbreviated  physical examination  
• SLEDAI -2K and PGA 
• Pre-dose SBP/DBP  (under the responsibility of the CSA) 
• Pre-dose 12- lead ECG ( under the responsibility of the CSA)  
• 24-hour ECG -Holter starting immediately  before first dosing  (under the responsibility 
of the CSA) 
• Hematology  (including coagulation tests), blood chemistry 
• Urine pregnancy test  (for WOCBP)  
• Additional serum sample for viral serology  
• ANA, anti -dsDNA antibodies, complement C3 and C4 
• Exploratory biomarkers 
• Lymphocyte subsets 
• Urine protein- to-creatinine ratio  
• Urinalysis  (dipstick) 
• Recording of AEs/SAEs: all AEs/SAEs occurring after signing of the ICF are to be reported in the eCRF and on an SAE form, if applicable. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 104/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
8.2.1.2 Visit 2 – Day 1 – Randomization and post-dose assessment  
After confirmation  of eligibility (i.e., verification of all entry criteria) by the investigator , 
randomization should occur via IRT to obtain randomization and study treatment kit 
number s. Study treatment should then be dispensed and the subject  should take t he first 
dose of study treatment .  
Visit 2 post- dose assessment s include: 
• Hourly 12- lead ECG and SBP/ DBP assessment s for 6 hours or until the patient meets 
the discharge criteria (under the responsibility of the CSA  [see Appendix 4] ). If 
discharge criteria are not met after 12 hours, the subject should be permanently 
discontinued. 
• Recording of AEs and SAEs . 
The subject  will be instructed to contact the site if she/he has any questions or problems. 
WOCBP  will be remin ded to use the methods of contraception defined for this study. The 
reminders must be documented in the hospital chart. 
An appointment for next visit will be scheduled and the subject will be instructed to: 
o bring back the remaining study medication for drug accountability 
o come fasted to the site  
o not take study treatment on the day of study visit prior to coming to the site  
o contact the principal investigator  / treating physician immediately in the event 
of the appearance of any symptoms (e.g.,  suggestive of an SLE flare) or any 
AEs or SAEs  or if a study treatment dose is missed.  
8.2.2 Visit 3  – Week 2 
The time window for this visit is ± 3 days. The date of the visit will be registered by the 
investigator or study staff in the eCRF only (no IRT visit registration a s no study drug 
dispensing at Visit 3).  All assessments may be performed up to 3 days prior  to or after 
this visit date. The visit include s: 
• Recording of change in concomitant medications and background SLE therapies since 
Visit 2 
• Recording  of methods of contraception (for WOCBP ) 
• Abbreviated physical examination  
• SBP/DBP  
• 12-lead ECG  
• Spirometry  (under the responsibility of the pulmonary function laboratory technician 
or expert ) 
• Ophthalmological examination ( under the responsibility of the ophthalmologist) 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 105/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• Hem atology (including coagulation tests), blood chemistry 
• Urine pregnancy test  (for WOCBP ) 
• Urinalysis  
• PK sampling  
• Study drug accountability  for compliance review  
• Recording of AEs and SAEs 
• Remind WOCBP to use the methods of contraception defined for this study 
• Schedule an appointment for the next visit and instruct the subject to: 
o bring back any remaining study medication  for drug accountability 
o come fasted to the site  
o not take study treatment on the day of study visit prior to coming to the site  
(study drug wi ll be taken at the clinical site)   
o contact the principal investigator / treating physician immediately in the event 
of the appearance of any symptoms (e.g., suggestive of an SLE flare) or any 
AEs or SAEs or if a study treatment dose is missed.  
8.2.3 Visit 4 – We ek 4 and Visit 5 – Week  8 
The visit window for these visits is ± 5 days. The date of study treatment dispensing, 
preferably corresponding to the date of registration of the visit in the IRT system defines the date of the visit. All other assessments may be  performed up to 5 days prior to or after 
this visit date. The visit includes: 
• Recording of changes in concomitant medications  and background SLE therapies 
since previous visit 
• Recording  of methods of contraception (for WOCBP ) 
• Abbreviated physical examinat ion 
• SLEDAI -2K and PGA 
• SBP/DBP  
• 12-lead ECG  
• Spirometry  (under the responsibility of the pulmonary function laboratory technician 
or expert ) 
• Ophthalmological examination (under the responsibility of the ophthalmologist) 
• Hematology (including coagulation tests) and  blood chemistry 
• Urine pregnancy test (for WOCBP ) 
• ANA, anti -dsDNA antibodies, complement C3 and C4 
• Exploratory biomarkers 
• Urinalysis  
• PK sampling  
• Study drug dispensing and accountability 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 106/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• Recording  of AEs/SAEs  
• Remind WOCBP to use the methods of contraception defined for this study 
• Schedule an appointment for the next visit and instruct the subject to: 
o bring back an y remaining study medication for drug accountability  
o come fasted to the site  
o not take study treatment on the day of study visit prior to comi ng to the site  
(study drug will be taken at the clinical site)   
o contact the principal investigator / treating physician immediately in the event 
of the appearance of any symptoms (e.g., suggestive of an SLE flare) or any 
AEs or SAEs or if a study treatment dose is missed.  
8.2.4 Visit 6 – EOT  
The EOT visit will take place at Week 12 (± 5 days)  or earlier in case of premature 
discontinuation of study treatment . In all cases, the EOT visit must preferably take place 
1 day after the last dose of study treatment intak e but no later than 7 days after the last 
dose of study treatment  intake. The visit includes: 
• SF-36v2™ questionnaire (to be completed prior to any other assessment)  
• Recording of changes in concomitant medications  and background SLE therapies 
since Visit 5  
• Recording  of methods of contraception (for WOCBP ) 
• Complete physical examination  
• Body weight 
• SLEDAI -2K and PGA 
• SBP/ DBP 
• 12-lead ECG  
• Echocardiography (under the responsibility of the echocardiography specialist) 
• Spirometry  (under the responsibility of the pul monary function laboratory technician 
or expert ) 
• Ophthalmological examination (under the responsibility of the ophthalmologist) 
• OCT (under the responsibility of the ophthalmologist) 
• Hematology (including coagulation tests) and  blood chemistry 
• Urine pregnan cy test  (for WOCBP ) 
• ANA, anti -dsDNA antibodies, complement C3 and C4 
• Exploratory biomarkers 
• Lymphocyte subsets 
• Urine protein- to-creatinine ratio  
• Urinalysis  
• PK sampling  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 107/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• Study drug accountability  
• Recording of AEs/SAEs  
• Remind WOCBP to use the methods of contraception defined for this study 
• Schedule an appointment for the next visit and instruct the subject to: 
o come fasted to the site  
o contact the principal investigator / treating physician immediately in the event 
of the appearance of any symptoms  (e.g., sugges tive of an SLE flare) or any 
AEs or SAEs  or if a study treatment dose is missed.  
8.3 Follow-up period 
8.3.1 Visit 7 – EOS  
The EOS visit will take place 6 weeks (± 5 days)  after last study treatment dose . The visit 
includes: 
• Recording of changes in concomitant medica tions and background SLE therapies 
since Visit 6  
• Recording  of methods of contraception (for WOCBP ) 
• Abbreviated  physical examination  
• SLEDAI -2K and PGA 
• SBP/ DBP 
• 12-lead ECG  
• Spirometry  (under the responsibility of the pulmonary function laboratory technician 
or expert ) 
• Ophthalmological examination (under the responsibility of the ophthalmologist) 
• Hematology (including coagulation tests) and  blood chemistry 
• Serum  pregnancy test  (for WOCBP ) 
• ANA, anti -dsDNA antibodies, complement C3 and C4 
• Exploratory biomarkers 
• Lymphocyte subsets 
• Urinalysis  
• PK sampling  
• Recording of AEs/SAEs  
A urine pregnancy test will be dispensed to WOCBP . 
8.3.2 Visit 8 and Visit 9 – follow -up (t elephone contact visit s) 
Eleven  weeks ± 5 days and 16 weeks  ± 5 days , after the last dose of study drug  has b een 
taken , telephone calls will be made and include:  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 108/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• Recording of SAEs 
• Urine pregnancy test  for WOCBP  (performed at home prior to telephone contact s 
with test kits dispensed at Visit 7 – EOS ) 
Note that the data reported at these visits will not be entered in the eCRF. Results of the 
urine pregnancy tests must be reported in the source data. SAEs will be reported to 
Global D rug Safety  and will be presented separately in the Clin ical Study Report.  
8.4 Unscheduled visits (U1, U2…) 
Unscheduled visits may be perform ed at any time during the study. These visits include 
(but are not limited to) those performed due to safety (e.g., occurrence of an AE, 
laboratory abnormalities), and/or SLE disease exacerbations (e.g., renal flare) . 
The date of the visit and the reason f or such visits as well as any data related to study 
assessments performed at unscheduled visits will be recorded in the eCRF.  
During an unscheduled visit, the following assessments must be performed:  
• Recording of changes in concomitant medications  and background SLE therapies 
since last visit 
• Recording of AEs/SAEs  
Additional assessments m ay be performed  at the discretion of the investigator including  
but not limited to:  
• Abbreviated  physical examination  
• SLEDAI -2K and PGA 
• SBP/ DBP 
• 12-lead ECG  
• Hematology (including coagulation tests) and  blood chemistry 
• Urine pregnancy test  (for WOCBP ) 
• ANA, anti -dsDNA antibodies, complement C3 and C4 
• Urine protein- to-creatinine ratio  
• Urinalysis  
Depending on the reason for the unscheduled visit (e.g., AE), additional assessment s will 
be performed based on the judgment of the investigator , and the results will be recorded 
in the eCRF. For the additional assessments performed during unscheduled visit which 
are not part of the standard study assessments, results are not to be reported in the eCRF. 
However,  any clinically relevant abnormalities detected must be reported as an AE or 
SAE as appropriate in the corresponding Adverse Event form of the eCRF . After an 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 109/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
unscheduled visit, the regular scheduled study visits must continue according to the planned visit and assessment schedule. 
8.5 Additional visits for re-initiation of study treatment  
Subjects may need to be monitored at the study site when re -initiating study drug 
following a study drug treatment interruption.  Re-initiation visits should be conducted for 
study treatment interruptions which started  prior to Day 14 [see Section  5.1.8] . 
Note that a  subject can be re- initiated only once during the study duration 
The same post -dosing procedure as described in  Section 8.2.1.2 (Visit 2 – Day 1 – 
Randomization and post- dose assessment) must be followed :  
• Hourly 12- lead ECG and SBP/D BP assessments for 6 hours or until the patient meets 
the discharge criteria (under the responsibility of the CSA [s ee Appendix 4] ). If 
discharge criteria are not met after 12 hours, the subject should be permanently discontinued. 
• Recording of AEs and SAEs ( please refer to Sections 7.2.2, 7.2.4 and 10.1.5 for 
reporting of AEs with onset on Day 1). 
• Recording of changes in concomitant medications and background SLE therapies 
since previous visit. 
• Study drug accountability  for compliance review . 
These vis its for post -dose monitoring of the subjects when re -initiating study treatment 
are additional unscheduled visits. The regular scheduled study visits must be resumed 
according to the original visit and assessment schedule. I f the visit occurs at the same 
time as a regular visit, all assessments of the regular visit have to be perfomed in 
addition. 
9 STUDY COMPLETION AND POST-STUDY TREATMENT / 
MEDICAL CARE 
9.1 Study completion  
For an individual subject, study completion  is reached  when EOT visit  and EOS visit 
have been completed .  
Ten weeks after the EOS visit, subjects will be contacted by  telephone to collect 
follow-up information on any SAE and/or pregnancy (follow-up).   
EOS on a study level occurs at the time all subjects have completed their EOS visits , as 
described above.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 110/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
9.2 Premature withdrawal from study 
Subjects may voluntarily withdraw from the study for any reason at any time. Subjects 
are considered withdrawn if they state an intention to withdraw further participation in all components of the study (i.e., withdrawal of consent), die, or are lost to follow -up. If a 
subject withdraws consent, no further data will be collected in the eCRF from the date of 
withdrawal onward. The investigator may withdraw a subject from the study (without 
regard to the subject ’s consent) if, on balance, they believe that continued participation in 
the study would be contrary to the best interests of the subject. Withdrawal from the study may also result from a decision by Actelion for any reason, including premature termination o r suspension of the study [see Section 9.3].  
If premature withdrawal  occurs for any reason, the reason for premature withdrawal from 
the study, along with who made the decision to withdraw (subject, investigator  or 
Actelion) must be recorded in the eCRF. 
If for whatever reason (except death or loss -to-follow- up) a subject was withdrawn  from 
the study, the investigator should make efforts to conduct a last visit/contact to assess the 
safety and well -being of the subject, collect unused study drug and discuss follow -up 
medical care. Data obtained during this last appointment  / telephone call w ill be recorded 
in the subject’ s medical records but will not be collected in the eCRF.  The investigator 
must provide follow -up medical care for all subjects who are prematurely withdrawn 
from the study or must refer them for appropriate ongoing care, as described in Section  9.4. 
Subjects are considered as lost to follow -up if all reasonable attempts by the investigator 
to communicate with the individual fail. The site must take preventive measures to avoid a subject being lost to follow -up (e.g., document different ways of contact such as 
telephone number, home address, e -mail address , person to be contacted in case the 
subject cannot be reached). If the subject cannot be reached, the site must make a reasonable effort to contact the subject, document all attempts and enter the loss of follow- up information into the eCRF. The following  methods must be used: at least three 
telephone calls must be placed to the last available telephone number , and one registered 
letter must be sent by post to the last available home address. Additional methods may be acceptable if they are compliant with local rules/regulations (e.g., site staff visit to the subject’s home), respecting the subject’s right to privacy. If the subject is still unreachable after all co ntact attempts listed above, she/he will be considered tob e lost to 
follow-up.  
9.3 Premature termination or suspension of the study 
Actelion reserves the right to terminate the study at any time globally or locally. Investigators can terminate the participation of their site in the study at any time.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 111/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Study-specific stopping rules will be applied separately for Part A and Part B:  
• Part A: the entire study will be put on hold ( all subjects will stop study treatment)  
if in Part A, 12 or more subjects out of the planned 36 subjects in the combined active dose groups of Part A (0.5, 1, or 2 mg), or 6 or more subjects out of the planned 12 subjects in the 2 mg dose group of Part A, have been discontinued due to meetin g any of the individual patient’s stopping rules as defined per safety area 
of interest [Table 4]. 
• Part B: if 4 or mo re subjects in the active dose group of Part B (4 mg), have been 
discontinued due to meeting any of the individual patient’s stopping rules as defined per safety area of interest [Table 4], all subjects included in Part B will 
stop study treatment.  
The entire study or Part B will be suspended and a detailed safety signal assessment will 
be conducted. An un- blinded data assessment reflecting the total study safety experience 
will be performed by the IDMC in a dose level specific way (as certain AEs are likely to be dose dependent and might occur in higher frequency with higher dose). 
Recommendations from IDMC and Health Authorities may allow a potential restart of 
the study or of the P art B.  
If the study is prematurely suspended or terminated, Actelion will promptly inform the 
investigators, the IRBs/IECs and health authorities, as appropriate, and provide the 
reasons for the suspension or termination. A potential restart of  the study will be allowe d 
only in agreement with H ealth Authorities and IRBs/IECs. 
The safety areas of interest have been defined by the clinical experience obtained for this 
class of comp ounds and are described in Section 5.1.10. Table 4 provides a summary of  
these events in these safety areas of int erest that will trigger subject’ s discontinuation or 
may results in the hold of the clinical study if a certain number of patients were to be discontinued from study treatment, as indicated above. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 112/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Table 4 Safety areas of interest  
Safety area of interest  
[See S ection  5.1.10 ] Specific study stopping criteria being applied to stop subject / study  
Cardiovascular  
 • HR < 40 bpm at two consecutive hourly 12 -lead ECG p ost-dose 
(Day  1 or re -initiation)  
• SBP < 90 mmHg at two consecutive hourly BP measurements 
post-dose (Day 1 or re -initiation)  
• Subject not meeting criteria for discharge from the hospital (Day 1 or 
re-initiation)  
• QTcF > 500 ms at any time as documented by 12- lead ECG  
• Symptomatic bradycardia or hypotension (e.g., syncope)  
Immune system and 
Infections  • Confirmed total lymphocyte count < 200 cells/ µL 
• Clinically relevant infection (e.g., serious infection, opportunistic 
infection)  
Respiratory system  
 • FEV1 and/or FVC > 15% decrease from the study baseline values 
which has been confirmed at repeat testing  
• Persistent respiratory AEs (e.g., dyspnea)  
Liver  • Abnormal LTs or signs and symptoms suggestive of DILI as 
explained in the study prot ocol [Section 5.1.10.5] 
Ocular  • Macular edema confirmed by Ophthalmology Safety Board  
AE = adverse event; BP = blood pressure; DILI = drug -induced liver injury; ECG = electrocardiogram; FEV1 = forced expi ratory 
volume in 1 second; FV C = forced vital capacity; HR = heart rate; LT  = liver test; SBP = systolic blood pressure.  
If the study is suspended or prematurely terminated for any reason, the investigator in 
agreement with Actelion must promptly inform all enrolled subjects, and ensure their appropriate treatment and follow -up, as described in Section 9.2 for subjects prematurely 
withdrawn from the study. The investigator may be informed of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the subjects’ interests.  
In addition, if the investigator suspends or terminates the study without prior agreement 
from Actelion, the investigator must promptly inform Actelion and the IRB/IEC, and provide both with a detailed written explanation of the termination or suspension. 
If the IRB/IEC suspends or terminates its approval  / favorable opinion of a study, the 
investigator must promptly notify Actelion and provide a detailed written explanation of 
the termination or suspension. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 113/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
9.4 Medical care of subjects after study completion / withdrawal from 
study  
After the subject ’s study completion or premature withdrawal from the study, whichever 
applies, the investigator/delegate will explain to subjects what treatment(s)  / medical care 
is necessary and available according to local regulations.  
In case of premature discontinuation from the study, WOCBP  should be instructed to 
continue the use of contraception  methods for at least 16 weeks after the l ast dose of 
study drug. 
10 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS 
10.1 Adverse events  
10.1.1 Definitions of adverse events  
An AE is any adverse change, i.e., any unfavorable and unintended sign, including an 
abnormal laboratory finding, symptom or disease that occurs in a subject during the course of the study  (i.e., after signing the informed consent), whether or not considered 
by the investigator as related to study  treatment.   
A treatment- emergent AE is any AE temporally associated with the use of study 
treatmen t (from study treatment initiation until 6 weeks  after study treatment 
discontinuation) whether or not considered by the investigator as related to study treatment.  
AEs include: 
• Exacerbation of a pre- existing disease.  
• Increase in frequency or intensity of a pre- existing episodic disease or medical 
condition. 
• Disease or medical condition detected or diagnosed during the course of the 
study, even though it may have been present prior to the start of the study. 
• Continuous persistent disease or symptoms present  at study start that worsen 
following the start of the study.  
• Abnormal assessments, e.g., change on physical examination, ECG findings, if they represent a clinically significant finding that was not present at study start or 
worsened during the course of the study. 
• Laboratory test abnormalities if they represent a clinically significant finding, 
symptomatic or not, which was not present at study start or worsened during the 
course of the study or led to dose reduction, interruption or permanent discontinuation of study treatment.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 114/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Overdose, misuse and abuse of the study treatment should be reported as an AE and, in addition, study treatment errors must be documented in the study drug log of the e CRF.  
10.1.2 Intensity of adverse events  
The intensity of clinical AE s is graded on a three -point scale – mild, moderate, severe – 
and is reported on specific AE pages of the e CRF.  
If the intensity of an AE worsens during study treatment administration, only the worst intensity should be reported on the AE page. If the AE lessens in intensity, no change in the severity is required.  
If the intensity of an AE with an onset date between informed consent signature and start of study treatment and which is ongoing at the start of treatment worsens after the start of study treatm ent, a new AE page must be completed. The onset date of this new AE 
corresponds to the date of worsening in intensity. 
The three categories of intensity are defined as follows:  
 Mild  
The event may be noticeable to the subject. It does not influence daily activities and 
usually does not require intervention. 
 Moderate  
The event may make the subject uncomfortable. Performance of daily activities may be influenced, and intervention may be needed. 
 Severe  
The event may cause noticeable discomfort  and usually inter feres with daily activities. 
The subject may not be able to continue in the study, and treatment or intervention is usually needed. 
A mild, moderate, or severe AE may or may not be serious [ see Section 10.2] . These 
terms are us ed to describe the intensity of a specific event. Medical judgment should be 
used on a case- by-case basis.  
Seriousness, rather than severity assessment, determines the regulatory reporting 
obligations. 
10.1.3 Relationship to study treatment  
Each  AE must be asse ssed by the investigator as to whether or not there is a reasonable 
possibility of causal relationship to the study treatment, and reported as either related or 
unrelated. The determination of the likelihood that the study drug caused the AE will be provided by an investigator who is a qualified physician. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 115/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
10.1.4 Adverse events associated to  study design or protocol- mandated procedures  
An AE is defined as related to study design or protocol -mandated procedures if it appears 
to have a reasonable possibility of a ca usal relationship to either the study design or to 
protocol- mandated procedures. Examples include discontinuation of a subject’s previous 
treatment during a washout period leading to exacerbation of underlying disease. 
10.1.5 Reporting of adverse events  
All AEs o ccurr ing after study start (i.e., signing of informed consent) and up to 6 weeks  
after study treatment discontinuation must be recorded on specific AE pages of the e CRF.   
10.1.6 Follow- up of adverse events  
AEs still ongoing more than 6 weeks after  study treatment discontinuation must be 
followed up until they are no longer considered clinically relevant. 
10.1.7 Adverse events of special interest  
A list of AESIs  is provided in Appendix 3. 
10.2 Serious adverse events 
10.2.1 Definitions of serious adverse events  
10.2.1.1 Serious adverse events  
An SAE is defined by the International Conference on Harmonisation (ICH) guidelines as 
any AE fulfilling at least one of the following criteria: 
• Fatal . 
• Life-threatening: refers to an event in which the subject was at risk of death at the 
time of the event. It does not refer to an event that hypothetically might have 
caused death had it been more severe.  
• Requiring inpatient hospitalization or prolongation of existing hospitalization. 
• Resulting in persistent or significant disability or incapacity.  
• Congenital anomaly or birth defect. 
• Medically significant: refers to important medical events that may not 
immediately result in death, be life -threatening, or require hospitalization but may 
be considered to be SAEs when, based upon appropriat e medical judgment, they 
may jeopardize the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in the definitions above.  
The following reasons for hospitalization are exempt from being reported:  
• Hospitalization  for cosmetic elective surgery, or social and/or convenience 
reasons.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 116/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• Hospitalization for pre -planned (i.e., planned prior to signing informed consent) 
surgery or standard monitoring of a pre -existing disease or medical condition that 
did not worsen, e.g., hospitalization for coronary angiography in a subject with 
stable angina pectoris.  
However, complications that occur during hospitalization are AEs or SAEs ( e.g., if a 
complication prolongs hospitalization). 
10.2.1.2 Serious adverse events associated wi th the stud y design or protocol- mandated 
procedures  
An SAE is defined as related to study design or protocol -mandated procedures if it 
appears to have a reasonable possibility of a causal relationship to either the study design 
or to protocol -mandated procedures. Examples include discontinuation of a subject’s 
previous treatment during a washout period leading to exacerbation of underlying disease or a complication of an invasive procedure that is specifically required by the protocol. 
10.2.2 Reporting of serious adverse events  
All SAEs occurring after study start (i.e., signing of informed consent) up to 16 weeks  
after study treatment discontinuation must be reported to the Actelion drug safety 
department within 24 hours of the investigator’s knowledge of the event on an S AE form, 
regardless of the investigator -attributed causal relationship with study treatment or study -
mandated procedures. 
All SAEs occurring after study start (i.e., signing of informed consent) up to 6 weeks 
after study treatment discontinuation must also  be reported using AE pages in the eCRF. 
10.2.3 Follow- up of serious adverse events  
SAEs still ongoing at the end of the 16- week follow -up period must be followed up until 
resolution or stabilization, or until the event outcome is provided, e.g., death.  
10.2.4 After the 16-week  follow- up period  
New SAEs occurring after the 16-week  follow- up period must be  reported to the Actelion 
drug safety department within 24 hours of the investigator’s knowledge of the event, only 
if considered causally related to previous exposur e to the study treatment by the 
investigator.   
10.2.5 Reporting procedures  
All SAEs must be reported by the investigator to the Actelion drug safety department  
within 24 hours of the investigator’s first knowledge of the event. 
All SAEs must be recorded on an SAE  form, irrespective of the study treatment received 
by the subject, and whether or not this event is considered by the investigator to be 
related to study treatment.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 117/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
The SAE forms must be faxed to the Actelion drug safety department (contact details are 
provided on the SAE form). The investigator must complete the SAE form in English and 
must assess the causal relationship of the event to study treatment.  
Follow- up information about a previously reported SAE must also be reported within 
24 hours of receiving it. The Actelion drug safety department may contact the 
investigator to obtain further information.  
If the subject is hospitalized in a hospital other than the study site, it is the investigator ’s 
responsibility to contact this hospital to obtain all S AE-relevant information and 
documentation. The reference safety document to assess expectedness of a suspect serious adverse 
reaction and reported by the sponsor to health authorities, IRBs /IECs  and investigators is 
the reference safety information section  of the IB [ACT -334441 IB].  
SLE exacerbations or SLE flares and associated symptoms are anticipated SAEs in this study as commonly seen with the underlying disease and therefore expected to occur in 
this subject population. These S AEs will be treated as “disease- related”  and expected  
(unless fatal)  and will therefore not require system atic unblin ding or expedited reporting 
to health authorities, IRBs/IECs, and investigators. However, t hese events  will be  
monitored during the study by the sponsor and  by the IDMC [see Section  10.4] . These 
SAEs are treated as waived SAEs for this study . 
10.3 Pregnancy 
10.3.1 Teratogenicity  
In embryo -fetal studies in rats and rabbits , ACT -334441 shows teratogenic potentia l. 
Therefore, appropriate precautions must be taken by WOCBP . Women must not become 
pregnant during the study and up to 16 weeks after study drug  discontinuation. The 
investigator must explain and stress the importance of using methods of  contraception 
[see Section  4.5.2] . 
If a woman becomes pregnant while on study treatment, study treatment must be discontinued. The investigator must counsel the subject and discuss the risks of continuing with the pregnancy and the possible effects on the fetus.  
10.3.2 Reporting of pregnancy  
Irrespective of the treatment received by the subject, any pregnancy occurring during the 
study including during the 16 weeks  following study treatment discontinuation must be 
reported within 24 hours of the investigator’s knowledge of the event.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 118/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Pregnancies must be reported on the Actelion Pregnancy form  up to 16 weeks following 
study treatment discontinuation , which is faxed to the Actelion  drug safety department 
(see contact details provided  on the Actelion Pregnancy form ), and on an AE page in the 
eCRF  up to 6 weeks following study treatment discontinuation (EOS).  
Male contraception  
Based on nonclinical data and human distribution models  [see Section 1.3], it is 
considered very unlikely that a significant dose of ACT-334441 would be delivered to the female by seminal transfer. Furthermore, the potential risk of harm to a human fetus by 
ACT -334441 is considered to be very low, based on the high safety margins  
[ACT -334441 IB]. Therefore , there is no specific recommendation for male contraception 
regarding ACT -334441. (Note: F or allowed concomitant therapies  during this trial that 
require contraception, the respective method of  contraception must be applied.)  
10.3.3 Follow-up of pregnancy  
Any pregnancy must be followed to its conclusion, and its outcome must be reported to 
the Actelion drug safety department.  
Any AE associated with the pregnancy occurring during the follow -up period after study 
drug discontinuation must  be reported on separate AE pages in the eCRF  up to 6 weeks 
following study treatment discontinuation (EOS) . Any SAE occurring during the 
pregnancy must be reported on an SAE form as described in Section 10.2.5.  
10.4 Study safety monitoring 
Clinical study safety information (AEs, SAEs, laboratory values, ECGs, vital signs, and project -specific labs/examinations as required) is monitored and reviewed on a 
continuous basis by the Actelion Clinical team (in charge of ensuring subjects’ safety as 
well as data quality) by periodically monitoring clinical studies’  activities from protocol 
conception to database closure. In addition, an IDMC is monitoring safety data  [see 
Section  3.4.1] . 
11 STATISTICAL METHODS 
11.1 General considerations 
All statistical analyses will be conducted by Actelion or by designated C ROs supervised 
by Actelion.  
The SAP for final analysis will be approved prior to database lock. The SAP for the 
interim safety review will be finalized prior to unblinding the study by the independent  
ISAC . The SAP s provide the full details of all analyses, data displays, and algorithms to 
be used for data derivations. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 119/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
All data will be listed , and endpoints will be summarized by appropriate descriptive 
statistics (tables or figures), typically including:  
• number of non- missing observations, number of missing observations, mean, standard 
deviation, median, Q1 (first quartile), Q3  (third quartile), minimum and maximum for 
continuous endpoints; 
• number of non- missing observations, number of missing observations and frequency 
with percentage per category (percentages based on the number of non- missing 
observations) for categorical endpoints; 
• number of subjects at risk, cumulative number of events, cumulative number of 
censored observations and Kaplan- Meier estimates of  the survival function for 
time-to-event endpoints. 
Baseline is defined as the last assessment prior to initiation of the study treatment.  
Absolute changes from baseline are defined as: post -baseline value minus baseline value, 
i.e., a positive sign indicates an increase as compared to baseline.  
A percentage (relative) change from baseline is defined as the absolute change from baseline divided by the baseline value (if the baseline value does not equal 0) multiplied 
by 100. 
11.2 Analysis Sets 
11.2.1 Screened Analysis S et 
This analysis set includes all subjects who were screened and received a subject number . 
11.2.2 PD Analysis S et 
The Pharmacodynamics Analysis Set (PDS) includes all subjects who received at least 
3 weeks of study treatment and have at least one lymphocyte count measurement between 
the Week 4 visit and Week 12 visit. Subjects will be analyzed according to the treatment they received.  
11.2.3 Full Analysis S et 
The Full Analysis Set (FAS) includes all randomized subject s. In order to adhere to the 
intention -to-treat principle as much as possible:  
• Subject s will be evaluated according to the dose they have been randomized to (which 
may be different to the dose they have received)  
• Unless otherwise stated , all available efficacy d ata up to the EOS  date will be 
included, irrespective of whether a subject  has stopped study treatment earlier or has 
received any SLE treatment other than that to which the subject  was randomized to.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 120/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
11.2.4 Per-Protocol S et 
The Per -Protocol Set (PPS) comprises data from all subject s included in the FAS  without 
selected major protocol deviations including but not limited to : 
• Subjects not adhering to the treatment regimen for mandatory co ncomitant 
medication ; 
• Subjects with < 80% compliance to study treatment; 
• Start of any prohibited systemic SLE therapies during the course of the trial.  
A complete list will be provided in the SAP. 
11.2.5 Safety Analysis S et 
The Safety Analysis Set includes all randomized subjects who received at least one dose 
of study treatment. Unless  otherwise stated, any analysis using the Safety Analysis Set 
will use  all available safety data up to 6 weeks  after discontinuation of study treatment. 
Subjects will be analyzed  based on actual dose taken, not the randomized dose.  
11.2.6  PK Analysis S et 
The P K Anal ysis S et will include all randomized subjects who received at least one  
ACT -334441 dose and provided at least one blood sample for PK evaluation. Subjects 
will be analyzed  based on actual dose taken, not the randomized dose.  
11.2.7 Other analysis sets  
Othe r analysis datasets are defined in the corresponding SAPs, e.g., Biomarker analysis 
sets. 
11.2.8 Usage of the analysis sets 
The primary analysis and supportive analysis of PD endpoints will be carried out on the PDS.  
All exploratory efficacy analyses will be perf ormed using the FAS. S ensitivity analys es 
of PD endpoints will also  be performed on the FAS. 
Supplementary analysis to test the robustness of the results for selected PD endpoints and for all exploratory efficacy endpoints will be performed based on the PP S. 
All safety data will be analyzed using the Safety Analysis S et. 
All PK analysis be analyzed using the PK  Analysis S et. 
11.3 Variables 
11.3.1 Main  pharmacodynamic variable 
The main  variable is the change in lymphocyte count from baseline to EOT , defined as:   
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 121/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• Total  lymphocyte count at EOT  – total lymphocyte count at baseline  
Last observation carried forward ( LOCF; using data from  the W eek 4 visit or later) will 
be used for subjects with a missing EOT  assessment.   
11.3.2 Other pharmacodynamic variables 
Other PD variables com prise : 
• Absolute values of total lymphocyte count at each timepoint; 
• Change in total lymphocyte count from baseline to each post -baseline assessment 
(expressed as absolute change from baseline and percent change from baseline).   
Absolute change and percenta ge changes are calculated as defined in Section  11.1. 
11.3.3 Safety variables 
The treatment -emergent period is defined as the time from first study treatment intake up 
to 6 weeks (inclusive) after last study treatment intake.  
• Treatmen t-emergent AEs, SAEs, and AE SIs [described in Appendix 3] ; 
• AEs leading to premature discontinuation of study tretment; 
• Change in 12- lead ECG variables  (heart rate, PR, QRS, QT, QTcB  and QTcF), 
from pre -dose to selected post -doses asse ssments (1 h, 2 h, 3 h, 4 h, 5 h, 6 h) on 
Day 1 and on day of study drug re- initiation ; 
• Occurrence of treatment -emergent 12 -lead ECG outliers . Full details of all outlier 
definitions will be provided in the SAP; 
• Occurrence of treatment -emergent 12 -lead ECG  abnormalities  at each scheduled 
assessment timepoint;  
• Occurrence of treatment -emergent  ECG -Holter  abnormalities  on Day 1 ;  
• Change in SBP and DBP  from baseline up to EOS; 
• Change in FEV 1 and FVC , expressed in absolute value (L) and percent value from 
basel ine up to EOS; 
• Occurrence of treatment -emergent decrease of FEV 1 or FVC >  15% from baseline 
values;  
• Change in laboratory parameters (hematology, blood chemistry, and urinalysis) 
from baseline up to EOS; 
• Change in protein- to-creatinine ratio from baseline to EOT ; 
• Treatment -emergent laboratory abnormalities according to CTCAE  2010 v4.03 
[CTCAE  2010 ] and FDA guidelines [FDA 2009]  (for ALT/AST/TB L); 
• Change in body weight from baseline to EOT . 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 122/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
11.3.4 Pharmacokinetic variables  
PK variables comprise  
• Ctrough ACT -334441 plasma concentrations prior to dosing at Weeks 2, 4, 8, and 
12 (EOT) ; 
• ACT -334441 plasma concentration at EOS (i.e., 6 weeks after study treatment 
discontinuation). 
 
11.3.5 Exploratory disease activity variables 
Exploratory disease activity variables comprise the following markers , including but not 
limited to : 
• Change from baseline in the SLEDAI -2K (modified to exclude leukopenia) score 
at each scheduled post -baseline assessment;  the SLEDAI -2K score at each visit is 
calculated as the sum of all individual item score/weight;  
• Change from baseline in PGA score at each scheduled post -baseline assessment;  
• Change from baseline in SLEDAI -2K mucocutaneous and/or muscoskeletal score  
at each scheduled post -baseline assessment . The SLED AI-2K mucocutaneous  
and/or muscoskeletal  score is calculated as the sum of each individual 
mucocutaneous (mucosal ulcers, rash, alopecia) and/or muscoskeletal  (arthritis 
and myositis) score/weight . 
All exploratory disease activity variables are calculated as the score at each visit minus  
the score at baseline. 
11.3.6 Quality of life variables 
Exploratory disease activity variables comprise: 
• Change from baseline to EOT in SF -36v2™ Health Survey domain and 
component scores , calculated as the score at EOT minus  the score at baseline. 
Calculation of the domain and component scores will be detailed in the SAP.  
11.3.7 Exploratory biomarker variables 
Exploratory biomarker variables comprise but not limited to : 
• Change in immunoglobulin serum levels (IgG, IgM, IgA) from baseline to each 
post- baseline assessment;  
• Change in ANA and anti -dsDNA antibody ti ters from baseline to each 
post- baseline assessment;  
• Change in serum complement components C3 and C4, CRP, fibrinogen, BLyS 
and CXCL10 from baseline to each post- baseline assessmen t; 
• Change in blood lymphocyte subsets from baseline to EOT and EOS  (expressed 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 123/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
as absolute change from baseline and percent change from baseline); 
Change from baseline is calculated as the measurement reported at each visit minus the 
measurement reported at  baseline. 
11.4 Description of statistical analyses 
11.4.1 Overall testing strategy  
An optimized contrast test according to the Multiple Comparison Procedure  and 
Modelling (MCP -Mod) approach [Bretz 2005]  for each considered dose -response model 
will be  performed. The existence of dose -response effects will be  tested using the 
maximum of the model -based contrast tests. Multiplicity adjusted p -values will be  
calculated using the Dunnett -distribution. 
11.4.2 Analysis of the main  pharmacodynamic variable(s) 
11.4.2.1 Hypotheses and statistical model 
The null hypothesis is that there is no dose response in terms of lowering of lymphocyte counts (p, which is a negative value for a lowering of the lymphocyte count ) from 
baseline to EOT , and the alternative hypothesis is th e existence of a dose response:  
 for all doses d = 0.5, 1, 2, 4 mg 
                                                vs 
 for at least 1 dose d =0.5, 1, 2, 4 mg 
If Part B of the trial is not performed , the hypothesis will be  
 for all doses d = 0.5, 1, 2 mg 
                                                vs 
 for at least 1 dose d =0.5, 1, 2 mg 
To meet the objective of demonstrating existence of a dose response of ACT -334441 on 
the lymphocyte count reduction f rom baseline in subjects with SLE , the null hypotheses 
must be rejected by the test with a one -sided significance level of 5% .  
11.4.2.2 Handling of missing data 
In the primary analysis, missing lymphocyte count at EOT  visit will be imputed utilizing  
LOCF  technique s (using data from  the W eek 4 visit or later). Patients with missing 
baseline lymphocyte count  and/or no lymphocyte count  at or after V isit 4 will be 
excluded from the primary analysis.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 124/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
11.4.2.3 Main analysis 
The MCP -Mod approach consists of a set of optimized cont rast tests for establishing the 
existence of dose- response effects. The overall strategy is described as follows:  
Definition of a set of likely dose -response relations [ see Section 11.6 for more details ] 
(the method allows for characteristics of the curve, such as maximum effect , to be 
defined at doses not studied): 
• Maximum effect ( Emax) with 50% of the maximum effect at dose 0.2 mg 
• Emax with 50% of the maximum effect at dose 0.4 mg 
• Emax with 50% of the maximum effect at dose 1. 0 mg 
• Quadratic with maximum effect at dose 3.0 mg  (only if the 4 gm dose is studied) 
• Sigmoid -Emax with 50% of the maximum effect at dose 0.4 mg and 95% of the 
maximum effect at dose 2.0 mg.  
The existence of dose -response effects will be assessed with the o ptimized contrast tests. 
Dose -response effects are established at one- sided level α=5%, if the following condition 
on the p value holds for at least one contrast i: 
, where 
describes the Dunnett- distribution with correlation matrix 
 . 
The model with the minimum p-value will be fitted to the data.  As a sensitivity analysis, 
all remaining significant models will be fitted to the data , and model -based dose 
estimates will be calculated.  
Given established dose -response effects with MCP -Mod, PD effects will be analyzed 
based on pairwise comparisons of reduction in lymphocyte count from baseline for each 
active dose levels to placebo using an analysis of covariance ( ANCOVA ) model, adjusted 
for baseline lymphocyte counts. Testing will be done with two -sided significance level 
5%. The type -1 error will be controlled via a hierarchical ordering of the tests: pairwise 
comparison will be conducted in decreasing dose order.  
The dose -response data will be summarized with point -wise an d model -based estimates, 
standard deviation and 95% confidence -intervals (CI) on the reduction in lymphocytes 
from baseline at the examined dose levels. A plot of the estimated dose -response curve 
with 95% credibility interval limits will be presented alon g with the observed response at 
each dose.  
This analysis will be performed on the PDS.  
11.4.2.4 Supportive/sensitivity analyses  
A supportive analysis will be performed on the FAS and PPS . The analysis described in 
Section  11.4.2.3 will also be repeated on observed data with no missing data imputation. 
Further analysis will be described in the SAP.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 125/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
11.4.2.5 Subgroup analyses 
Any subgroup analysis will be described in the SAP.  
11.4.2.6 Other  pharmacodynamic variables 
Absolute values, absolute change from baseline and percent change from baseline of total 
lymphocyte counts and blood lymphocyte subsets at each timepoint will be summarized 
descript ively. An ANCOVA model adjusted for baseline counts will be used to compare 
each dose to placebo at the EOT  visit only. 
11.4.3 Analysis of the safety variable(s) 
The Safety Analysis Set will be used to perform all safety analyses.  
If not otherwise stated, only treatment -emergent safety data (observations with onset or 
assessment dates at/after first intake of study drug up to 6 weeks  after study drug 
discontinuation) will be considered in tables and figures. All safety data will be included in listings, with flags for safety data not considered to be treatment- emergent.  
Specific safety events ( AEs, laboratory tests, ECG findings, etc .) will be considered. In 
general, they consist of one or more well -defined safety events that are similar in nature 
and for which there is a specific clinical interest in connection with ACT -334441.  
For specific AESIs, the number and percentage of subject s with at least one event will be 
reported. Point estimates and 95% CIs for safety -event incidences and the relative risk 
ratio relative to placebo will be provided without adjustment for multiplicity.  
Exploratory analy sis of time to first onset of safety event s of interest  may be displayed by 
Kaplan -Meier estimates.  Subject s not experiencing the safety event will be censored  at 
the minimum of the EOS  date and  6 weeks  after last dose of study drug. Where 
applicable, study treatment doses will be c ompared with placebo by hazard ratios and 
corresponding 95% CI s from Cox’s regression model.  
11.4.3.1 Adverse events  
All AEs will be coded using the latest version of the Medical Dictionary for Regulatory 
Activities  (MedDRA ) available at the time of database closu re. 
11.4.3.1.1 Treatment -emergent AEs and SAEs  
Treatment -emergent AEs, SAEs and AEs leading to premature discontinuation of study 
drug will be tabulated by study dose, System Organ Class (SOC) and preferred terms 
within each SOC: the number and percentage of subjects who experienced at least one (S)AE, at least one (S)AE within each SOC and at least one S(AE) within each preferred term will be displayed.  (S)AEs will also be summarized by decreasing frequency of 
preferred term. (S)AEs will also be tabulated by maximum intensity and relationship to 
each ACT -334441 dose or placebo.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 126/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
11.4.3.1.2 AEs and SAEs for screening failure patients  
AEs an d SAEs  during screening  will be listed for patients who are s creening failures and 
do not enter the study treatment period . 
11.4.3.1.3 AESIs 
The number  and percentage of subjects who experienced at least one AESI, at least one 
AESI within each category  and at least one AESI within each preferred term will be 
summarized by dose. The relative risk of having an AE SI in each dose group compared to 
placebo wi ll be summarized using forest plots. 
11.4.3.1.4 Post-treatment AEs and SAEs 
Post- treatment (S)AEs occurring over 6 weeks  after treatment discontinuation will be 
summarized in a similar manner as described in Section  11.4.3.1.1.  
11.4.3.1.5 Deaths 
Fatal SAEs occurring any time after the start of treatment will be summarized in a similar 
manner as described in Section  11.4.3.1.1.  
11.4.3.2 Cardiac safety 
11.4.3.2.1 12-lead ECG assessments 
Descriptive summary statistics by visit and study treatment will be provided for observed treatment -emergent values and absolute changes from pre-dose in numeric 12- lead ECG 
values ( HR, PR, QRS, QT, QTcB, QTcF). Data will be summarized from pre -dose to 
each post-dose assessments on Day 1 and also at the re-initiation of study drug. 
Notable abnormalities for selected 12 -lead ECG parameters ( HR, PR, QT, QTcF) will be 
summarized for all data on Day 1, Week 12 and also at the re-initiation of study drug.  
In addition treatment- emergent morphological ECG abnormalities will be summarized  
descript ively (using data from the ECG provider).  
11.4.3.2.2 Cardiac safety events  
Cardiac safety events will include:  
• treatment -emergent QTc > 450 ms (male), > 470 ms ( female), > 500 ms (male), and 
> 520 ms (female) 
• treatment -emergent QTc increase from baseline > 30 ms, > 60 ms  
• other treatment -emergent abnormalities observed by 12- lead ECG  
• treatment -emergent (serious) cardiac AE SIs.
 
 
Cardiac safety events will be summarized descriptively.   
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 127/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
11.4.3.2.3 24-hour Holter ECG 
Treatment -emergent abnormalities as  assessed by 24 -hour Holter ECG monitoring will be 
summarized by dose group and presented similarly to AEs. H ourly mean HRs will be 
summarized descriptively.    
11.4.3.3 Pulmonary safety 
11.4.3.3.1 Pulmonary function t esting  
Descriptive summary statistics by visit and study do se will be provided for observed 
treatment -emergent values and changes from baseline by visit in FEV 1, FVC and 
FEV 1/FVC ratio (all expressed in absolute change, % change and % of predicted value).  
The number and proportion of treatment -emergent decrease of percent -predicted FEV 1 or 
FVC >  15 percentage points from baseline at any time up to the last treatment will b e 
summarized by dose. 
11.4.3.3.2 Pulmonary safety events 
Pulmonary safety events will include:  
• treatment -emergent decrease of FEV 1 or FVC to < 85% of base line values  
• (serious) pulmonary AE SIs  
• withdrawal due to pulmonary reasons / AE  
 
Pulmonary safety events will be summarized descriptively.   
11.4.3.4 Vital signs  
Descriptive summary statistics by visit and study dose will be provided for observed 
treatment -emergent values and absolute changes from baseline in  HR, BP and body 
weight.  
Treatment -emergent notable BP abnormalities will also be summarized. The definition 
for notable abnormalities is provided in Appendix 7. 
11.4.3.5  Laboratory endpoints 
11.4.3.5.1 Laboratory tests  
Descriptive summary statistics by visit and study dose will be provided for observed 
treatment -emergent values and absolute changes from baseline for laboratory tests 
(hematology, blood chemistry, urinalysis). Data will be displayed in S tandard 
International units whenever possible, and graphical approaches will be applied. 
11.4.3.5.2 Laboratory safety events 
Laboratory safety events will include:  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 128/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
• treatment -emergent laboratory test abnormalities based on normal ranges of the central 
laboratory and accordin g to CTCAE 2010 v4.03 [ CTCAE  2010]  
• treatment -emergent laboratory test abnormalities  based on FDA guidance for DILI  
[FDA 2009]  (for ALT/AST/TBL)  
• lymphocyte count reversibility after EOT, expressed in absolute chang e and percent 
change from baseline  
 
The definitions for marked abnormalities is provided in Appendix 7. Laboratory safety 
events will be summarized descriptively.   
11.4.3.6 Ocular safety  
Ocular safety events will include:  
• treatment -emergent ocular AE SIs 
11.4.4 Analysis of the exploratory efficacy variables  
The analysis of the exploratory efficacy endpoint change from  baseline in SLEDAI -2K 
score at Week 12 will be performed using an AN COVA with treatment and baseline 
score as factors. Missing values at  Week 1 2 will be imputed using LOCF. The mean 
treatment difference including 9 5% CI for each ACT -334441 dose compared to placebo 
will be presented. A sensitivity analysis will be performed using observed data without imputation.  
Other changes from baseline  variables will be analyzed in a similar manner using an 
ANCOVA.  
All exploratory efficacy endpoints will be analyzed on the FAS and PPS. 
No multiplicity adjustments will be made on exploratory efficacy endpoints. Other 
analyses will be described in the SAP. 
11.4.5 Analysis of other variable(s) 
11.4.5.1 Pharmacokinetic endpoints 
Concentrations will be summarized by descriptive statistics.  
11.4.5.2 Exploratory biomarkers 
Descriptive statistics of mean, median, CV,  standard error of the mean , 95% CI for each 
time point and variable wi ll be summarized . 
Statistical analysis of means (time -point and variable) for each ACT -334441 dose group 
against placebo  will be conducted. 
Statistical analysis on the exploratory disease activity endpoint SLEDAI -2K will be 
performed on the difference between subjects with an explora tory biomarker value ≤ the 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 129/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
25th percentile compared to subjects with a value ≥ the 75th percentile. Depending on the shape of the dose-response curve observed for the main  PD endpoint, dose groups may be 
combined to increase the power to observe differences.  
Modeling of exploratory biomarkers together with PK, PD or efficacy variables might be 
conducted and will be described in the SAP. 
The list of statistical analysis on exploratory biomarkers data is not exclusive. 
11.4.5.3 Exploratory analyses 
Exploratory, data- driven analyses may be performed  and will be described in the SAP. 
The relationship between ACT -334441 concentrations and any safety or tolerability, 
disease activity , biomarker, or PD data might be investigated on an exploratory basis. 
Whenever possible, a model will be established to describe these relationships.  
11.5 Interim safety review  
Prior to enrolling any subject into study Part B , the ISAC  will perform a n interim analysis 
of Part A  data, which will be reviewed by the IDMC .  
The IDMC will operate according to an IDMC charter jointly agreed between the IDMC 
members and Actelion . 
11.5.1 Objectives  
The objective of the interim safety review is to evaluate the safety profile of ACT -334441 
in SLE patients and to determine if the study should continue as planned with initiation of 
Part B or if the study  should be amended with protocol changes or if the study should be 
discontinued to ensure subject safety. 
11.5.2 Timing  
The interim safety review will be conducted when all subjects enrolled into Part A have 
completed Visit 4  (Week 4) , unless prematurely discontinued.  
11.5.3 Unblinded IDMC review  
After blinded data review by blinded Actelion staff, a n ISAC  (a CRO  or an Academic 
Research Organization not otherwise involved with study conduct or statistical analysis ) 
will generate an unblinded interim analysis report exclusively for review by the IDMC.  
No interim database lock will occur. Actelion staff will remain blinded to study treatment 
after the interim safety review is performed.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 130/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Based on the interim safety review with cut -off at Visit 4 and an IDMC recommendation, 
the study  will continue as planned with Part B initiation or be amended (protocol changes 
or study discontinued to ensure subject safety). 
11.5.4 Variables  
The interim data will include the following  variables : 
• Demographics a nd disease characteristics  
• Patient disposition  
• Background and concomitant medications 
• SAEs, AEs  (including AESI), and AEs leading to study treatment discontinuation 
• 12-lead ECGs and 24-hour ECG Holter  data  
• Spirometry  data  
• Hematology data including total ly mphocyte counts, neutrophils and platelet  
counts 
• Blood clinical c hemistry data including liver function parameters and 
immunoglobulin levels (IgM, IgG, IgA) 
• ACT -334441 plasma concentration  data. 
 
Data will be displayed using summary tables, listings, figur es and  patient  profiles . 
11.6 Sample size  
11.6.1 Sample size justification  
The sample size for the study was determined based on simulations. A sample size of 
64 subjects (12 in each ACT -334441 dose group of 0.5 mg, 1 mg, 2 mg, 4 mg and 16 in 
the placebo group) would provide an average power of at least 90% to show a significant 
dose- response relationship at a one -sided alpha significance level of 5%, under the 
assumption of a lymphocyte % reduction compared to baseline of 0% (mean at Week 12 
= 2.0 × 109/L) for placebo  and a maximum of 70% for any ACT -334441 dose (mean at 
Week 12 = 0.6 × 109/L). A maximum lymphocyte % reduction compared to baseline of 
70% was assumed based on results obtained in Phase 1 with ACT -334441 and with other 
S1P modulators. The pooled standard deviation is assumed to be 0.45 × 109/L. This takes 
into account 10% of subjects being excluded from the PDS.  
If Part B is not conducted and the 4 mg dose is not tested then there will be an average 
power of at least 80% to show a significant dose-respons e relationship with three  doses at 
a one -sided significance level of 5%, using the same assumptions as above (based on a 
total sample size of 48 subjects [12, 12, 12 and 12 in placebo, 0.5 mg, 1 mg and 2 mg , 
respectively ]). 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 131/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Assuming a % reduction  in lymphocyte counts  of between 25% to 70% (and pooled 
standard devi ation = 0.45 × 109/L) compared to placebo , any single pairwise dose 
comparison will have between 77% and 100% power to detect a difference at a 2 -sided 
significance level  of 5%.  
Assumptions on the  placebo response rate, maximum effect sizes and candidate 
dose- response models are based on the observed lymphocyte counts in study 
AC-064-101. 
Figure 4 Reduction in total lymphocyte count dose -response s hapes  
 
 
12 DATA HANDLING 
12.1 Data collection 
The investigator/delegate is responsible to ensure the accuracy, completeness, and timeliness of the data reported. All source documents should be completed in a neat, legible manner to ensure accurate interpretation of the data. Data reported in the eCRF  
derived from source documents must be consistent with the source documents. 
eCRF data will be captured via electronic data capture using the Rave system provided by 
Medidata So lutions, Inc., a web- based tool. The investigator and site staff will be trained 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 132/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
to enter and edit the data via a secure network, with secure access features (username, password and identification – an electronic password system). A complete electronic 
audit trail will be maintained.  
Physician -reported e ntries recorded in the PGA are considered source data.  
Subject Screening and Enrollment data will be completed for all subjects (i.e., eligible and non- eligible) through the IRT system  and e CRF.  
For each subject enrolled, regardless of study treatment initiation, a n eCRF must be 
completed and signed by the investigator/delegate. This also applies to those subjects who fail to complete the study. If a subject withdraws from the study, the reason must be noted on the e CRF.  
12.2 Maintenance of data confidentiality 
The investigator/delegate must ensure that data confidentiality is maintained. On eCRFs 
or other documents submitted to Actelion, subjects must be identified only by number, and never by name or initials , hospital numbers or any other identifier. The 
inves tigator/delegate must keep a subject identification code list at the site, showing the 
randomization number, the subject’s name, date of birth and address or any other locally accepted identifiers. Documents identifying the subjects (e.g., signed ICFs) mus t not be 
sent to Actelion, and must be kept in strict confidence by the investigator/delegate. 
12.3 Database management and quality control 
eCRFs will be used for all subjects. The investigator will have access to the site eCRF 
data until the database is locked . Thereafter, they will have read -only access.  The eCRF 
must be kept current to reflect subject status at any timepoint during the course of the study.  
While entering the data, the investigator/delegate will be instantly alerted to data queries by validate d programmed checks. Additional data review will be performed by Actelion 
on an ongoing basis to look for unexpected patterns in data and study monitoring. If discrepant data are detected, a query specifying the problem and requesting clarification will be  issued and visible to the investigator/delegate via the eCRF. All electronic queries 
visible in the system either require a data correction (when applicable) and a response from the investigator/delegate to clarify the queried data directly in the eCRF, o r simply a 
data correction in the eCRF. The investigator/delegate must, on request, supply Actelion 
with any required background data from the study documentation or clinical records. This is particularly important when errors in data transcription  are sus pected. In the case of 
health authority queries, it is also necessary to have access to the complete study records, 
provided that subject confidentiality is protected. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 133/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
This process will continue until database closure. 
Laboratory samples , 12 -lead ECG, 24-hour Holter ECG, and spirometry  will be 
processed through a central reader , and the results will be sent electronically to Actelion.  
After the database has been declared complete and accurate, the database will be closed. 
Any changes to the database after that time may only be made as described in the 
appropriate SOP. After database closure, the investigator will receive the eCRF of the 
subjects of her/his site (including all data changes made) on electronic media or as a 
paper copy.  
13 PROCEDURES AND GOOD CLINICAL PRACTICE 
13.1 Ethics and Good Clinical Practice 
Actelion and the investigators will ensure that the study is conducted in full compliance with ICH -GCP Guidelines, the principles of the “Declaration of Helsinki” and with the 
laws and regulations of the country in which the research is conducted.  
13.2 Independent Ethics Committee / Institutional Review Board 
The investigator will submit this protocol and any related document provided to the subject (such as Subject Information Leaflet used to obtain informed consent) to an IRB 
or IEC. Approval from the committee must be obtained before  starting the study and 
must be documented in a dated letter to the investigator, clearly identifying the study, the documents reviewed, and the date of approval.  
Modifications mad e to the protocol after receipt of the approval must also be submitted as 
amendments by the investigator to the IRB/IEC in accordance with local procedures and 
regulations [ see Section  13.6] . 
A list of members participating in the IRB/IEC meetings must be provided, including the 
names, qualifications and functions of these members. If that is not possible, the attempts made to obtain this information along with an explanation as to why it cannot be obtained or disclosed must be documented in the study documentation. If a study staff member was present during a meeting, it must be clear that this person did not vote. 
13.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according to ICH -GCP guidelines and local regulations from each individual participating in this 
study and/or legal representative. The investigator/delegate must explain to subjects that they are completely free to refuse to enter the study, or to withdraw from it at any time 
for any reason.  
The ICF will be provided in the country local language(s). 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 134/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Site staff authorized to participate to the consent process and/or to obtain consent from the subject and/or legal representative will be listed on an Actelion Delegation of 
Authority form. A study physician must always be involved in the consent process.  
The subject and/or legal representative must sign, personally date and time (if appropriate) the ICF before any study- related procedures (i.e., any procedures required by 
the protocol) begin. The ICF must also be signed, personally dated and timed (if the first 
study- mandated procedure was performed on the same day informed consent was 
obtained) by the authorized site staff listed on the Actelion Delegation of Authority form. 
A copy of the signed and dated ICF is given to the subject and/or legal representative; the 
original is filed in the site documentation.  
The informed consent process must be fully documented in the subject’s medical records, including study reference, subj ect number, date/time (if applicable) when the subject was 
first introduced to the Actelion clinical study, date/time (if applicable) of consent, who 
participated in the consent discussion, who consented the subject and any additional person present during  the consent process (e.g., subject family member), copy of the 
signed ICF given to the subject / legal representative.  
In the case that the site would like to recruit a subject who would be considered as vulnerable (e.g., subject cannot read or write , doe s not speak or understand the ICF 
language), additional measures must be implemented in order to ensure subject rights are respected and the consent obtained is legally valid. Actelion, the regulatory authorities (if applicable) and the IRB/IEC must be informed prior to the recruitment. The consent process (e.g., involvement of an impartial witness) must be fully described, submitted to, and approved by the IRB/IEC, according to procedures and before subjects are recruited .  
13.4 Compensation to subjects and investigators 
Actelion provides insurance in order to indemnify (with both legal and financial coverage) the investigator/site against claims arising from the study, except for claims that arise from malpractice and/or negligence.  
The compensation of the subject in the event of study -related injuries will comply with 
applicable regulations. 
13.5 Protocol adherence/compliance 
The investigator must conduct the study in compliance with the approved version of the protocol and must not implement any deviation/change from the protocol, except when deviation is necessary to eliminate an immediate hazard to the subject .  
If a protocol deviation occurs, the investigator/delegate will inform Actelion or its representative in a timely manner. The investigator/delegate must do cument and explain 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 135/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
any deviation from the approved protocol. IRB/IEC and regulatory authorities must be informed, according to their requirements, but no later than 15 calendar days after the event.  
13.6 Protocol amendments 
Any change to the protocol can only be made through a written protocol amendment. A protocol amendment must be submitted to the IRB/IEC and regulatory authorities, 
according to their requirements. 
13.7 Essential documents and retention of documents 
The investigator/delegate must maintain adequate records necessary for the 
reconstruction and evaluation of the study. A number of attributes are considered of universal importance to source data and the records that hold those data. These include that the data and records are accurate, legible, contemporaneous, original (or certified copy), attributable, complete, consistent, enduring and available when needed. 
These records are to be classified into two different categories of documents: 
investigator’s file and subject clinical source documents.  
These records must be kept by the investigator for as long as is necessary to comply with 
Actelion’s requirements (e.g., as specified in the clinical study agreement) and national and/or international regulations, whichever would be the longest period. If the investigator cannot guarantee this archiving requirement at the investigational site for any 
or all of the documents, special arrangements, respecting the data confidentiality, must be made between the investigator and Actelion to store these documents outsi de the site, so 
that they can be retrieved in case of a regulatory inspection. No study document should be destroyed without prior written approval from Actelion. Should the investigator wish to assign the study records to another party, or move them to another location, Actelion must be notified in advance.  
If the site is using an electronic/computerized system to store subject medical records, it 
can be used for the purpose of the clinical study if it is validated (as per 21 CFR Part 11 or equivalent standard) and if the CRA  has been provided personal and restricted access 
to study subjects only, to verify consistency between electronic source data and the eCRF 
during monitoring visits.  
If the site is using an electronic/computerized system to store subje ct medical records but 
it could not be confirmed that the system is validated or if the CRA  could not be provided 
access to the system, the site is requested to print the complete set of source data needed for verification by the CRA . The printouts will be  considered as the official clinical study 
records and must be filed either with the subject medical records or with the subject’s eCRF .  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 136/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
In order to verify that the process the site uses to prepare certified copies is reliable, the CRA must be able to observe this process and confirm that the comparison of the source 
documents and the certified copy did not reveal inconsistencies. The CRA  does not need 
to verify this process for all data of all subjects but at least for some of them (e.g., first subject , regular check during the study of critical data like inclusion/exclusion criteria, 
endpoints for some subjects) as per Actelion’s instructions. If it were not possible for the monitor to observe this process, it would not be possible to rely on the site’s c ertified 
copies , therefore the site cannot be selected for the clinical study. The printouts should be 
filed either with the subject medical records or with the subject’s eCRF.  
13.8 Monitoring 
Prior to study start, a site initiation visit (SIV) will be performe d after the required 
essential study documents are approved by Actelion. The study treatment will be shipped to the site upon approval of the required essential documents.  
The principal investigator  must ensure that all site personnel involved in the stud y will be 
present during the SIV and will dedicate enough time to it. Site Information Technology 
support should also be available during the initiation visit.  The SIV must be completed before the site can start the screening of study subjects. 
Following the SIV, a copy of the completed initiation visit report and follow -up letter 
will be provided to the principal investigator  and filed in the i nvestigator site file  (ISF). 
During the study, the CRA  will contact and visit the investigational site regularly and, on 
request , must be permitted to have access to trial facilities and all source documents 
needed to verify adherence to the protocol and the completeness, consistency and accuracy of the data being entered in the eCRFs and other protocol -related docum ents. 
Actelion monitoring standards require full verification that informed consent has been provided and verification of adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of the main efficacy, safety and tolerability endpoints. 
Additional checks of the consistency of the source data with the e CRFs will be performed 
according to the study -specific monitoring plan.  The frequency of the monitoring visits 
will be based on subject recruitment rate and critical data collecti on times.  
The principal investigator must ensure that the eCRF is completed after a subject’s visit 
to the site and that all requested subject files (e.g., ICFs, medical notes/charts, other documentation verifying the activities conducted for the study) ar e available for review 
by the CRA . The required site personnel must be available during monitoring visits and 
allow adequate time to meet with the CRA  to discuss study- related issues.  
The investigator agrees to cooperate with the CRA (s) to ensure that any issues detected in 
the course of these monitoring visits are resolved. If the subject is hospitalized or dies in 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 137/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
a hospital other than the study site, the investigator is responsible for contacting that hospital in order to document the SAE , in accordance with local regulations . 
A close- out visit will be performed for any initiated site and when there are no more 
active subjects and after all study data have been accepted by medical review and all follow- up issues have been resolved. In case a site does not enroll any subjects, the 
close- out visit may be performed prior to study database closure at the discretion of 
Actelion.  
13.9 Investigator site file 
Each site will be provided with an ISF prior to the initiation visit. It will contain all the essential documents that are required to always be up- to-date and filed at site as per 
ICH-GCP section 8. 
The ISF will include a table of content s listing the  essential documents. All study -related 
documentation must be maintained in the ISF. 
In some cases, exceptions can  be discussed with the CRA  regarding the filing of the study 
documents outside the ISF. It should be clearly documented where each document is 
filed. This note to file should be present in the specific tab of the document in the ISF. 
The ISF must be stored in a secure  and access -restricted  area during and after the study. It 
must be kept by the site for as long as needed to comply with any applic able rules and 
regulations, ICH -GCP as well as instructions from Actelion. If the site needs to transfer 
the ISF to another location and/or if site facility ca n no longer store the ISF, the principal 
investigator must inform Actelion immediately.  
If the principal investigator change s, or if the site relocates , the CRA  must be notified as 
soon as possible.  
13.10  Audit  
Actelion’s Global Quality Management representative s may audit the investigator site 
(during the study or after its completion). The purpose of this visit will be to determine 
the investigator’s adherence to ICH -GCP, the protocol, and applicable regulations ; 
adherence to  Actelion’s requirements (e.g., SOPs)  will also be verified. Prior to initiating 
this audit, the investigator will be contacted by Actelion to arrange a time for the audit.  
The investigator and staff must cooperate with the auditor(s) and allow access to all study documentation (e.g., subject records) and facilities. 
13.11  Inspections 
Health authorities and/or IRB/IEC may also wish to conduct an inspection of Actelion’s 
clinical study (during the study or after its completion).  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 138/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Should an inspection be requested by a health authority and/or IRB/IEC, the investigator 
must inform Actelion immediately (usually via the  CRA ) that such a request has been 
made.  
The investigator and staff must cooperate with the inspector(s) and allow access to all 
study documentation (e.g., subject records) and study facilities.  
13.12  Reporting of study results and publication  
Study r esults will be documented in a Clinical Study Report that will be signed by 
Actelion representatives and the coordinating i nvestigator (or principal  investigator for 
single -center studies).  
The coordinating investigator, if any, will have the opportunity to review the analysis of 
the data and to discuss the interpretation of the study results with Actelion prior to publication. 
Actelion will post results from its clinical studies on Actelion’s C linical Trial Register 
and on external/national registries, as required by law. 
Actelion’s Policy on Disclosure of Clinical Research Information can be found at:  
http://www.actelion.com/documents/corporate/poli cies_charters/policy_clinical- research -
information.pdf 
In accordance with the Good Publication Practices and ethical practice, the results of the 
study will be submitted for publication in a peer -reviewed journal. Study results can be 
submitted for present ation at a congress before publication in a peer -reviewed journal. 
Authorship will be determined in accordance with the International Committee of Journal Editors criteria and be based on: 
• substantial contributions to: the conception or design of the study, or the 
acquisition, analysis or interpretation of data; and 
• drafting of the publication or critical review for important intellectual content; and  
• providing final approval of the version to be published; and 
• agreement to be accountable for all aspects o f the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved.  
The list of authors of any publication of study results may include representatives of Actelion and will be det ermined by mutual agreement.  
Any study- related publication written independently by investigators must be submitted 
to Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments and may also request alterations and/or 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 139/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period. 
Actelion’s policy on s cientific publications can be found at: 
http://www.actelion.com/documents/corporate/policies -charters/policy -scientific -
publications.pdf 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 140/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
14 REFERENCES 
[Abu-Shakra 1995] Abu-Shakra M, Urowitz MB, Gladman DD, Gough J . Mortality 
studies in systemic lupus erythema tosus. Results from a single center. I. Causes of 
death. J Rheumatol 1995;22(7):1259-64. 
[ACR 1997] 1997 Update of the 1982 American College of Rheumatology Revised 
Criteria for Classification of Systemic Lupus Erythematosus; 
http://www.rheumatology.org/Pr actice/Clinical/Classification/Classification_Criteri
a_for_Rheumatic_Diseases/#5 . 
[ACR 1999] Guidelines for referral and management of systemic lupus erythematosus in 
adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus  Guidelines. Arthritis Rheum. 1999 Sep;42(9):1785-96. 
[ACT -334441 IB] Investigator’s Brochure for ACT -334441 S1P1 receptor agonist, 
version 5. Actelion Pharmaceuticals, Ltd, January  2015. 
[Alarcón  2002] Alarcón GS et al. Baseline characteristics of a multi ethnic lupus cohort: 
PROFILE. Lupus. 2002;11(2):95-101. 
[Alperovich 2007] Alperovich G, Rama I, Lloberas N, et al . New immunosuppresor 
strategies in the treatment of murine lupus nephritis. Lupus. 2007;16(1):18-24. 
[Alvarez 2007] Alvarez SE, Milstien S, Sp iegel S Autocrine and paracrine roles of 
sphingosine-1-phosphate. Trends Endocrinol Metab 2007;18(8):300-7. 
[Amissah -Arthur 2010] Amissah -Arthur MB and Gordon C. Contemporary treatment of 
systemic lupus erythematosus: an update for clinicians . Ther Adv Chronic Dis. Jul 
2010; 1(4): 163–175. 
[Ando 2010] Ando S, Amano H, Amano E, et al. FTY720 exerts a survival advantage 
through the prevention of end- stage glomerular inflammation in lupus -prone BXSB 
mice. Biochem Biophys Res Commun. 2010 Apr 9;394(3):804-10.  
[Bertsias 2008] Bertsias  G, Ioannidis  JPA, Boletis  J, et al. EULAR recommendations for 
the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics . Ann Rheum Dis 2008;67:195-205. 
[Bombardier 1992] Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH.  
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630-40. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 141/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
[Borchers 2010] Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The 
geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010 Mar;9(5):A277 -87. 
[Bossingham 2003] Bossingham D. Systemic lupus erythematosus  in the far north of 
Queensland. Lupus. 2003;12(4):327-31. 
[Boumpas 1995a ] Boumpas DT, Austin HA, 3rd, Fessler BJ, et al . Systemic lupus 
erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Annals of internal medicine 1995; 122:940-50. 
[Boumpas 1995b] Boumpas DT, Fessler BJ, Austin HA, 3rd, et al . Systemic lupus 
erythematosus: emerging concepts. Part 2: Dermatologic and join t disease, the 
antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Annals of internal medicine 1995; 123:42-53. 
[Bretz 2005] Bretz F, Pinheiro JC, Branson M; Combining Multiple Comparisons and 
Modeling Techniques in Dose- Response Studies; Biometrics 2005; 61; 738-748. 
[Brinkmann 2007] Brinkmann V. Sphingosine 1 -phosphate receptors in health and 
disease: Mechanistic insights from gene deletion studies and reverse pharmacology.  Pharmacol Ther 2007;9 (11):883–897. 
[Brinkmann 2010] Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): 
discovery and dev elopment of an oral drug to treat multiple sclerosis. Nat Rev Drug 
Discov 2010;115:84–105. 
[Cervera 2009] Cervera R,  Khamashta MA,  Hughes GR. The Euro -lupus project: 
epidemiology of systemic lupus erythematosus in Europe. Lupus. 2009 Sep;18(10):869-74. 
[Chiu 2010] Chiu YM, Lai CH Nationwide population- based epidemiologic study of 
systemic lupus erythematosus in Taiwan. Lupus 2010;19(10)1250-5. 
[Cyster  2005] Cyster JG. Chemokines, sphingosine -1-phosphate, and cell migration in 
secondary lymphoid organs. Annu Rev Immunol 2005;23:127–59. 
[CTCAE  2010] Common Terminology Criteria for Adverse Events (CTCAE) Version 
4.0 Published: May 28, 2009 (v4.03: June 14, 2010); U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES; National Institutes of Health; National Cancer Institu te; http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_8.5x11.pdf. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 142/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
[Danchenko 2006] Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic 
lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-18. 
[Danza 2013] Danza A , Ruiz -Irastorza G.  Infection risk in systemic lupus erythematosus 
patients: susceptibility  factors and preventive strategies.  Lupus. 2013 
Oct;22(12):1286-94. doi: 10.1177/0961203313493032. 
[Ding 2013] Ding HJ, Gordon C. New biologic therapy for systemic lupus  
erythematosus. Curr Opin Pharmacol. 2013 Jun;13(3):405-12. 
[Dooley 2011] Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus  
azathioprine as maintenance therapy for lupus nephritis. N Engl J Med  
2011;365:1886-95. 
[EMA 2013] EMA . Guideline on clinical investigation of medicinal products for the 
treatment of systemic lupus erythematosus, cutaneous lupus and lupus nephritis. 2013. 
[EMA Benlysta] EMA Benlysta® label. Document can  be downloaded:  
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002015/WC500110152.pdf. 
[EMA Gi lenya] EMA Gilenya® label. Document can  be downloaded:  
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002202/WC500104530.pdf. 
[FDA  2009] Guidance to industry: Drug -Induced Liver  Injury: Premarketing Clinical 
Evaluation (2009). 
[FDA 2010] FDA Guidance for Industry, Systemic Lupus Erythematosus -Developing 
Medical Products for Treatment (June, 2010). 
[FDA Benlysta] FDA Benlysta
® label. Document can  be downloaded:  
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125370s016lbl.pdf. 
[FDA Gilenya ] FDA Gilenya® label. Document can  be downloaded:  
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf. 
[FDA Plaquenil] FDA Plaquenil® label. Document can  be downloaded: 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/009768s041lbl.pdf. 
[Fortin 2008] Fortin PR, Abrahamowicz M, Ferland D et al. Steroid -sparing effects of 
methotrexate in systemic lupus erythematosu s: a double blind, randomized, 
placebo -controlled trial. Arthritis Rheum 2008;59:1796-804. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 143/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
[Furie 2011] Furie R, Petri M, Zamani O, et al.  A Phase III, Randomized, Placebo -
Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stim ulator, in Patients With Systemic Lupus Erythematosus; Arthritis 
& Rheumatism 2011; 63:3918-3930. 
[Furst 2013] Furst DE,  Clarke AE,  Fernandes AW,  et al . Incidence and prevalence of 
adult systemic lupus erythematosus in a large US managed -care population. 
Lupus. 2013 Jan;22(1):99-105. 
[Gladman 2002] Gladman  D, Ibañez D and Urowitz  MB. Systemic lupus erythematosus 
disease activity  index 2000. J Rheumatol 2002;29;288-291. 
[Govoni 2006 ] Govoni M, et al. Incidence and prevalence of systemic lupus 
erythematosus i n a district of north Italy. Lupus. 2006;15:110-113. 
[Grammer 2003a ] Grammer AC , Lipsky PE . B cell abnormalities in systemic lupus 
erythematosus.  Arthritis Res Ther. 2003;5 Suppl 4:S22-7.  
[Grammer 2003b] Grammer AC , Slota R, Fischer R, et al. Abnormal ger minal center 
reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest. 2003 Nov;112(10):1506-20. 
[Gurevitz 2013] Gurevitz SL, Snyder JA, Wessel EK, Frey J, Williamson BA . Systemic 
lupus erythematosus: a review of the disease and treatment options. Consult Pharm 2013;28(2):110-21. 
[Helmick 2008] Helmick CG, Felson DT, Lawrence RC, et al.  Estimates of the 
prevalence of arthritis and other rheumatic conditions in the United States. Part I.  
National Arthritis Data Workgroup. Arthritis Rheum. 2008 Jan;58(1):15-25. 
[Hochberg 1997] Hochberg MC. Updating the American College of Rheumatology 
revised criteria  for the classification of systemic lupus erythematosus. Arthritis 
Rheum. 1997;40(9):1725. 
[Jung 2010] Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on 
thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010 
Mar;62(3):863-8. doi: 10.1002/art.27289. 
[Kalunian 2009] Kalunian K, Merrill JT. New directions in the treat ment of systemic  
lupus erythematosus. Curr Med Res Opin 2009;6:1501-14. 
[Kappos 2010] Kappos L, Radue EW, O'Connor P, et al. A placebo -controlled trial of 
oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 144/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
[Kataoka 2004] Ka taoka H,  Koike T. Lupus  mortality  in Japan. Autoimmun Rev. 2004 
Aug;3(6):421-2. 
[Klinman 1991 ] Klinman DM, Shirai A, Ishigatsubo Y, Conover J, Steinberg AD. 
Quantitation of IgM - and IgG -secreting B cells in the peripheral blood of patients 
with systemic lu pus erythematosus. Arthritis Rheum. 1991 Nov;34(11):1404-10. 
[Lerang 2012] Lerang K, Gilboe I, Garen T, Thelle DS, Gran JT. High incidence and 
prevalence of systemic lupus erythematosus in Norway. 
Lupus. 2012 Oct;21(12):1362-9. 
[Maruish 2011] Maruish, M. E. (Ed.). User’s manual for the SF -36v2 Health Survey (3rd 
ed.). Lincoln, RI: QualityMetric Incorporated. 
[Miller  2005a ] Miller MR, Crapo R, Hankinson J, et al,; ATS/ERS Task Force. General 
considerations for lung function testing. Eur Respir J. 2005 Jul;26(1):153-61. Review.  
[Miller 2005b ] Miller MR, Hankinson J, Brusasco V, et al; ATS/ERS Task Force. 
Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. 
[Mok 2011] Mok CC. Epidemiology and survival of systemic lupus erythematosus in 
Hong Kong Chinese. Lupus. 2011 Jun;20(7):767-71. 
[Mosca 2010] Mosca M, Tani C, Aringer M, et al . European League Against 
Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.Ann Rheum Dis. 
2010 Jul;69(7):1269- 74. doi: 10.1136/ard.2009.117200. Epub 2009 Nov 5. 
[Navarra 2011] Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of 
belimumab in patients with active systemic lupus erythematosus: a randomised, placebo -controlled, phase 3 trial. Lancet 2011;377(9767):721-31. 
[Nived  2008] Nived O, Bengtsson AA, Jönsen A, Sturfelt G. Progressive multifocal 
leukoencephalopathy - the importance of early diagnosis illustrated in four cases.  
Lupus. 2008 Nov;17(11):1036-41. 
[Okazaki 2002] Okazaki H, Hirata D, Kamimura T, et al. Effects of FTY720 in 
MRL -lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J 
Rheumatol. 2002 Apr;29(4):707-16.  
[Olsson 2014] Olsson T, Boster A, Fernández O, et al. Oral ponesimod in relapsing -
remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg 
Psychiatry 2014;85(11):1198-208. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 145/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
[Petri 2005] Petri  M, et al for the OC -SELENA Trial . Combined Oral Contraceptives in 
Women with  Systemic Lupus Erythematosus . N Engl J Med 2005; 353:2550-2558. 
[Petri 2012] Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the 
Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86.. 
[Pinschewer 2000] Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FTY720 
immunosuppression impairs effector T cell peripheral homing without affecting 
induction, expansion, and memory. J Immunol 2000;164:5761–70.  
[Pons- Estel 2010] Pons -Estel GJ, Alarcón GS, Scofield L, et al. Understanding the 
epidemiology and progression of systemic lupus erythematosus. Semin Arthritis 
Rheum. 2010 Feb;39(4):257-68. 
[Quanjer 1993] Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced 
ventilatory flows. Report Working Party Standardization of Lung Function Tests, 
European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5–40. 
[Quiñones 2003] Quiñones MA, Douglas PS, Foster E, et al. ACC/AHH clinical 
compet ence statement on echocardiography: a report of the American College of 
Cardiology/American Heart Association/American College of Physicians - 
American Society of Internal Medicine Task Force on Clinical Competence (Committee on Echocardiography). J Am Coll Cardiol 2003,41:687-708. 
[Rahman 2008 ] Rahman A, Isenberg DA. Systemic lupus erythematosus. The New 
England journal of medicine 2008; 358:929-39. 
[Ravirajan 2001] Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA. An analysis of 
clinical  disease activity a nd nephritis -associated serum autoantibody profiles in 
patients with systemic lupus erythematosus: a cross -sectional study.  Rheumatology 
(Oxford). 2001 Dec;40(12):1405-12. 
[Ruiz -Irastorza  2010] Ruiz -Irastorza G, Ramos -Casals M, Brito -Zeron P, Khamashta 
MA. Clinical efficacy and side effects of antimalarials in systemic lupus 
erythematosus: a systematic review.  Ann Rheum Dis 2010;69(1):20-8. 
[Schwab 2007] Schwab JM, Cyster JG. Finding a way out: lymphocyte egress from 
lymphoid organs. Nat Immunol 2007;8:1295–301. Impact of anti -interleukin -6 
receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 146/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
[Selmaj 2013 ] Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with 
relapsing -remitting multiple sclerosis (BO LD): an adaptive, dose -ranging, 
randomised, phase 2 study. Lancet Neurol 2013;12(8):756-67. 
[Steiner 2007] Steiner I, Kennedy PG, Pachner AR. The neurotropic herpes viruses: 
herpes simplex  and varicella-zoster. Lancet Neurol 2007;6:1015–28. 
[Swaak 1986] Sw aak AJ, Groenwold J, Bronsveld W. Predictive value of complement 
profiles  and anti -dsDNA in systemic lupus erythematosus. Ann Rheum Dis. 1986 
May;45(5):359-66. 
[Tan 1982] Tan EM, Cohen AS, Fries JF, et al . The 1982 revised criteria for the 
classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-7. 
[Vaclavkova 2014] Vaclavkova A, Chimenti S, Arenberger P, et al. Oral ponesimod in 
patients with chronic plaque psoriasis: a randomised, double -blind, placebo -
controlled phase 2 trial. Lancet. 2014 Aug 8. pii: S0140-6736(14)60803-5. 
[Ward 2006] Ward MM,  Pajevic S,  Dreyfuss J,  Malley JD. Short  
term prediction of mortality  in patients  with  systemic lupus erythematosus: 
classification of  outcomes  using random forests. Arthritis Rheum.  2006 Fe b 
15;55(1):74-80. 
[Wenderfer 2008] Wenderfer SE, Stepkowski SM, Braun MC. Increased survival and 
reduced renal injury in MRL/lpr mice treated with a novel sphingosine -1-phosphate 
receptor agonist. Kidney Int. 2008 Nov;74(10):1319-26. 
[Yildirim- Toruner 2011] Yildirim- Toruner C, Diamond B. Current and novel 
therapeutics in treatment of SLE. J Allergy Clin Immunol 2011;127:303- 14. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 147/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Appendix 1 Prohibited anti -arrhythmic or heart rate lowering  medications  
The use of t he following drugs at any time during the study is prohibited [ see 
Section  5.2.5] : 
•         Adenosine   •         Ivabradine  
•         Acetobulol   •         Lidocaine  
•         Ajmaline   •         Lorajmine  
•         Amiodaron e  •         Lorcainide  
•         Aprinidine   •         Metoprolol  
•         Atenolol   •         Mexiletine  
•         Azimilide   •         Morcizine  
•         Bepridil   •         Nadolol  
•         Bisiprolol   •         Phenytoin  
•         Betaxolol   •         Pilocarpin  
•         Bretylium   •         Prajmaline  
•         Bunaftine   •         Procainamide  
•         Cibenzoline   •         Propafenone  
•         Diltiazem   •         Propranolol  
•         Digoxin   •         Quinidine  
•         Disopy ramide   •         Sotalol  
•         Dofetilide   •         Sparteine  
•         Dronedarone   •         Tedisamil  
•         Encainide   •         Timolol  
•         Esmolol   •         Tocainide  
•         Flecainide   •         Verapamil  
•         Ibutilide   •         Vernakalant  
If, in the judgment of the investigator, it is in the best interests of the subject  to receive 
any of the drugs listed above, study drug must be permanently discontinued. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 148/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Appendix 2 List o f medications with risk of torsades de pointes  
The use of the following QT -prolonging medications with a known risk of torsades de 
pointes at any time during the study is prohibited [s ee Section  5.2.5] : 
 
• Arsenic trioxide   • Halo fantrine  
• Astemizole   • Haloperidol   
• Anagrelide   • Levomethadyl  
• Azithromycin   • Mesoridazine  
• Bepridil   • Methadone  
• Chlorpromazine    • Moxifloxacin  
• Cisapride   • Ondansetron  
• Citalopram   • Pentamidine  
• Clarithromycin   • Pimozide  
• Cocaine   • Probucol  
• Domperidone   • Sevo flurane  
• Dronedarone   • Sparfloxacin  
• Droperidol   • Sulpiride  
• Erythromycin   • Terfenadine  
• Escitalopram   • Thioridazine  
• Flecainide   • Vandetanib  
 
If, in the judgment of the investigator, it is in the best interests of the subject  to receive 
any of the drugs lis ted above, study treatment must be permanently discontinued.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 149/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Appendix 3 Adverse events of special interest  
AESIs  will include the anticipated risks of treatment with ACT -334441 or the known 
class effects or the ev ents that may be related to SLE comorbidities (e.g. , cardiovascular 
AEs) and will  address the following safety areas:  
 
• Effect on HR and rhythm related AEs  
• Hypotension related AEs 
• Hypertension related AEs 
• Hepatobiliary disorders / l iver enzyme abnormality  related AEs  
• Pulmonary related AEs  
• Eye disorders related AEs 
• Infection related AEs 
• Skin malignancy related AEs 
• Malignancy (non-skin) related AEs 
• Cardiovascular related A Es 
A list of AESIs  (MedDRA preferred terms) will be defined in  the SAP.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 150/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Appendix 4 Criteria for discharge from hospital on D ay 1 and on the first day 
of re- initiation following treatment interruptions  
At the time of discharge (i.e., 6 h post -dose) on Day 1 and on the first day of re -initiation 
of study treatment  following drug interruptions, the following criteria must be met: 
 
• ECG -derived resting HR > 45 bpm; and if HR < 50 bpm it must not be the lowest 
value post-dose 
• SBP > 90 mmHg; 
• QTcF < 500 ms; 
• No persistent ECG abnormality (e.g., AV block second degree or higher) or ongoing 
AE requiring continued hospitalization. 
 
Should the subject  not meet the criteria for discharge 6 h post -dose, she/he will be 
monitored until 12 h post -dose with 12- lead ECG and BP measurements performed 
hourly and may be disc harged after any of the hourly measurements , provided that 
discharge criteria are met until 12 h post -dose. If at 12 h post -dose, the subject does not 
meet discharge criteria, he/she must be permanently discontinued from study treatment. 
Subject s who are p ermanently discontinued should not be discharged from the monitored 
setting before vital signs return to near baseline values and until there are no persistent 
ECG abnormalit ies (e.g., AV block second degree or higher) or ongoing AE requiring 
continued hos pitalization , or until a diagnosis is established. 
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 151/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Appendix 5 American College of Cardiology / American Heart  Association / 
American College of Physicians  Training Requirements for 
Performance and Interpretation of Adult Transthoracic 
Echocardiography 
 
 Cumulative Duration of 
Training  Minimum Total Number of  
Examinations Performed  Minimum Number of 
Examinations Interpreted  
Level 1  3 months  75 150 
Level 2  6 months  150 (75 additional)  300 (150 aditional)  
Level 3  12 months  300 (150 aditional)  750 (450 aditional)  
 
From: Quiñones 2003  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 152/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Appendix 6 SLEDAI -2K: DATA COLLECTION SHEET  
Enter weight in SLEDAI -2K score column  if descriptor is present at the time of the visit 
or in the preceding 10 days. 

ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 153/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
 
Note that Le
ukopenia will not be evaluated for reasons of functional blinding  [see 
Section  5.1.4.2]  and CH50 will not assessed by central laboratory. 
Hematuria, proteinuria a nd pyuria are evaluated by dipstick  at each visit assessing 
SLEDAI -2K. If the dipstick results are positive , urine sample will be further anal yzed as 
clinically indicated (i.e., microscopic analysis of WBC, RBC, casts, and protein 
quantification).  
 

ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 154/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Appendix 7 Notable abnormalities for ECG, BP and laboratory variables 
 
Notable abnormalities for ECG and BP  
Notable abnormalities for ECG and BP that are related to the potential effects of 
ACT -334441 will address the following variables: 
• Morphological ECG findings (defined as any abnormal finding not present prior to 
start of treatment)  
• HR outliers (bpm), based on ECG 
• PR interval (ms)  
• QT/QTc interval (ms), based on Bazett’s or Fridericia’s formula 
• BP (mmHg)  
The definition of the abnormal values to be reported will be described in the SAP. 
Laboratory abnormalities 
Laboratory values below or above the normal range will be graded at three levels (H, HH, HHH for values above normal range and L, LL, LLL for values below the normal range)  
where L stands for “low”, H for “high”. 
The term “marked abnormality” describes laboratory values  above or below the 
thresholds, with grading of abnormalities at two levels: LL/HH and LLL/HHH. These 
thresholds have been defined by the sponsor in order to flag and/or communicate 
abnorm al laboratory results from the central laboratory  to the investigators, and for the 
purpose of standardized data analysis and reporting  by the sponsor . The definitions of 
marked abnormal values are based mainly on the Common Terminology Criteria for 
Adverse Events  (CTCAE) grading system  (2010 v4.03) and, in specific cases (e.g. , 
lymphocyte levels), are adjusted based on the known PD effect of the study drugs (e.g., 
LLL threshold for lymphocytes) [ CTCAE  2010] .  
The term ALERT here corresponds to protocol -defined test result threshold requiring an 
action from the investigator as described in the protocol (e.g., repeat the test; interrupt or 
discontinue the study drug) and should not be confused wi th the te rm “call alert” used by 
the central laboratory for laboratory results , which will be communicated to the 
investigator. Not all ALERTS listed in this table will be “call alerts”  from the central 
laboratory and vice versa. 
PLEASE NOTE: Thresholds fo r abnormality of level L or H are not provided in this 
appendix but will be provided in the laboratory manual. Parameters for which no 
threshold is defined in Table 5 below may be defined in the central laboratory manual.  
ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 159/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Appendix 9 Physician ’s Globa l Assessment Visual Analog Scale 
From : Petri 2005 

ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 160/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 
Appendix 10 SF-36v2™ 
United States (English) SF-36v2 Standard 

ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 161/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 

ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 162/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 

ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 163/166 Confidential  EudraCT 2014- 002984- 14 
Doc No D- 15.156  
 
 

ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 164/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
 

ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 165/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 

ACT -334441  
Systemic lupus e rythematosus  
Protocol AC-064A201  
Version 2  
25 Marc h 2015 , page 166/166 Confidential  EudraCT 2014 -002984 -14 
Doc No D- 15.156  
 
